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Abstract 
Polycystic ovary syndrome (PCOS) is the most common endocrinopathy disorder in 
reproductive age women. The symptoms of this disorder are the androgen excess 
seen with anovulation/oligoovulation or morphologically ovarian cysts. The aim of 
the study was to assess the efficacy of public health nutrition intervention designed to 
enhance healthy eating and lifestyle modification among PCOS patients attended the 
obstetrics and gynecology clinic at the American University of Beirut Medical Centre 
(AUB-MC) in Beirut, Lebanon. 
A prospective hospital based public health nutrition intervention was proposed in 
which 76 women with PCOS were recruited in the pilot study and 588 women were 
recruited in the scale-up intervention divided between PCOS and non-PCOS. 
During the scale up phase non-PCOS women were recruited to study the effect of 
the nutritional counseling on them as a way to compare the outcome with PCOS 
women. Recruited population were divided into 8 groups; group A: 
overweight/obese PCOS patient’s intervention (received weight management 
program with nutritional guidelines). Group B: overweight/ obese PCOS controls 
(received the usual heath care by the gynecologist), Group C: lean PCOS controls 
(received the usual heath care by the gynecologist), Group D: lean PCOS 
intervention (received weight maintenance program with nutritional guidelines ), 
Group E: overweight/obese non-PCOS patient’s intervention (received weight 
management program with nutritional guidelines) ,Group F: overweight/ obese non-
PCOS controls, Group G: lean non- PCOS intervention (received weight 
maintenance program with nutritional guidelines), Group H: lean non-PCOS 
controls 
Data were collected using a pre-validated questionnaire to capture socio- 
demographic variables, nutritional status, and physical activity, psychological and 
medical status. Blood analysis was carried out to determine biochemical indices. 
Assessment of study indicators were carried out at baseline, after 3 and 6 months 
from inception of intervention (pilot as well scale up). Patients in intervention groups 
attended a 6 month tailored nutrition counseling/education program (2 sessions per 
month), to enhance their understanding of their dietary intake and assist them with 
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weight management, physical activity, healthy cooking, lifestyle, and food 
shopping.  
Following a six months pilot study intervention results have shown that 7% weight 
loss was achieved in overweight/ obese intervention groups and weight 
maintenance in lean intervention groups( Group A,B,C and D). There was a 
significant reduction in waist (-4.2 cm (±5.6)) and hip circumference (-3.1cm (±3.5)) 
with P < 0.001. There was no significant biochemical markers change (fasting blood 
sugar, CRP, LDL-C,HDL-C,TG,total cholesterol, fasting insulin, total 
testosterone,Vit D), however  there was an increase in physical activity (3.1 
hours/week (±1.5)) ,  and decrease in anxiety and depression score ( BDI-II and 
BAD-7); -0.8 (±0.8) and -0.7 (±0.7) with P<0,001 compared to interventions. 
Following six months scale up intervention, the results have shown a weight 
reduction among overweight/obese PCOS women (group A) who lost, on average, 
8.2 kg (P=0.001). Whilst non-PCOS women lost, on average 11.6 kg 
(P<0.001)(Group E). Controls gained weight ( Group B, D F and H). 
The biochemical, psychological and reproductive profile showed significant 
improvements among PCOS women (P<0.001). Pregnancy rate increased to 70% 
among women trying to conceive. 
The results of this study have shown this intervention to be effective in Lebanese 
women with PCOS, decreasing their initial body weight by 5%- 10% and improving 
their reproductive, metabolic and endocrine profiles. This suggests the need for a 
nutritional intervention (nutritional guidelines) for women diagnosed with PCOS 
patients as a first line treatment. The study results support the effectiveness of 
lifestyle modification diet for PCOS women. 
Keywords: Polycystic ovary syndrome; Obesity; Lean; Physical activity; Weight 
management; Obesity; Lean; Physical activity; Weight management 
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Polycystic Ovarian (ovary) syndrome or PCOS first described in 1935 by Stein and 
Leventhal, is the most common endocrinopathy affecting 5-10% of women in their 
reproductive age worldwide (Pfeifer et al.,2009). Seventy-eight years were enough 
to dramatically change our understanding of PCOS pathophysiology. PCOS is 
defined by imbalanced hormones and irregular menses causing fertility problems.  
It has many short-term and long-term health implications varying from 
oligomenorrhea, amenorrhea, infertility, insulin resistance, diabetes mellitus and 
cardiovascular disease, to increased risk of endometrial cancer and excessive body 
hair (Pfeifer et al.,2009). Up till 1990, PCOS was a poorly understood condition 
when it was fully defined in the National Institutes of Health (NIH) conference of 
PCOS. The conference offered standard international criteria to serve the 
researchers and clinicians to more understand and manage this syndrome. It was 
followed by a consensus workshop in 2003 in Rotterdam in the Netherlands where 
a new diagnostic criteria was created, the Rotterdam Criteria that states that at 
least two of the following three features must exist: 1-oligomenorrhea/amenorrhea, 
2-clinical and biochemical evidence of hyperandrogenemia, 3-polycystic ovaries 
documented on ultrasonography. The Androgen Excess (AE) and PCOS Society 
proposed the AE-PCOS Criteria in 2006.  PCOS has been diagnosed in female as 
young as 6 years and in fact some girls are possibly born with this syndrome. The 
fact that PCOS is found more at adulthood is possibly due to the difficulty in 
diagnosing the disorder before puberty, a time at which seeking help for irregular 
menses or presence of acne do not take place. PCOS is affecting women in their 
reproductive age and thus causing these women to be unable to get pregnant. This 
has a major cost on the personal and social level, women with PCOS have lower 
chances of getting pregnant if left undiagnosed and thus untreated. The costs for 
this is being unable to have children, increasing the cost of medical treatments and 
thus putting the health status as barrier to marriage in few cultural norms. 
 
 
Diagnostic Criteria for Polycystic Ovary Syndrome 
The polycystic ovary syndrome (PCOS) was first described in 1935 by Stein and 
Leventhal as a combination of hyperandrogenism and oligo- ovulation. Over time, 
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several hypotheses have been proposed regarding the characterization and 
description of the disease, and in this regard three models are the most accepted 
by clinicians (Table 2)(De Paolo, 2012; Housman and Reynolds, 2014; Livadas and 
Diamanti-Kandarakis, 2012; Rotterdam ESHRE/ASRM-Sponsored PCOS 
Consensus Workshop Group, 2014).  
The Rotterdam ESHRE/ASRM- Sponsored PCOS Consensus in 2003, the 
attendees of the workshops built the diagnostic criteria base on the NIH model in 
1990 and the androgen excess and polycystic ovary syndrome society 
recommendation. The NIH model was revised and modified by a group sponsored 
by the European Society of Human Reproduction and Embryology (ESHRE) and 
The American Society for Reproductive Medicine (ASRM). In accordance, the 
PCOS does not represent a single entity, but rather occurs on a spectrum; for that 
reason, the inclusion criteria were widened in order to deflect missing certain 
patients. Consequently, the new diagnostic criteria include two of the following 
three symptoms: oligo – or anovulation, clinical or biochemical signs of 
hyperandrogenism, and polycystic appearing ovaries (PCO) on imaging, giving that 
other similar disease are excluded (Rotterdam consensus workshop,2003). 
The assessment of the ovarian stromal volume as a ratio of the stromal area to total 
area of the ovary (S/A ratio) was also proposed as a parameter to be considered. 
However, even though this factor allowed for a better differentiation between 
females with and without PCOS, it was not adopted by any of the existing 
diagnostic criteria ( Fulghesu e al.,2001) .  
The anti- Mullerian hormone (AMH) was recently introduced as a new parameter 
that can replace the ultra-sonographic characterization of PCOS, and this will 
ensure a 97.1% specificity and 94.6% sensitivity if the Rotterdam model is used 
and a 97.2% specificity and 95.5% sensitivity using the NIH model ( Eirlertsen et 
al.,2012) . 
The diagnosis of hyperandrogenism in women is usually difficult to assess at the 
clinical as well as the biochemical assessment levels.  Assays to measure 
androgen levels were designed for males and calibrations to develop commercial 
ones for females were not done. Furthermore, the diagnosis of clinical 
hyperandrogenism is subjective and dependent on the examiner. 
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Evidence of PCO morphology demonstrated by ultrasonography are not fully 
accepted in the diagnosis of PCOS. The reason for this is that PCO morphology is 
not only present in patients with PCOS, but rather it is found in 20-30% of the normal 
population, and thus it is considered as a manifestation of PCOS only when the other 
criteria are also present ( Michelmore et al .,1999) . 
 PCOS is characterized by clinical or biochemical hyperandrogenism, chronic 
anovulation, and polycystic ovarian morphology seen by ultrasound (Refer table 2 ). 
Other symptoms might also be present but they do not necessarily indicate this 
disease; these include obesity, luteinizing-hormone elevations, and insulin 
resistance) (De Paolo, 2012; Newell-Price, 2014; Sedighi et al., 2014). 
Table 1 Prevalence of PCOS according to NIH, Rotterdam criteria and AAE—
PCOS criteria 
Population NIH criteria Rotterdam 
criteria 
AE-PCOS criteria 
728 Australian 
women 
8.7% 17.8% 12.0% 
820 Iranian 
women 
7% 15.2% 7.92% 
929 Iranian 
women 
7.1% 14.6% 11.7% 
392 Turkish 
women 
6.1% 19.9% 15.3% 
 
Table 2 PCOS phenotypes based on the 2003 Rotterdam criteria ( Housman 
and Reynolds,2003). 
Phenotype Clinical features 
Severe PCOS Irregular menses, polycystic ovaries, 
hyperandrogenemia, and hyperinsulinemia 
Hyperandrogenism and 
chronic anovulation 
Irregular menses, normal ovaries, 
hyperandrogenemia, and hyperinsulinemia 
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Ovulatory PCOS Normal menses, polycystic ovaries, 
hyperandrogenemia, and hyperinsulinemia 
Mild PCOS Irregular menses, polycystic ovaries, mildly 
raised androgen levels, and normal insulin levels 
 
Prevalence and Epidemiology of PCOS 
PCOS is the most common endocrine disease affecting about 14.6%of females in 
the reproductive age (Tehrani et al.,2011). The prevalence of PCOS presents 
ethnic and regional variations and is mostly dependent on the diagnostic criteria 
adopted. To illustrate the truth of this, a retrospective birth cohort in Australia 
presented a prevalence of 8.7% using NIH criteria, 17.8% using Rotterdam criteria, 
and 12% using AES criteria. PCOS prevalence is higher among Mexican than 
American females indicating the importance of lifestyle in addition to the ethnic 
diversity in the occurrence of PCOS (Rotterdam ESHRE/ASRM-Sponsored PCOS 
Consensus Workshop Group, 2004). 
The prevalence of PCOS has been determined among women in different 
countries: Australia 8.7%, Spain, 6.5%, Greek Island of Lesbos 6.7%, the 
southeastern United States 4%,Sweden 4.8%, China 2.2%, Mexico 6%, and 
Pakistan 17.6% (Asuncion et al., 2000; Chen et al., 2008; Diamanti-Kandarakis at 
al., 1999; Fauzia et al., 2007; Knochenhauer et al., 1998, Lindholm et al., 2008; 
March et al., 2010; Moran et al., 2010). The difference in prevalence is due to the 
different diagnostic criteria used to study the prevalence. Each study used different 
criteria (Refer to table 1).  
Prevalence estimates for PCOS, as defined by the NIH criteria, indicate that PCOS 
affects 4-8% (Sirmans and Pate, 2013). However, given the broader definition 
described in the Rotterdam criteria, the prevalence of PCOS has subsequently 
been noted to range from 15-18% (Housman and Reynolds, 2014).  
Not surprisingly, women with menstrual abnormalities appear to have higher 
prevalence rate ranging from 37-90%. PCOS prevalence is also increased in the 
presence of certain diseases where it is shown to be greater in women with 
epilepsy than in women without epilepsy (Zacur, 2003). 
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Obesity in PCOS 
Obesity can promote the occurrence of PCOS in predisposed women. Moran et al., 
in 2015 have shown that PCOS appeared after weight gain in some women. 
Obesity aggravates insulin resistance and thus insulin resistance cause excess 
androgens productions in the body. Further long term studies are needed to 
evaluate these correlations and the effect of weight management (weight loss and 
weight maintenance) on the treatment of PCOS. 
The prevalence of obesity among PCOS patients (42-74 %) is higher than the 
general population, although it is not a feature of PCOS ( Sedighi et al., 2014). The 
clinical presentation of the disorder is aggravated (reproductive and metabolic 
effects) by obesity (Sedighi et al., 2014). Obese PCOS women have 
hyperinsulinemia than normal weight PCOS women ( Sedighi et al., 2014).Obesity 
aggravates the intrinsic insulin resistance among PCOS women. Furthermore, 
hyperinsulinemia can worsen hyperandrogenism and this due to the gonadotropin 
regulation and steroidogenesis ( Sedighi et al., 2014). Hyperinsulinemia affects the 
sex hormone –binding globulin synthesis and cause excess androgen production 
(Pagan et al., 2003). 
The prevalence of obese PCOS women with BMI > 30kg/m 2 is 40-60% (Hoeger, 
2006).  The prevalence of obesity and its clinical manifestations among PCOS 
women suggests the need for a weight management intervention as a lifestyle 
modification to significantly improve the metabolic effects. Weight loss among 
PCOS women reduces hyperandrogenism and thus improve ovulation ( Hoeger et 
al., 2006) . Insulin resistance is reduced by physical activity regardless of weight 
reduction. The present literature didn’t define clearly the role of physical activity on 
insulin resistance in PCOS women and the effect of physical activity on the clinical 
presentation of PCOS.  
 
Scale of the problem and epidemiology of the disease 
PCOS is a broad spectrum disorder that represents a serious health concern for 
women across their life span(Sedighi et al., 2014).Its effects go beyond the 
reproductive (menses disorders, failure to ovulate, late menopause), metabolic 
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(dyslipidemia, hypertension), physical (central obesity, acne, hirsutism, hair loss 
and baldness) and psychological consequences (depression, stress and anxiety); it 
is a leading cause of anovulatory infertility and a risk factor for endometrial 
dysfunction and uterine cancer. It also increases pregnancy complications and 
gestational diabetes risk (Lin and Lujan, 2014; Moran et al., 2015; Sedighi et al., 
2014). Importantly, PCOS patients since their puberty are considered to have high 
reproductive and cardio metabolic risks. Women with PCOS are 2-4 times more 
likely to have metabolic syndrome than are women without PCOS. The metabolic 
syndrome among PCOS patients ranges between 40-50% worldwide (Eckel, 2012). 
These patients are four times more prone to develop type 2 diabetes mellitus at 
younger age, and have increased cardiovascular risk factors (Moran et al., 2015). 
They are more prone to gain weight which further exacerbates their condition. All of 
the mentioned facts highlight the need to target these women for prevention and 
management (Moran et al., 2015). The lack of knowledge about lifestyle 
modifications using nutritional guidelines is enlarging the scale of the problem 
causing obesity to increase among the PCOS population.  
It is estimated that 105 million women suffer from PCOS universally (Sedighi et al., 
2014). This syndrome occurs in a striking proportion of women who are in their 
fertile years, ranging from 6-18% worldwide (Lin and Lujan, 2014). The lifestyle 
modification focus on PCOS population can exert beneficial effects. 
 
Prevalence of PCOS at regional and national levels 
The prevalence of PCOS is well studied in the European and American 
populations. Despite of the few studies done on the Middle East women, there are 
no published data regarding the prevalence of this syndrome among the Lebanese 
women ( Musmar et al.,2013 ; Al Khaduri et al., 2014 ; Hussein and Alalaf, 2013). 
As listed in appendix 1, two Iranian studies found PCOS prevalence to be 7.1% and 
7% (Mehrabani et al., 2011; Tehrani et al.,2011).Regarding the Arab world, out of 
137 study patients selected from female university students at An-Najah National 
University-Palestine, 10 students met the NIH criteria for diagnosis of PCOS 
making the prevalence rate to be 7.3% (Musmar et al., 2013In Lebanon, a 
descriptive review of cases of 160 females with hirsutism presenting to an 
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endocrine clinic showed that 72.6% are found to have PCOS (Zreik and Nasrallah, 
2014). Till now, there is no identification study assessing the prevalence of PCOS 
among pure Lebanese women. The prevalence of PCOS in Lebanon is still scarce 
and presents a great challenge. Women in Lebanon does not present to the 
obstetrics and gynecology clinics unless they are experiencing irregularity of 
menses or infertility which is one of the very private cultural norms in our society. 
Lebanon shares common ethnic and socio-demographic factors with different Arab 
world populations. This could make us estimate that PCOS prevalence might be 
similar to the other studied Arab populations. 
 
PCOS as a Public Health Problem 
PCOS is an endocrine and reproductive syndrome which is of a clinical and public 
health importance. The NIH stated that worldwide the public is largely unaware of 
this condition and health care providers do not seem to fully understand it (De 
Paolo, 2012). 
As mentioned earlier, PCOS patients have a likelihood of developing serious 
reproductive and metabolic consequences. This imposes a wide range of 
symptoms and life-long implications on women’s health that subject them to 
undesirable mental health outcomes and impairment in quality of life at the 
emotional, physical, and social levels (Ghazeeri et al., 2013). 
Evidence indicating a genetic influence includes a well-documented familial 
clustering of PCOS; an increased prevalence of its components, including 
hyperandrogenism and type 2 diabetes mellitus, in first-degree relatives of women 
with PCOS (Legro et al., 1998; Ehrmann et al., 2005). Genetic effect is estimated to 
explain approximately 65% of PCOS risk (Vink et al., 2006). In a Dutch twin study, 
the heritability of PCOS was estimated (Vink et al., 2006). Results demonstrate a 
large influence of genetic factors to the pathogenesis of PCOS and suggest that the 
syndrome’s etiology is strongly heritable (Vink et al., 2006).  
In Lebanese patients presenting with hirsutism, the family history was noted in 
12.4% of the PCOS patients (Zreik and Nasrallah, 2014). This makes the syndrome 
to have probable implications on offspring and relatives (Baldani et al., 2013). 
Furthermore, this syndrome incurs heavy costs on healthcare systems in different 
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countries. For example, in 2004, the United States of America spent 4.36 billion 
dollars to treat PCOS and its complications. More than 40% of this cost was spent 
on infertility and menstrual period impairments and another 40% was spent on 
treatment and diabetes control (Sedighi et al., 2014). 
Although in Lebanon there are no data regarding PCOS, it is a syndrome that 
necessitates public health awareness to control a lot of its preventable 
consequences on both the patient and the society. 
Research aim and objectives 
Aim 
 
The aim of the study was to assess, design and implement the efficacy of public 
health nutrition intervention designed to enhance healthy eating and LSM among 
PCOS patients attending the obstetrics and gynecology clinic at the American 
University of Beirut Medical Centre (AUB-MC) in Beirut, Lebanon.  
 
Objectives 
 
The objectives of the study are: 
i. To achieve and encourage a primary weight loss (from 5-10% of initial body 
weight) among overweight/ obese PCOS, and weight maintenance among 
lean PCOS patient. 
ii. To design and optimize educational sessions tailored to PCOS patients in 
order to raise their nutritional awareness, enable informed healthy food 
choice and engage them in physical activity. 
iii. To assess the rates of regularities of menses (examined by pregnancy onset 
and ovulation) in the participant groups and in matched control PCOS 
population receiving no intervention. 
iv. To evaluate the efficacy of public health nutrition through the pre-intervention 
versus the post-intervention assessment employing the study indicators 
(positive deviation to healthy life style, adequate/balance dietary intake, 
healthy body weight, optimum physical activity, optimum blood pressure, 
improved biochemical indicators) via pilot/scale up intervention. 
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v. To develop and optimize the nutrition framework for people living with PCOS 
in Lebanon. 
MPhil is presented through objective i, ii, and iii 
PhD is presented through objective iv and v  
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Chapter 2 
Literature review 
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2.0 Introduction  
This chapter includes the literature review and current interventions and findings in 
the data as well as the nutritional intervention in PCOS. It shows and justifies how 
nutritional interventions improve some health concerns and reproductive outcomes 
among PCOS women and fill few gaps in the reproductive endocrinology area in 
Lebanon. 
 
2.1 The Heritable Basis of PCOS 
2.1.1. Familial Aggregation studies 
Initially, studies have suggested an autosomal dominant mode of inheritance of 
PCOS with a relatively high prevalence rate (51- 66%) in the first degree relatives 
of a female presenting the disease. Accordingly, all of the symptoms, including the 
oligomenorrhea and hirsutism, were caused by a single gene (Carey Et al. 
.,1993). Moreover, the genome-wide association study (GWAS) on PCOS in a Han 
Chinese population identified variants mapping to three loci (2p16.3, 2p21 and 
9q33.3) (Chen Et al., 2011). A second GWAS in a larger cohort of Han Chinese 
PCOS patients discovered variants mapping to eight risk loci (2p16.3, 9q22.32, 
11q22.1, 12q13.2, 12q14.3, 16q12.1, 19p13.3 and 20q13.2) for PCOS (Shi et al., 
2012).Genetic approaches are rapidly uncovering new regions of the genome that 
appear to confer risk for PCOS. The strongest association was on chromosome 
8q24.2, and other association signals were located at 4q35.2, 16p13.3, 4p12, 
3q26.33, 9q21.32, 11p13 and 1p22. The strongest signal was located upstream of 
KHDRBS3 gene, which is associated with telomerase activity, and could drive 
PCOS and related phenotypes.  
 
2.1.2The Candidate-Gene Era 
Challenges of the Candidate Approach 
The candidate approach was largely adopted in the study of PCOS; however, it was 
not very beneficial due to many factors. First, small to moderate cohorts were used 
in the studies where a single gene was investigated (Goodarzi et al.,2008). 
Consequently, false negative and false positive results cannot be prevented. 
Second, PCOS is associated with multiple genes each contributing to a small risk to 
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the disease, that is why a huge number of samples are needed for the study, and 
this was not available until recently (Goodarzi et al.,2011; Chua et al.,2012). The 
future treatment modalities are based on identifying the susceptible genes in PCOS 
drawing the pathophysiological pathways, and maybe preventing the disorder. 
 
Epigenetics in PCOS 
Epigenetics is the study of changes in an organism and is usually caused by 
modifications of the gene expression rather than alteration of the genetic code 
itself. Epigenetic changes can be influenced by many factors and its mechanisms 
include methylation, phosphorylation, acetylation (Muhonen et al.,2009). 
PCOS was hypothesized to be caused by certain epigenetic changes leading to its 
pathogenesis (Li et al.,2008). The theory suggests that female fetuses exposed to 
increased androgen in utero will develop PCOS- like symptoms and might have 
permanent metabolic or reproductive abnormalities (Abbott et al.,2005). 
 
2.2 Functional Underpinnings in Polycystic Ovaries 
Androgens have been shown to cause alteration in the early folliculogenesis since 
a significant decrease in the follicle atresia was seen in follicles treated with 
androgens in ovo(Vendola et l.,1999; Qureshi et al.,2008). The primary follicles 
were the most affected since they are the ones with the highest amount of 
androgen receptors (AR) on their surface (Rice et al.,2007). Furthermore, the 
prenatal exposure to androgens has been associated with an adult PCOS 
phenotype (Forsdike et al.,2007)  
 
2.2.1 Theca Dysfunction in PCOS 
One important characteristic feature of PCOS is hyperandrogenism which is mainly 
of ovarian origin. According to the recent experiments, exaggerated 
steroidogenesis is present in the theca cells of PCOS, in addition to the increased 
responsiveness of these cells to LH ( Gilling-Smith et al.,1997). This is due to the 
increased expression of the CYP17 gene that encodes for both the 17 alpha-
hydroxylase and 17,20 lyase involved in the conversion of pregnenolone to 17 α-
hydroxypregnenolone and then to DHEA, in addition to the increased expression of 
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the 3 ß HSD responsible for the conversion of DHEA to androstenedione and finally 
testosterone( Gilling-Smith et al.,1997)..   
The hyperandrogenism is detected in females even before any ovarian change 
occurs implying the role of the androgens as a cause of PCOS and not a result 
(Gilling-Smith et al.,1997).. 
To add to the intrinsic factors favoring the production of androgens, one can list 
both the LH and the hyperinsulinemia which are present in females with PCOS.  
 
2.2.2 Ovulatory Dysfunction 
 Although numerous follicles are recruited in PCOS, their development stops once 
their size reaches 5-8 mm ( Franks et al .,1985).The reason behind that dysfunction 
has been attributed to many factors one of them is the androgen overproduction. 
This androgen excess has been defined to be caused by an increase in the serum 
LH level resulting in premature luteinization (Franks et al .,1985). This hypothesis 
has been further supported by the fact that LH receptor mRNA in women with 
PCOS is overexpressed in granulosa cells (Franks et al .,1985).  
Furthermore, abnormalities in the FSH secretions are another factor leading to 
ovulatory dysfunction since the selection and maturation of the follicle is FSH- 
dependent. Experiments have shown that FSH levels are lower in PCOS patients 
and granulosa cells have stronger binding and responsiveness to FSH ( McNatty et 
al.,1982). 
There is a strong relation between insulin resistance and anovulation; obese 
insulin-resistant females with PCOS started to have ovulatory cycles when they lost 
weight and they had improved insulin sensitivity parameters ( Dunaif et al.,1997). 
 
2.2.3 Energy Balance 
During the division and the maturation of the follicles, energy derived from glucose 
through the glycolytic pathway should always be supplied through the follicular fluid 
which has a comparable glucose concentration to plasma. In PCOS, the insulin- 
mediated lactate accumulation is due to the weak glucose uptake and the reduction 
in the glycolytic pathway in the cells resulting in an impaired growth and 
development of granulosa cells (Oktem et al., 2008).  
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In that regard, metformin, the insulin- sensitizing drug used in the treatment of 
PCOS, was effective due to its role in increasing the glucose uptake and 
metabolism of the cells by increasing the amount of the GLUT-4 transporter in their 
plasma membrane (Tang et al., 2006). 
 
2.3 The Role of the Adrenal Glands in the Hyperandrogenism Associated with 
Polycystic Ovarian Syndrome 
Adrenal Androgens and PCOS 
Till now, the source of the elevated androgens in PCOS patients is still unknown. 
Some studies have identified it as being the ovaries, others pretended it to be the 
adrenal glands, and finally some evidence supported the fact that both are 
contributing to the hyperandrogenism( Futterweit et al., 2006). 
Both, the ovaries and the adrenal glands, contain certain steroid-producing tissues 
derived from the same embryonic origin; so the androgen production by the ovaries 
can affect the steroidogenesis in the adrenal glands, and the increased levels of 
androgens produced by the adrenal can cause increased steroidogenesis by the 
ovaries as well resulting in a subsequent increase in the LH (McGee et al ., 2012).  
 
The Role of the Adrenal in Childhood and Subsequent Development of PCOS 
PCOS after adolescence have been seen in children (<8 years) with the congenital 
adrenal hyperplasia (CAD) that is accompanied with excessive production of 
androgens. Studies have revealed that fetus or pubertal girls exposed to androgens 
might have subsequent alterations of the hypothalamo- pituitary- ovarian axis that is 
characteristic of PCO (Abbott et al., 2008). During this study obesity during 
adulthood wasn’t observed as a factor of excess androgen production in order to 
make a correlation between obesity in adolescences and PCOS.  
Children with premature adrenarche characterized by increased DHEA were also 
seen to develop PCOS subsequently. The increased DHEA might be caused by an 
increased activity of the enzyme CYP17A1 (P450c17 α) that is responsible for the 
17 hydroxylation of pregnenolone and progesterone, and the deletion of C20 and 
C21 from the product to form DHEA and androstenedione due to its lyase 
activity(Abbott et al.,2009). Abnormalities in the lyase function of the enzyme cause 
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increased levels of DHEA and androstenedione as a result of the active conversion 
of the progesterone in the ovaries since the enzyme is active in the adrenal as well 
as the ovaries (Abbott et al., 2009). 
 
Adult with PCOS and the Role of Adrenal Androgens 
Once PCOS is diagnosed after the signs and symptoms are fully manifested, it 
would be very difficult to determine the source of the excess androgens. Certain 
researchers suggest that the excessively secreted androgens are converted to 
estrogen and then they act by feedback on the pituitary gland to increase LH; this is 
the case where the excess androgens originate from the adrenal. The other group 
assumes that the ovarian androgens block the hydroxylation of the 17 
hydroxyprogesterone and the 11 deoxycortisol in the adrenal thus enhancing the 
channeling of the precursors into the androgen production; this how the ovaries can 
be the source of the androgen excess (Yoshida et al., 1978).  
Kumar et al. have proved that the increased DHEA and especially DHEA-S are 
evidences supporting the adrenals being the origin of the hormonal excess in 
PCOS since DHEA-S is produced only by the zona reticularis of the adrenals while 
DHEA is produced by both, the ovaries and the adrenals (Kumar et al., 2005). 
A more recent study has been done by Rosenfield (2011) showed that PCOS 
patients present typical and atypical phenotypes with ovarian or adrenal origin of 
the hyperandrogenism.  
 
2.4 The Hypothalamus- Pituitary Axis in PCOS 
Neuroendocrine Function in Normal Reproduction  
The regulation of the menstrual cycle is accomplished by the hypothalamus and the 
pituitary through the GnRH, LH, and FSH, and the ovaries response to 
gonadotropins through ovulation and secretion of estradiol, progesterone, inhibin A, 
and inhibin B (Hall  et al., 2012) 
In a normal female, GnRH is secreted in a regulated pulsatile manner across the 
cycle to ensure repetitive cycles of the development of follicles. 
To start a new cycle, the pulsatile LH-GnRH secretion increases from a frequency 
of 1 every 4h to 1 every 90 min early in the follicular phase. At the mid-follicular 
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phase, it increases to 1 every hour. Following the ovulation, GnRH secretion 
decreases back to 1 every 90 min and finally to 1 every 4h due to the increased 
level of circulating progesterone in the presence of high estrogen. Concerning FSH, 
the slow release of GnRH stimulates its synthesis, whereas the fast release of 
GnRH stimulates the secretion of LH. 
 
What Causes the Neuroendocrine Abnormalities in PCOS 
The Role of Androgens 
Under the previously mentioned condition, the theca cells of the ovaries increase 
their production of androgen substrates. The co-presence of a low FSH level 
causes a deficiency in the aromatization of these androgens resulting in a milieu 
where the maturation of the follicles and the ovulation cannot occur. 
The removal of the tumor cells producing the excess androgens, the wedge 
resection, or the ovarian drilling have proven to be effective in the restoration of the 
normal cycle (Dunaif et al.,1984). 
 
The Potential Role of Altered Progesterone Negative Feedback 
Progestin’s use can transiently decrease the GnRH/LH pulse frequency and 
improve the LH/FSH ratio that is abnormal in PCOS patients. The progesterone 
binds to the PgRMC1 receptor present in GnRH neurons and exerts a negative 
feedback decreasing the LH secretion as a result of the reduction of the intracellular 
calcium. So in PCOS patients, the effect of progesterone on GnRH is reduced. 
Furthermore, the treatment with flutamide (antiandrogen) for four weeks restores 
the sensitivity to progesterone and the GnRH pulse becomes normal. 
Consequently, one can say that the elevated levels of androgens in PCOS are the 
cause of the increased GnRH pulse frequency. 
New evidences suggest that the decreased sensitivity to the progesterone is highly 
related to the hyperinsulinemia (Gill et al., 2001) 
In PCOS females, the ovulatory defect can be corrected by the correction of the 
FSH levels through the use of estrogen receptor blockers that reduce the negative 
feedback exerted by estrogen (Brown et al., 2006).  
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In addition, studies have shown that the prenatal exposure to androgens elevates 
the LH levels and contribute to PCO morphology (Abbott et L., 2005).  
Adolescent girls start their puberty as a result of an increase in LH and a mean FSH 
(Hall et al., 2005). GnRH secretion is influenced by the negative feedback of the 
diurnal increase in progesterone early in the morning. This is followed by an 
increased GnRH pulse frequency within 24h. The presence of increased androgen 
levels during this stage can lead to the impaired sensitivity to progesterone and 
subsequently to PCOS (Ibanez et al., 1994) 
 
2.5 Modifiers of the Neuroendocrine Axis in PCOS  
The Role of Obesity 
Obesity is highly present in PCOS patients suffering from anovulation. BMI and 
percent body fat are inversely related to LH, so obese PCOS patients usually have 
a normal LH/FSH ratio. 
It was thought that the effect of obesity in PCOS is exerted at the hypothalamic 
level; however, the GnRH pulse frequency was not affected by the BMI, and 
evidences support the fact that its effect is exerted at the pituitary resulting in a 
decreased LH responsiveness to GnRH.  
 
Impact of Hyperinsulinemia 
50-75% of lean and obese female with PCOS have insulin resistance and 
hyperinsulinemia. 
Insulin resistance is not only affected by obesity. 
Evidences suggest that insulin acts at the level of the pituitary. The insulin receptor 
in the gonadotropin-derived LßT2 cell line is present in the plasma membrane of 
the pituitary. Absence of the IRS-2 and IR causes abnormalities in LH levels, 
absence of ovulation, and decreases the sensitivity to GnRH (Navratil et al.,2009). 
 
Role of Leptin 
High levels of leptin are present in PCOS women and it is usually related to BMI. Its 
level is inversely related to LH amount. Those studies have revealed that leptin is 
the agent that mediates the effect of BMI on LH release.   
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Folliculogenesis and anovulation disorders are the results of neuroendocrine 
dysfunction in PCOS. Hyperandrogenemia is the cause of disturbed hypothalamic -
pituitary axis. At the pituitary level, obesity and hyperinsulinemia cause 
neuroendocrine disorder. Thus ovulation is affected these abnormalities and insulin 
resistance. Intervening at the insulin and obesity level improve folliculogeneis and 
promote fertility. 
 
2.6 Insulin resistance in PCOS 
The main symptoms of Polycystic Ovary Syndrome (PCOS) are androgen excess 
and anovulatory infertility in women. However, it has been shown through numerous 
studies that other metabolic anomalies like metabolic syndrome, glucose intolerance, 
type 2 diabetes, endothelial dysfunction and others are more prevalent in the PCOS 
patients thus having a connection with it. One of the most recurrent associated 
conditions is insulin resistance. Altogether, managing these metabolic conditions can 
help with the manifestation of the syndrome. It has been decided by several scientific 
communities to diagnose PCOS if the patient has: 
1. Hyperandrogenism 
2. Dysfunctional ovaries in the form of oligo-anovulation and polycystic ovaries. 
Nonetheless, other common feature for PCOS patients are high BMI (Body 
Mass Index), insulin resistance (70% of women with PCOS) and 
compensatory insulinemia. Since not all PCOS patients have insulin 
resistance it is not clear if this symptom is a cause or a contributor to the 
syndrome, thus the necessity to determine its relation with PCOS. 
 
Definitions of insulin resistance 
Anatomically, Insulin is a hormone secreted by the pancreas. Two ranges of effects 
are in place: The metabolic effects and the mitogenic effects. 
Its metabolic effects consist of promoting glucose intake, inhibiting lipolysis and 
glycogen synthesis in tissues sensitive to it like the liver, skeletal muscles and 
adipose tissue. This whole process depends on the levels of insulin in the blood and 
glucose in the blood. 
The mitogenic effects consist of cell proliferation and differentiation. 
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When the tissues that are affected by insulin lose their sensitivity to it, insulin 
resistance is in place. Insulin can no longer execute its metabolic effects whereas 
mitogenic effects may remain intact. In other words, insulin resistance results in 
excess glucose levels in the blood since it is no longer picked up by the tissues in 
question resulting afterwards in an increase in insulin secretions 
(hyperinsulinemia)(DeFronzo et al.,1979). 
 
Evolution of Insulin Resistance Knowledge in PCOS 
Several studies across the years tried to uncover the relationship between insulin 
resistance and PCOS. 
In 1920, Emile Charles Achard and Joseph Thiers were the first to associate insulin 
resistance to hyperandrogenism called then the Achard-Thiers syndrome defined as 
highly virilized women who developed type 2 diabetes (not called PCOS 
then)(Bellanger et al.,2012). 
In 1980, the comparison between obese PCOS patients and healthy control women 
with the same BMI by Burghen and his colleagues determined a significant 
correlation between insulin levels and androgen circulating in the blood as well as 
insulin and testosterone or androstenedione ( Burghen et al.,1980). 
Another study by Dunaif in 1997 and colleagues suggested that insulin resistance in 
PCOS is not caused by high BMI but by the syndrome itself. 
However, other studies that followed in which women with PCOS and healthy ones 
with different BMI were put in comparison showed that lower insulin sensitivity was 
present in obese PCOS patients but not as much as in lean PCOS women (Pawlak 
et al.,2002). Moreover, fit PCOS patients with insulin resistance lost this insulin 
resistance after a correction for truncal-abdominal subcutaneous fat distribution 
(Pawlack et al., 2002). Thus, concluding that the fat distribution is the main cause of 
Insulin resistance not the PCOS itself ( Druce et al., 2005). 
These differences in the studies’ results are mainly caused by the heterogeneity of 
PCOS phenotypes across the studies (Lam et al., 2007). The findings are limited to 
certain genotypes.   In conclusion, the literature across research reveals that insulin 
resistance and hyperinsulemia aggravate and may trigger PCOS in predisposed 
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subjects. The limitation of this conclusion is that PCOS can cause insulin resistance 
after excess weight gain and his needs to be further investigated. 
 
Insulin and Hyperandrogenemia in PCOS 
Insulin resistance as shown above is caused by factors affecting insulin signaling 
pathways in the insulin sensitive tissues. The resulting hyperinsulinemia leads to 
alterations in the androgen biosynthesis pathway so helping the PCOS phenotype to 
uncover. 
 
In Vivo observations 
Numerous studies tried to find the correlation between the role of insulin and 
androgen production. 
In 1989, a reduction of free and total testosterone levels because of a diazoxide 
intake that lowered fasting and glucose-stimulates insulin levels was observed. The 
same result was observed with a treatment with acarbose (slows intestinal glucose 
absorption) for 6 months. In lean normo-insulinemic women with PCOS, the same 
treatment with diazoxide also caused a significant drop in free testosterone and 
androstenedione levels. Thus proving the relation between insulin and 
hyperandrogenemia even in lean PCOS patients (Hilll et al., 2006; Mozafffarian et 
al., 2011; Church et al., 2011). The study findings are limited to the diazoxide intake 
with no clear investigation about the nutritional intake of each participant.  
Similarly, treatment with insulin sensitizing drugs such as metformin and rosiglitazone 
showed improved free-testosterone levels. Metformin was attributed the effect of 
lowering circulation insulin levels whereas rosiglitazone was said to lower androgens 
by restoring the androgenic response to insulin (Wren et al., 2001; Pereira-Lancha 
et al.,2010). There is limited data in the literature about the effect of a defined 
percentage of weight loss on androgenic response to insulin with no pharmaceutical 
agent’s intervention. 
A recent study reported that increased circulating progesterone and androstenedione 
levels was caused by GnRH-agonist stimulation during insulin infusion and after 
adrenal steroidogenesis suppression with dexamethasone, compared to when 
administered during saline infusion. However, LH and FSH hormone levels remained 
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the same between infusion conditions thus concluding that hyperinsulinemic 
condition potentiated ovarian androgenic response to gonadotropic hormone 
stimulation (Tosi et al.,2012). 
In general, studies showed that a decrease in basal androgen production is not 
triggered by a lowering in insulin levels. In conclusion, it can be said that 
hyperinsulinemias in itself do not cause PCOS in a normal woman but can cause 
hyperandrogenemia in women with PCOS whether they are insulin-resistant or 
insulin-sensitive. 
Another link between insulin and hyperandrogenemia is the sex hormone-binding 
globulin (SHBG) levels. SHBG binds to testosterone in the plasma which makes the 
testosterone unable to circulate freely. In PCOS women, the level of SHBG in the 
plasma is lower than for healthy women thus the high levels of testosterone 
circulating. The treatments with diazoxide and acarbose lower the SHBG levels so 
treating hyperandrogenemia( Farooqi et al., 2006; Speliotes et al., 2010).  
 
In vitro Observations 
Insulin resistance PCOS patients, alter the insulin signaling pathway. Normally, the 
molecules of insulin interact with its receptors on the insulin-sensitive tissue in a way 
that the receptor undergoes dimerization and autophosphorylation by its own tyrosine 
kinase activity (Baillargeon et al., 2003). This results in the activation of the first 
protein (IRS) in the signal transduction which in turn either activates the pathway 
which is responsible for the metabolic function of insulin or the pathway that activates 
the mitogenic effects of insulin. 
Insulin resistance emanates from anomalies in those pathways (Baillargeon et al., 
2003). 
It is still scarce to confirm whether hyperandrogenemia is caused insulin resistance 
is the cause or the consequence of it. Both of them are factors of PCOS depending 
on the genotype. Insulin resistance contributes to PCOS differently between women 
and intervening on a prevention and treatment level of IR is a great challenge for 
scientists. Preventing IR to occur among PCOS women is mainly by genetic but 
without any factors such as glucose increasing food, IR can be prevented. 
Lipotoxicity and the exposure to fat intake is a key contributor to IR thus decreasing 
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the body fat can decrease the risk and androgen levels. The exact cause of PCOS 
is unclear between metabolic and endocrine abnormalities however, it is important 
to study the implication of dietary intervention and the possible improvement to 
have a better insight to the PCOS mechanisms. The disorder characteristics are 
important in order to have a clear insight on the effect of nutritional support via 
weight loss in order to improve anovulation and hyperandrogenemia as a new 
therapeutic line. This line can better prevent, or treat PCOS development. 
 
2.7 Obesity, Metabolic Dysfunction, and Inflammation in Polycystic Ovary 
Syndrome 
Modern dietary habits, high intake of fats, salt and sugar, sedentary life and more 
recently discovered epigenetics related to the fetal environment have been shown 
to have contributed to the growth of the obesity pandemic in industrialized and 
developing countries. The excess adipose tissue present worsens the symptoms of 
PCOS like for example insulin resistance (Aubuchon t al., 2012). Additionally, 
adipose tissue stores energy and act as an endocrine and immunological organ. 
 
Medical Disorders Associated with Obesity 
Obesity has been linked to many other medical conditions:  
• Impaired glucose tolerance (IGT) (Stein et al., 2007). 
• Dyslipidemia: Lipoprotein (LDL, apolipoprotein B, VLDL) and triglycerides 
are elevated In the body of an obese person which delays hepatic clearance 
moreover, HDL tends to be low in their bodies (Stein et al., 2007). 
• Hypertension: it is caused by the increase of circulating leptin, insulin, FFA 
which activates the sympathetic nervous system and the renin-angiotensin-
aldosterone system which triggers excess sodium retention thus 
hypertension. Other cases face vasoconstriction because of endothelial 
dysfunction and nitric oxide decreased responsiveness thus causing 
hypertension (Stein et al., 2007). 
• Type 2 diabetes mellitus: the insulin resistance in obese people causes an 
increase in the secretion of insulin in the pancreas and then contribute to the 
failure of the pancreatic Beta-cells (Stein et al., 2007). 
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• Cardiovascular diseases: increases proportionally to body weight (Stein et 
al., 2007). 
• Risk of sleep apnea: related to the increase of body fat percentage and 
visceral fat (Stein et al., 2007). 
 
Metabolic Dysfunction in PCOS: Prevalence and Risk 
Women with PCOS show these medical disorders and symptom independently of 
obesity. Studies have shown that non-obese women with PCOS have higher LDL-C 
and higher total cholesterol than non-obese healthy women. Indeed these 
conditions are more likely to occur with a PCOS patient (Ford et al.,2008;  Boutzios 
et al.,2013). 
It is said that hyperinsulinemia affects the pulsatile patterns of FSH and LH and 
androgen production which is associated with anovulatory infertility (Ford et 
al.,2008).  
 
Impact of Obesity on PCOS 
Obesity is more probably to happen in PCOS patients (42-74%) than in the general 
population (25%) and insulin resistance is more prevalent in obese individual with 
PCOS or not than with normal-weight PCOS women. In fact, fit(normal BMI of 18-
24.9 kg/m2 ) PCOS patients have a milder form of insulin resistance that only 
results in postprandial hyperinsulinemia (Yildiz et al., 2008). 
When obese women have PCOS the case of hyperinsulinemia worsens which 
causes excess androgen production and stops hepatic sex hormone-binding 
globulin (SHBG) synthesis, enhances LH pituitary secretion and enhances the 
androgenic response to LH. 
When Obesity is superimposed with PCOS the woman shows more symptoms of 
hirsutism and menstrual disturbances than a normal weight PCOS patient. This is 
because of the greater elevations in circulating free testosterone cause by the low 
levels of SHBG found in obese PCOS women. Thus when treated for anovulatory 
infertility, obese women need more fertility drugs (Aubuchon et al., 2012). The 
limitation of this study is the generalizability to obese women with PCOS while lean 
women with PCOS are yet to be investigated. 
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The hypothesis that PCOS induces obesity is based on the fact that the PCOS 
patients have disordered hunger and satiety signals caused by ghrelin irregularities 
and that the superimposed obesity promotes more weight gain. However, the 
energy expenditure is the same for a PCOS patient and a healthy one with the 
same BMI (Aubuchon et al., 2012). The study findings are limited to the fact of 
similarity in energy expenditure among PCOS and healthy women and this is not 
clearly seen among other studies. There is a limited data about the exact energy 
expenditure among PCOS women.  It is suggested to study the basal metabolic 
rate among PCOS and health women to detect the molecular activity in the 
metabolic rate.  
 
Obesity-induced PCOS 
It is hypothesized that the occurrence of PCOS is promoted by obesity in 
predisposed women (Aubuchon et al., 2012). Indeed, it has been shown that the 
disorder was encountered for some women after progressive weight gain while it 
should have been developed at menarche like it does for normally (Aubuchon et al., 
2012). Weight loss triggered the suppression of the symptoms: acne, menstrual 
cyclicity disturbances and derangement in hyperandrogenemia (Abuchon et al., 
2012). According to the study finding hirsutism remained after the change in the 
lifestyle but stopped progressing. In other words, if predisposed with PCOS the 
individual shows signs after weight gain. The study finding is limited to the 
phenotype with no further investigation about the biochemical level of androgens. It 
is suggested to study the effect of lifestyle modification and its relation to changes 
in biochemical and clinical levels of androgens. 
PCO (polycystic ovaries) may be present in a menopausal woman (24-32%) but 
does not mean that PCOS has developed. If weight gain occurs the signs and 
symptoms start showing. If no weight gain is observed PCO resolve with age. So 
the insulin resistance of obesity affects ovarian functions when PCO are present at 
the time of the weight gain. Further, long term longitudinal studies are needed to 
evaluate these correlations. 
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Perpetuation of Medical Risks of Metabolic Dysfunction 
Women with PCOS whether obese or not are more prevalent to develop chronic 
medical disorders (Aubuchon et al., 2012). The fat accumulation at the abdominal 
and visceral areas that happens in obese women with PCOS is correlated with 
insulin resistance, fat accumulation in the liver, reduced hepatic insulin clearance 
and induction of hepatic insulin resistance (Aubuchon et al., 2012). 
 
2.7.1 Metabolic Inflammation in PCOS 
Obesity and inflammation 
Obesity is shown to be a prooxidant, proinflammatory state (Weisberg et al., 2003). 
The circulating MNC migrate to the adipose stromal-vascular compartment after the 
adipocyte death by hypoxia. Then these MNC become resident macrophages 
which induces membrane-bound nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase activity (Groemping et al., 2003). In turn this oxidation produces 
ROS a superoxide that activates the transcription factor nuclear factor Kb that 
triggers inflammation by its translocation on the DNA promoting the transcription 
inflammatory mediators. These events promote insulin resistance and 
atherogenesis (Baldwin et al.,2001). 
The inflammation of the adipose tissue in obesity is superimposed with the PCOS 
symptoms. 
 
Chronic low-grade inflammation in PCOS 
Proinflammatory genes like those that encode TNFɑ and the type 2 TNF receptors 
that are the genetic basis for the chronic low-grade inflammation that is observed in 
PCOS. To test for chronic low-grade inflammation, it is necessary to measure CRP 
levels that should be normally less than 3 mg/L. However, only obese PCOS 
patients have more than 3 mg/L while fit PCOS individuals are in the norm 
(Aubuchon et al., 2012). 
 
Diet-Induced Inflammation in PCOS 
Dietary components as glucose and lipids are factors that contribute to a prooxidant 
inflammatory response (Aubuchon et al., 2012). In fact, ingesting glucose and lipids 
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increases in MNC-derived ROS generation and NFkB which are markers of 
oxidative stress and inflammation that eventually cause insulin resistance and 
atherogenesis. Promoting nutritional guidelines with health option sources of 
glucose and lipids can decrease the inflammatory response in PCOS women.  
The Relative Impact of Excess Abdominal Adiposity in PCOS 
Excess abdominal adiposity is present in PCOS patients regardless of weight 
however with a prevalence of 30% for fit individuals who trigger insulin resistance 
and atherogenesis. In normal-weight PCOS with no excess abdominal adiposity, 
the proinflammatory state is triggered by diet (glucose and lipid ingestion) (Carmina 
et al., 2007). 
Thus, abdominal adiposity is not related to insulin resistance in normal-weight 
women with PCOS which would support the hypothesis that the amount of inflamed 
excess adipose tissue present in the abdomen in the absence of increased body 
weight may be insufficient to promote systemic insulin resistance (Gonzale et al., 
2012). 
Obesity with adipose tissue accumulation can increase inflammation and thus 
metabolic and endocrine disorders. Obesity worsens PCOS presentation such as 
hyperandrogenia and anovulation. Dietary behavior can contribute to inflammation 
in PCOS pathophysiology, and insulin resistance is underpinned by the oxidative 
stress induced by diet. The alterations at the molecular level can be the lead to 
ovulatory dysfunction and insulin resistance. In light to what is known till now, there 
is no study that assessed the effect of standardized nutritional guidelines and the 
needed period to decrease the inflammatory state in PCOS neither at the molecular 
or public health level. 
 
2.8 Pharmaceutical therapy for PCOS 
Managing the symptoms of PCOS by pharmaceutical agents is an essential 
part of the treatment and enhances their reproductive profile. The decrease 
in knowledge about dietary intake can lead to obesity, excess weight gain 
and unhealthy lifestyle. 
Insulin-Sensitizing Drugs:  
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Hyperinsulinemia is a factor in disturbances of metabolic and reproductive 
functions in women; therefore, insulin-sensitizing drugs (ISDs) for women 
with PCOS have attracted a great deal of appeal over the past decade.  
Metformin 
Metformin is an FDA-approved biguanide used for the management of type 
2 diabetes mellitus. Many of its physiological effects are found however its 
mechanism of action is still unknown (Lord et al., 2003). It is proposed that 
it lowers fasting serum insulin levels in insulin-resistant states averting 
hypoglycemia. Additionally, it induces in the reduction of insulin 
requirements in insulin-dependent and non-insulin-dependent diabetes 
(Matthaei et al., 2000).  
Thiazolidinediones 
Thiazolidinediones (TZDs) gain their status of ISD through their role in 
refining insulin signaling and raising glucose uptake in adipose and muscle 
tissue mainly. The drug ,however, causes so many complications such as 
cardiovascular problems that it was removed from the market (Baillargeone 
et al.,2003). 
Role of Statins in PCOS Management 
Statin therapy is a new suggested way of treating PCOS patients. In vitro and 
clinical evidence of its efficacy in treating PCOS while also describing the risks and 
limitations it presents. Statin therapy appeared to also lower cholesterol levels but 
not the triglycerides levels while reducing cardiovascular risk. 
 
Medical Strategies for Achieving Ovulation 
Clomiphene Citrate (Clomid, Serophene) 
Being the first choice to treat infertility with PCOS patients, Clomiphene citrate (CC) 
is a selective estrogen receptor modulator (SERM). Its way of working would be to 
block the estrogen-mediated negative feedback on the hypothalamo-pituitary axis 
which results in an increased secretion of FSH from the anterior pituitary (Speroff et 
al.,2011) Then, follicular growth, development and selection to dominance are 
promoted. Tamoxifen can also be added to the treatment for the same effects. 
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From a chemical point of view, CC is a racemic mixture of en- and zu-clomiphene 
with the en-clomiphene being the more active component leading to fertility and the 
one with the shorter half-life while the zu-clomiphene accumulating in the tissues for 
months after treatments. 
From a general point of view, it can be said that CC mimics the physiological 
ovulatory cycle when administered in a way that minimizes the risk of ovarian 
hyperstimulation syndrome and multiple gestations. 
Aromatase inhibitors 
Aromatase inhibitors are an alternative treatment to CC therapy in case of 
resistance to CC. It is found in the ovarian granulosa cells of premenopausal 
women, adipose tissue, brain and skin fibroblasts (Pavone et al., 2013). 
Its mechanism consists of decrease the aromatization of androgens into estrogens 
which would result in the pituitary release of FSH thus stimulating follicular 
development (Casper t al., 2006). 
Gonadotropins 
PCOS patients who failed to show effective result after treatment for 4-6 ovulatory 
cycles of CC or AI undergo gonadotropin therapy (Lunenfeld et al.,2004). 
Gonadotropins for ovarian stimulation can be of a natural source from purified urine 
of postmenopausal women containing FSH and LH or from recombinant human 
FSH (rFSH). However, it comes with the negative effects of multiple pregnancies, 
OHSS and multi-follicular ovarian response which indicate that the treatment and 
the patient should be monitored closely. 
 
 
In Vitro Fertilization 
IVF is more successful than all the fertility treatments. However, it is costly and 
invasive. It is recommended for infertile women in general and more precisely for 
PCOS patients with tubal disease or severe male factor. 
Even if PCOS patients undergoing IVF manifest longer stimulation period, higher 
number of developing follicles and higher number of cumulus-oocyte complexes 
(COC), the pregnancy, miscarriage and live birth rates are the same when 
compared to a non-PCOS woman undergoing the same treatment as shown by 
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studies ( Heijnen et al., 2006). When the patient demonstrates limited ovarian 
response or exaggerated response (OHSS) the treatment is cut off. 
In vitro maturation 
The difference between IVF and IVM is that the oocytes in IVM are extracted 
immature then allowed to attain maturity in vitro over 24 to 48 h period. Since the 
first pregnancy through IVM in 1991 this technique has shown successful cases. 
When comparing it with IVF we can see that it has fewer side effects and less 
medication intake and monitoring. 
Mechanism: after a natural or induced menstruation a baseline ultrasound is done 
(1-3 days after menstruation) to retrieve information about the follicles and their 
morphology as well as baseline monitoring of FSH and E2. On cycle day 6-8 early 
selection of dominant follicles and assessment of endometrial thickness is done. 
Then between days 8-10 the physician retrieves the follicles whether mature or not. 
When the dominant follicle reaches an appropriate size it is injected with hCG to 
begin the maturation process while on the other hand the endometrial priming is 
being undergone by the patients through injections of E2 and then progesterone 
support ( Cha et al., 1991). 
The success rates have been shown to be less than with the IVF procedure which 
even with more risk of OHSS has made IVF the preferred alternative. 
Treatment of Hirsutism 
A definitive solution for hirsutism is not present, when it comes to treating it means 
to slow it growth and make it less coarse. And this is what a patient should know 
clearly before beginning treatment. 
 
Pharmacotherapy for managing hirsutism 
Managing hirsutism means lowering the circulating androgen levels and limiting its 
action on the hair follicle itself. This type of therapy takes time and do not show 
results in the short term (McAvey B et al., 2014). 
The treatment consists of oral contraceptive pills (OCPs) which suppresses 
steroidogenesis causing the lowering of androgen production. In response hepatic 
cells secrete (SHBG) which decreases testosterone in the blood. The use of OCP 
has positive effect on treating hirsutism and acne in general. The percentages of 
	
	
46	
	
improvement vary from patient to patient (McAvey et al., 2014).In addition to OCP, 
anti-androgens can also be used.  
 
2.9  Nutrition role in PCOS :Lifestyle modifications and Weight Loss 
High BMI ( > 30 kg/m2 ) in women has a negative effect on ovulation and fertility. 
Indeed, it is shown that the correlation of central obesity with fertility is stronger 
than the correlation of overall BMI and age with fertility. As a result, a weight loss 
would certainly result in improved chances of getting pregnant even after losing 5% 
of initial body weight (Sedighi et al., 2014). The limitation of this study is the 
generalizability of results with no further investigation about the role of weight loss 
on biochemical markers by incorporating a lifestyle modification and not an 
intervention study for a temporarily period.  
In the case of fertility treatments, obese women need to take more medication and 
may not have a response to the treatment (Sedighi et al., 2014). Thus, losing 
weight before treatment is necessary. Thus this study did not assess the role of 
fertility treatment with tailored weight loss guidelines for PCOS women. 
Treating PCOS means treating the medical conditions related to it like insulin 
resistance, hyperinsulinemia, obesity, dyslipidemia. However, in the cases of PCOS 
patients, lifestyle interventions can help with the symptoms of these conditions. 
Indeed, losing weight through hypocaloric diet and more importantly balancing the 
dietary macronutrients that can help with the disorder can altogether help restore 
insulin sensitivity and levels. 
  
 
Why Diet Makes a Difference in Women with PCOS 
The condition of insulin resistance consists of the inability of the insulin to regulate 
glucose levels in the blood which would in turn makes the pancreas secrete more 
insulin resulting in hyperinsulinemia. Moreover, in this state, glucose gets stored as 
fat in the body instead of being used to generate energy and the use of fatty acids 
is haltered. In the long run, the pancreatic beta cells that are secreting the excess 
insulin get impaired and stop functioning properly causing type 2 diabetes, a 
common symptom of PCOS (Hue et al., 2009). Promoting healthy food items with 
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45%-50% complex carbohydrates can decrease the risk of type 2 diabetes in 
PCOS women. It is suggested to promote healthy guidelines.  
Other occurrences in a woman with PCOS are weight gain, craving for 
carbohydrates (CHO) and sweets and symptoms of hypoglycemia like dizziness, 
fatigue, headaches etc. Patients with PCOS encounter what is called reactive 
hypoglycemia: following the ingestion of carbs, the individual suffering from 
hyperinsulinemia secretes a large amount of insulin in his/her blood which would 
trigger a precipitous drop in glucose levels in the blood after the ingestion which 
would once again make the person feel hungry and craving for sweets (Hue et 
al.,2009). This study didn’t assess the effect of complex carbohydrates to reactive 
hypoglycemia and thus this cannot be generalized to all PCOS women. Women 
with PCOS conditions should follow structured guidelines tailored o this population. 
For these reason, we can say that PCOS can be treated by a correct, appropriate 
diet. An appropriate diet would consist of: 
• The right amount of ( 1200-1500  average caloric intake per day for weight 
loss and 1800 calories average caloric intake for weight maintenance ) to 
take per day that is specific to each woman to help her lose weight or 
maintain it.  
• The right time intervals between meals (3-5 hours) that would inhibits the 
effects of reactive hypoglycemia. 
• Low glycemic index food and carbohydrates intake to lower insulin 
resistance and inflammation. 
• A balance between carbs, proteins and fats (45-50%, 20% and 30 % 
respectively). 
 
Dietary Carbohydrates 
Mainly, the dietary carbohydrates (CHO) are originated from plant compounds (fruit, 
vegetables) and are used as fuel for the body. However, milk is the only animal-
based food that contains CHO while other types of food like cookies, fruit juice, soft 
drinks, ice cream and candy bars contain unhealthy dietary CHO using high 
glycemic index CH such as white sugar. In fact, the more refined and processed the 
CHO is the faster is its digestion  and get absorbed in the stomach and intestines 
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thus, refined carbs have more effect on the glycemic response thus on insulin 
release. 
Glycemic Index of Foods 
By definition the glycemic index (GI) is the measurement of the increase in blood 
glucose after ingesting the food. Each food has a GI and the numerical range 
makes it easier to compare between the foods. A low GI (50-70) means that the 
blood glucose response is slow, more satiety thus helping control appetite and 
weight. A high dietary fiber content of the food often slows down its absorption thus 
its GI. A high GI (70-100) refers to foods that contain CHO that is broken down 
more easily and rapidly with a much more effect on blood glucose.  
A low-GI diet is adequate for a PCOS patients so that the insulin levels in the blood 
are regulated as well as the weight (Futterweit et al.,2006). Moreover, it is better 
than a high-GI diet for cardiovascular medical conditions. A study compared obese 
PCOS women who lost weight either with a low-GI diet or with a normal healthy diet 
with moderate GI: studies have shown that the women who followed the low-GI diet 
experienced a threefold greater improvement in whole body insulin sensitivity and 
menstrual cycle regularity (Mehrabani et al., 2012).  
Limitations of Using the Glycemic Index for PCOS Patients 
Several limitations present themselves when talking about PCOS patient following 
a low GI diet to treat the symptoms of PCOS: 
1. Often GI charts present the GI of the food if it is eaten alone, however when 
combining the food while eating the individuals GIs are not precise anymore 
because of their effects on each other. For example combining dietary fat or 
fiber with high GI components lowers the GI of the whole meal. Thus 
rendering the GI system ineffective.   
2. The physical state of the food (ripeness, cooking method, processing…) 
affects the GI. For example a brown banana has a higher GI than a yellow 
banana.  
3. Nutritional content of the food is not related to the GI. A low GI food may not 
bring healthy amounts of macronutrients and vice versa 
Guidelines for Dietary Carbohydrate 
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Since PCOS patients suffer from insulin resistance, obesity and likely type 2 
diabetes reducing but not eliminating carbohydrates is necessary. Indeed 
carbohydrates cannot be eliminated because they also carry nutritional benefits. 
Generally, a carbohydrate-moderate diet for PCOS patients should include 40% of 
the calories from carbs in order to optimize circulating glucose and insulin while 
providing the benefits on the weight of a low-GI diet (Stamets et al.,2004). 
Fruit and PCOS 
Fruits contain CHO in good amounts (15g of CHO in 60g calories) and no proteins 
or fat. It also contains other benefits coming from vitamins, fibers, antioxidants and 
minerals which are good for the well-being. Generally only two servings of 30g 
should be consumed in a diet for a woman with PCOS. The latter should also avoid 
fruit juices because of their high CHO content without the other benefits and 
canned fruits in heavy syrup (Krystock et al.,2014). 
Vegetables and PCOS 
Vegetables are divided into 2 categories: starchy and non-starchy (refer to table 3). 
However, both of them are abundant in vitamins, fibers, minerals and antioxidants. 
 
Table 3 The difference between non starchy and starchy food 
Non starchy Starchy 
• Example: lettuce, spinach, 
broccoli, green beans, onions, 
mushrooms… 
• Low in calories and CHO 
• High in fibers 
• Promote satiety 
• Can be typically consumed in 
unlimited amounts (at least 3 
servings in the diet) 
• Example: corn, peas, winter 
squashes, plantains, potatoes… 
• High content of CHO 
• Bigger impact on insulin levels 
• Lowering but not eliminating 
them from the diet 
 
 
 
Dietary Fiber and PCOS 
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Dietary fibers, the indigestible compound of plant-based food that passes through 
the gastrointestinal tract in its original form, contain lots of benefits. Food with high 
level ( > 50 g of fibers)of fibers contribute to the feeling of fullness and satiety, 
delays gastric emptying, demonstrated a cholesterol lowering effect because of the 
products of its bacterial digestion in the colon and more importantly it helps stabilize 
glucose levels in the blood and prevent reactive hypoglycemia( Krystcok et al., 
2014). 
Recommendations for Fiber and PCOS 
The general guideline for women with PCOS is to consume 25-30 g of fibers a day. 
Reading labels is a great help when in need of knowing if the food is a good source 
of fibers: >3g of fibers per serving is considered a good fiber source while >5g of 
fibers per serving is considered a high fiber source.  
Protein 
Proteins are very important for the body’s structure; they are the building blocks of 
many components of the human body such as tissues, neurotransmitters, tendons, 
antibodies… It is recommended that a woman with PCOS takes 25-30% of the total 
calories consumed from proteins and to choose lean instead of high-fat sources of 
protein. The benefits of protein are to help the person feel fuller while helping with 
the regulation of insulin in the blood since they promote the decrease of CHO 
consumption. 
Lipid Abnormalities in PCOS and Relevance of Dietary Fat 
Two-thirds of women with PCOS experience dyslipidemia linked to 
hyperandrogenemia, central obesity, insulin resistance and hyperinsulinemia. The 
derangements in the lipid profile of the PCOS patients are much related when 
comparing it with type 2 diabetes. They are characterized by high levels of LDL 
(>130 mg/dL) and triglycerides (> 160 mg/dL) and low levels of HDL (<50 mg/dL) 
(Yildirim et al., 2003). 
Triggered lipolysis and release of FFA into the blood are caused by 
hyperandrogenemia and hyperinsulinemia which trigger secretion of VLDL by the 
liver causing hypertriglyceridemia. 
 
Dietary Fat and PCOS 
	
	
51	
	
Fatty acids are the basic unit of fats and oils and their different combination creates 
the different types of fats we know. Any type of fat consumed contains 9 cal/g which 
is higher than the number for CHO or proteins. Regulating the fat intake in quantity 
and quality for a PCOS patient can help her enhance the absorption of fat-based 
vitamins as well as feel more satiated while gaining sexual benefits since sex 
hormone are fat-based. The different types of fats are: 
1. Monounsaturated fatty acids (MUFAs): consisting of certain vegetable oils 
like olive oil, vegetable oil, peanut oil; they can be a great help to regulate 
the cholesterol and insulin levels as well as aid in blood glucose control. 
2. Polyunsaturated fatty acids (PUFAs): found in almonds, cashews, avocados 
fish and seafood, they are essential to human beings and can’t be 
manufactured in vivo. Omega-3 and omega-6 are types of PUFAs. 
• Omega-3 fats: found in fatty cold-water fish, seeds, nuts, beans and 
leafy vegetable, they have anti-inflammatory functions when 
associated with low-grade systemic inflammation which is a great help 
for PCOS patients. Additionally, consuming omega-3 fats has other 
benefits on the bodily functions when it comes to cardiovascular, 
brain, mood and immune function. 
• Omega-6 fats: found in animal fats, bakery goods; they contribute to 
systemic inflammation. Their high consumption in western diet is bad 
for the health especially for PCOS patients. Thus their intake should 
be decreased while increasing omegs-3 fats.  
3. Saturated fatty acids: found in high-fats cuts of meat, whole milk dairy 
products and chicken skin, coconut oil and palm oil; they raise cholesterol 
levels. It is recommended to be taken for less than 10% of total calories 
consumed per day. 
4. Trans fatty acids: Processed vegetable oils to become semisolid at room 
temperature; they damage body tissues and compromise immune functions 
while promoting inflammation, various cancers and promoting coronary 
disease by raising LDL levels and lowering HDL levels( Katan et al.,1995). 
 
Dietary Calcium 
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Having the effect of lowering blood pressure, skeletal health and enhancing insulin 
signaling, calcium is a necessary dietary component for PCOS patients. Calcium 
can be found mainly in dairy foods. 
Dietary Sodium and PCOS 
Sodium is found generally in most foods we consume and is often added to them. 
Its excess can worsen the predisposition of PCOS patients to have premature 
atherosclerosis and propensity of endothelial dysfunction (Dittas et al.,2007). 
Caloric needs and PCOS 
Harris Benedict equation is a method to calculate the individual’s calorie needs in 
function of age, sex, weight, body composition and individual’s own metabolism. 
Harris Benedict equation determines the BMR (1) which represents how many 
calories and individual burns at rest, and based on that and on the individual’s 
activity level (2) the total allowed calories is determined. 
1. BMR=655+(4.35×weight in pounds)+(4.7×height in inches)-(4.7×age in 
years) 
2. Sedentary : BMR×1.2 
Lightly active: BMR×1.375 
Moderately active: BMR×1.55 
Very active: BMR×1.725 
Extra active: BMR×1.9 
 
Behavior Modification in PCOS Management 
Snacking and Optimal Meal patterns 
Ideally, a person with PCOS should eat small snacks spaced every 2 to 4h while 
consuming breakfast 1h after waking up. The snacks should be around 60-100 
calories containing 0-20 g of CHO, 0-7g of fat and a 2-8g of proteins. This pattern 
will help reduce cravings and fight the effect of reactive hypoglycemia. 
Importance of Exercise for PCOS Management 
The diet for PCOS women should be accompanied by regular exercising for more 
weight management, reducing insulin levels, optimizing lipid profile and 
improvement of insulin sensitivity. Additionally to physical benefits, mental health is 
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also benefited: working out boosts self-esteem, regulate mood swings and lower 
depression and anxiety.  
Exercise Recommendations 
It is recommended to work out more than 150 minutes a week of moderate-intensity 
exercise or 75 minutes of intense exercise (Krystock et al.,2014). 
 
2.10 Current International interventions  
International nutrition and weight loss intervention in PCOS have high potentials of 
alleviating the syndrome’s symptoms and thus the disease itself. Everyday nutrition 
is a crucial aspect of healthy living, and its intervention in PCOS can improve its 
clinical spectrum.  The elements of a diet have proven to be critical for the 
development and maturation of the ovarian follicles (Huijgen et al, 2015). The study 
findings didn’t define the needs and the forbidden items needed for ovarian follicle 
maturation. There is still a lack in the literature about the nutraceutical food 
components need to ovarian follicles development.  Lifestyle modification with 
weight loss for overweight/obese and maintain weight for lean PCOS women using 
nutritional guidelines adapted to the PCOS population  provides healthy ovules and 
decreases both the risk of PCOS and manages its current treatment. Consequently, 
deficiencies in the diet link to improper programming of the ovarian follicles and 
contribute to the severity of PCOS phenotype. 
Huijgen and his colleagues (2015) conducted a study to determine the association 
of diet inadequacies with the severity of PCOS. Their analysis showed a positive 
correlation such that an inadequate diet (measured using the PDR score) was 
significantly higher in PCOS than in controls (PDR score 3.7 vs. 3.5; p = 0.017), 
further linked to greater risks of the hyperandrogenic phenotype. However, the 
inadequacy in dietary behavior is different between obese and lean PCOS women. 
This should be further confirmed by a study assessing the nutritional behavior for 
different weight scale PCOS women. In addition to this, Rondanelli and her 
colleagues (2014) coordinated another study aiming at evaluating the nutritional 
correlates of PCOS and the optimum diet for these abnormalities. The study 
showed that PCOS patients exhibit instability in adipokines (adiponectin, leptin, 
visfatin) production and in omega6/omega3 PUFA ratio. This means that lifestyle 
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changes are the basis of PCOS treatment. The diet therapy includes a set of goals 
– insulin resistance modifications, adipokines secretion and reproductive function. 
All of these can be achieved by lowering the sugar consumption (lower glycemic 
index), portioning the food intake into small and frequent meals, and either 
increasing the fish intake to about 4 times a week, or using   omega3 PUFA 
supplements. Vitamin D and chromium supplementations are also necessary in low 
serum level cases. This confirms that a lifestyle modification is the optimum choice 
for PCOS women rather than an interventional weight management for a defined 
period. 
Not only can a balanced diet alleviate the symptoms of PCOS, but also weight loss, 
in overweight and obese women, improve their metabolic, reproductive health and 
regenerate fertility (Milone et al.,2016). Thus, weight loss is a type of lifestyle 
intervention, similar to the nutrient intake. In a recent study carried out by Legro and 
his associates, they examined differences in pregnancy outcomes among PCOS 
patients that used birth pills, and a second group of PCOS overweight or obese 
women that underwent lifestyle changes. Among the 49 women assigned to the 
birth control intervention, five gave birth compared to the 50 women in the lifestyle 
intervention group who delivered 13 babies (WHW, 2015).The most favorable 
weight loss diet aims at reducing excess body fat percentage, whilst maintaining 
the lean mass, altogether reducing the adipokines and the fatty acids released by 
the adipose (Kasim-Karakas et al, 2009). This has been seen to be achieved by 
following a low-carbohydrate (< 40 % total carbohydrates)/high-protein diet (> 30 % 
total protein), decreasing excess body fat (Phy et al.,2015). However, this study has 
different limitations such as using the elimination diet behavior by reducing 
carbohydrates and increasing protein intake. Elimination diet is not recommended 
for PCOS women who need a lifestyle nutritional management and not an 
intervention for a short period of time. A lifestyle modification should not eliminate 
any food component in order to be suitable for different PCOS women coming from 
different socio economic background. Any elimination of food group or reduction 
can thus reduce the vitamins and minerals intake and lead to deficiencies. It is 
suggested to have all food components with tailored energy intake. The study 
carried out by Kasim-Karakas showed that a hypocaloric diet, with protein 
	
	
55	
	
supplements caused greater weight loss and fat mass loss compared to a diet 
supplemented with simple sugars (Kasim-Karakas et al, 2009). The study method 
used elimination diet. The findings of this study confirmed weight loss but used an 
elimination diet that can't be incorporated into a lifestyle modification. This suggests 
filling the gap in the literature where no lifestyle modification nutritional guidelines 
are proposed and well assessed on the PCOS population. 
Overall, PCOS remains a syndrome whose first line intervention remain the 
management of lifestyle, including a proper balanced diet, leading to weight loss in 
case of overweight or obesity. 
 
2.11 Nutrition problems in PCOS 
Obesity remains one of the most encountered nutrition problems worldwide. 
However, PCOS and obesity are seen to share a cause-effect relationship, where 
some studies indicate that PCOS women have a high tendency to develop nutrition 
problems of obesity and high levels of carbohydrate cravings (Jeanes et al.,2017). 
The findings of this study are limited to the fact that PCOS women have high 
tendency to obesity, but Jeanes and his colleagues didn’t study the effect of obesity 
itself on the onset of PCOS in controls who are not receiving any nutritional 
management.  
Many studies have been developed to show that PCOS women are inclined to 
becoming obese. Worldwide numbers estimate between 38% and 88 % of the 
PCOS patients suffering from obesity (Hoeger et al, 2012). In Mumbai for example, 
70-75% of the PCOS women are obese (Sen et al., 2014). Recently, a study was 
conducted, including 62 PCOS women and 23 control women with matching body 
weight. It was observed that all PCOS women, compared to the controls, had 
decreased basal metabolic rates (Hoeger et al, 2012). BMR is a representative of 
the energy expenditure while at rest, and its low values indicate a higher inclination 
towards weight accumulation. Thus, with low BMRs, women are more likely to 
become obese. In Lebanon there is no studies about the weight accumulation in 
PCOS women who represents a certain population with high social concerns about 
infertility and family. 
	
	
56	
	
It is clearly understood that PCOS and obesity are linked in one way or another. To 
understand the link, it is important to note that androgens have an important role in 
determining the composition of the body, where women normally accumulate more 
fat in the lower parts of the body. However, women with PCOS were shown to be 
more likely to develop upper body fat, as demonstrated by the high waist to hip ratio 
compare to same BMI controls (Sam, 2007). Thus, studies, although many remain 
contradictory prove that obesity in women is due to PCOS and is referred to as a 
nutrition problem that comes with it. It is yet needed to be investigated further about 
the link between obesity, PCOS and weight gain. 
To understand why some PCOS women face problems of obesity, it is important to 
note that the polycystic ovary syndrome is associated with the inability of the body 
to use insulin. This leads to the accumulation of insulin and glucose in the 
bloodstream, also referred to as insulin resistance. Due to high levels of insulin, 
large quantities of the male androgen hormone are secreted, leading to hirsutism, 
acne, irregular periods, and weight gain (Ehrman et al.,2005). Consequently, the 
extensive weight gain leads to obesity. An alternative explanation for the 
fundamental system, in the development of obesity in PCOS women is a 
combination of genetic predisposition to obesity with an obese inducing 
environment that includes a poor diet and lack of exercise (Moran et al.,2015). 
Thus, the hormones play a role in the weight gain, but women who are predisposed 
to accumulating fat, are more likely to develop obesity with their PCOS. 
In addition to all this, women with PCOS are known to suffer from excessive 
carbohydrate cravings. This can be due to the insulin resistance found in all PCOS 
women. The inability of the body cells to take in the glucose for muscle energy 
causes the body to constantly require more food, namely carbohydrates. The 
cravings therefore do not help with the aforementioned obesity problem, increasing 
the chances of weight gain, with eventual obesity, even more. 
It is crucial to note however, that obesity can worsen both the clinical and endocrine 
features of PCOS, furthermore it results in the prevalence of irregular menses and 
menorrhagia, as well as increased serum androgen concentrations. Obesity 
additionally leads to a significant reduced response to ovulation induction regimens 
and reduces the chances of fertility treatments to succeed (Hoeger et al, 2012). All 
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the consequences discussed add to the already established complications of PCOS 
and thus understanding the connection between the two complex diseases- obesity 
and PCOS- aids in founding an appropriate treatment that targets the initial problem 
of weight gain, which has eventually lead to further complications. 
 
2.12 Role of nutrition as interventional prime line to PCOS 
To reverse the insulin resistance, the body needs to become re-sensitized to its 
own insulin. To do so, one must follow a diet with very few to no simple 
carbohydrates. If the amount of glucose in the bloodstream exceeds the body's 
daily needs, the cells can no longer absorb it. The blood glucose stays high and to 
try and bring it down, the pancreas secretes even more insulin Therefore, weight 
loss, by a low carbohydrate diet and physical exercise to burn fat, can restore the 
insulin sensitivity of the cells and tackle the other problems underlying insulin 
resistance, such as the factors of the metabolic syndrome affecting women with 
PCOS. 
Losing the excess weight, by using a low glycemic index diet for example, will help 
recover the normal functioning of the cells, thus restoring insulin sensitivity. As a 
result, there would be no excessive glucose in the blood stream that could lead to 
high LDL cholesterol levels and blood pressure, furthermore reducing cravings and 
weight gain brought about by insulin resistance. With improved aspects of the 
metabolic syndrome, the risks of cardiovascular disease, stroke and diabetes are 
exponentially reduced. 
Studies have shown that it takes a small amount of weight loss, as much as 5-10% 
of the initial body weight to see improvements in  both the mild symptoms of PCOS 
as well as the risk factors mentioned previously (Moran et al.,2006). With a reduced 
BMI, the normal functioning of the ovaries can be reestablished, as well as normal 
hormone production. In PCOS patients, the androgen male hormones are 
increasingly secreted, due to insulin resistance, leading to acne, hirsutism, irregular 
periods and weight gain. With regular hormonal functioning, as a result of weight 
loss, the ovulation is restored, the menstrual cycle is regulated, fertility is improved, 
and the female self-esteem is boosted (Moran et al.,2006). Thus, weight loss not 
only helps with lethal risk factors but also with the symptoms of PCOS of excessive 
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hair growth, acne, and scalp hair loss. Moran and her colleagues concluded that 5-
10% is sufficient to improve the PCOS symptoms following a structured weight loss 
plan. However, previous data have shown that weight loss can decrease the 
inflammatory states. Thus, Moran's study findings are limited and a further 
investigation need to be added to the scientific literature about the effect of 
nutritional guidelines on the long run for PCOS women. The limitations of Moran 
and her colleagues are the structured interventional approach to PCOS women and 
the short period of times used. 
Weight loss thus remains the number one solution for the problems encountered in 
PCOS and it is considered as a treatment for the symptoms of the syndrome. 
Combined with physical exercise, a balanced, healthy diet reduces the lethal risk 
factors associated with the metabolic syndrome and plays a major role in PCOS 
(Palomba et al., 2010). 
 
2.13 Nutritional Intake of Women with PCOS Worldwide and in the Middle East 
The nutritional intake and diet of women with PCOS is an issue that is commonly 
studied since polycystic ovary syndrome is very common worldwide. There are 
several takes and perspectives considering the different regions of the world as well 
as the common nutritional trend that comes along with the disease itself. 
A study looked at PCOS patients and whether they display altered dietary intakes 
and eating behaviors compared to controls (Larsson et al., 2016). It showed 
compliance with several other studies that BMI of women with PCOS is higher that 
than of women without PCOS (Larsson et al., 2016). However, that could have 
been explained by several contributing factors since PCOS (polycystic ovaries 
syndrome) is characterized by numerous symptoms. However, Larsson and 
colleagues didn’t compare the nutritional intake between obese and lean PCOS 
women sharing the same symptoms in order to further investigate the difference of 
intake and energy expenditure among them. A large study is needed to assess the 
difference in caloric intake among all weight scale range of PCOS women. 
One that was commonly found in several studies is hyperinsulinemia and insulin 
resistance in both overweight and lean women with PCOS. This might push women 
to weight gain due to insulin’s effects in addition to changes in energy usage and 
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diet (Wright et al., 2004). The hyperandrogenism associated with PCOS can lead to 
more carbohydrate cravings and a more carbohydrate rich diet (Lindén Hirschberg 
et al., 2004). This study showed that intake of glycemic index foods is higher 
among PCOS than non-PCOS (Lindén Hirschberg et al., 2004).  There is a large 
gap in the literature about the intake of food in the Middle Eastern society and this 
is needed to be further investigated. 
In addition, it was also shown that a decreased (1232 versus 1964 pmol x min/l) 
secretion of CCK and the fluctuations in appetite regulation is associated with the 
increased (2.3 versus 1.4 nmol/l) testosterone which all aid in the increased 
occurrence of binge eating and weight gain in women with PCOS (Lindén 
Hirschberg et al., 2004). 
A study that took place in turkey involving 94 adolescent women with or without 
PCOS to compare body dissatisfaction, eating attitudes and body esteem scales in 
both groups (Karacan et al., 2014). It showed that the scores on these tests of the 
group with PCOS are not significantly higher than patients without PCOS (Karacan 
et al., 2014).  
Another study that involved 210 women with PCOS in the UK was based on a 7-
day-estimated food and activity diary and questionnaire (Barr et al., 2011). It 
showed that women with PCOS showed a higher proportion of energy from fat (38 
%) and a lower proportion of energy from carbohydrates (Barr et al., 2011). Another 
study that took place in the Middle East was a comparative study of 65 women with 
PCOS and without PCOS in Iran (Sedighi et al., 2014). It showed that women with 
PCOS have a different lifestyle and food habits than women without PCOS in the 
sense of paying more attention to nutrition and exercise (Sedighi et al., 2014). 
In conclusion, a general trend in the eating habits and nutritional intake of women 
with PCOS worldwide was found, since there are consequences of the disease that 
link women from different countries to one another up to a certain extent. On the 
other hand, how the women deal with the weight gain and diets is also strongly 
affected by the personal, cultural and environmental factors that vary from one case 
to the other. By comparing all the previous study we conclude one point and it is the 
high caloric intake among PCOS women and this generalized as no study have 
investigated the highest food component intake using a food frequency 
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questionnaire adapted to their cultural regime. A more precise study is needed to 
use a more precise methodology and compare the food frequency questionnaire to 
their 24 hour recalls as part of control over the analysis. 
 
2.14 Energy Requirement of women with PCOS 
PCOS is a disease that affects the metabolism among several other effects; 
however, the metabolism is what affects energy production and requirements of 
women with PCOS. 
In a study that took place in 2015, the BMI of women with PCOS is higher (28.5 
versus 24.6 kg/m2) than the BMI of women without PCOS that is congruent with 
most of the studies addressing the same topic (Larsson et al., 2016).  The resting 
metabolic rate shows whether women with PCOS have a higher energy 
requirement due to their metabolic rate or not. The same study has shown that the 
resting metabolic rate is the same in women with or without PCOS after taking age 
and BMI into consideration; however, the respiratory exchange ratio was higher in 
women with PCOS in comparison to the controls (Larsson et al., 2016).  In addition 
there were discrepancies in the sources of energy used by women with PCOS and 
without; such that a higher energy percentage was obtained from carbohydrates 
(49 % versus 44 %) while a lower energy percentage of alcohol (2.4 % versus 
4.1%) was also obtained (Larsson et al., 2016).  
There are some defects of endocrine origins associated with PCOS such as insulin 
resistance, hyperinsulinemia and metabolic syndrome. Other effects observed to be 
related to PCOS, is the increased leptin levels in women with PCOS. This showed 
to be related to weight loss since studies have shown that with weight loss of 
women with PCOS, came as a decrease in the leptin levels (Rondanelli et al., 
2014).The previous studies used small sample size. However, these findings are 
still general and the discrepancies between hyperinsulinemia and increased leptin 
level facts should be concluded by a large sample size study. 
 
2.15 The European Perspective on Weight Loss in PCOS 
One of the main indicators of PCOS is usually weight gain. There is a degree of 
variance in diagnosis of PCOS in different countries of the world; however, 
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according to the European Society for Human Reproduction and 
Embryology/American Society for Reproductive Medicine criteria, the occurrence of 
PCOS can be up to 15 to 20 percent (Sirmans and Pate, 2013) 
It is crucial for weight loss to be included in the treatment strategies of PCOS. 
Physicians believe that it is involved in a vicious cycle that starts with androgen 
excess leading to abdominal fat deposition, which then triggers the insulin 
resistance and eventually hyperinsulinemia and consequently further increases 
ovarian androgen secretion (Harrison et al., 2011). 
The European perspective aim on weight loss for women with PCOS suffering from 
obesity focuses mainly on lifestyle change, which includes exercise and diet 
(Conway et al., 2014). Diet and exercise aimed at weight loss is a very beneficial 
treatment for PCOS and has shown promising results by a follow up study involving 
obese women with PCOS following lifestyle programs of 1200-1400 kcal/day diet 
for the duration of 6 months as well as physical activity (Pasquali et al., 2011).  
Although there is a lot of variety in how women responded to the weight loss; more 
than one third of the women may have experienced full recovery from symptoms of 
PCOS (Pasquali et al., 2011). It was also shown that weight loss also aids in 
ovulation and aids in overcoming the reproductive adversaries imposed by PCOS 
(Consensus on infertility treatment related to polycystic ovary syndrome, 2008)( 
Tarlatzis  et al., 2008). 
Another mean for weight loss associated with obese and especially morbidly obese 
women with PCOS is bariatric surgery (Conway et al., 2014). It proved to be an 
efficient mean for weight loss as well as reversing some of the effects of PCOS in 
morbidly obese patients (Conway et al., 2014). Studies have shown that bariatric 
surgery can reverse some of the metabolic syndrome as well as provide 
reproductive assistance since weight loss is strongly linked to PCOS and hence 
might be quite therapeutic (Legro et al., 2012). Bariatric surgery also showed to 
help with other symptoms of PCOS through bringing back the hypothalamic–
pituitary axis, decreasing cardiovascular risk and even improving pregnancy 
outcomes (Malik et al., 2012).  However, the previous studies ' conclusion is crucial 
to many PCOS women where bariatric surgery can decrease the mineral and 
vitamins absorption. Bariatric surgery could be a lifetime solution for weight loss for 
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many obese PCOS cases. But this cannot be generalized and thus bariatric surgery 
cannot be a first time treatment to obesity in PCOS rather a lifestyle modification 
should be proposed with infertility treatment. 
 
2.16 The right diet for PCOS 
PCOS is a disease of over-nutrition and a primary management should focus on a 
nutritional approach. 
An ideal diet should prevent nutritional deficiencies by providing adequate nutrients 
and energy for human development and reproduction. It should, also motivate the 
well-being and longevity by reducing the risks of diet-related chronic illnesses. 
In the short term, the nutritional management of PCOS should focus on weight loss, 
and improvement of symptoms. In the long term, nutritional management must 
address the augmented risk of type 2 diabetes, CVD and certain cancers that are 
associated with PCOS. Figure 1 illustrates the process of nutritional intervention 
helping improving PCOS. 
 
 
 
Figure 1  The effect of diet on PCOS 
For a better response, the dietary management is preferred to be a combination of 
limiting the intake of a certain macronutrient and increasing physical activity. 
Here is a literature review of the recommended dietary guidelines that this project 
will follow: 
Calorie needs and restrictions for PCOS women 
Healthy	food	
choice(whole	
grains	,	low	
trans-fat	high	
fruits	and	
vegetavles	)	
and	physical	
activity
Decrease	fat	
mass	(to	25	%	
of	the	total	
body	weight)	
and	decrease	
androgen	
levels
Improving	
PCOS	and	
health	status	
regarding		
metabolic	
syndrome	
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PCOS patients should follow a hypocaloric diet including all the macronutrients for 
a short-term and long-term effects. Restricting one macronutrient could affect the 
long-term commitment to keep weight in the ideal range.  
To study the calorie needs, it is possible to check the individual calories intake 
allowance. Daily women’s calorie allowance differs according to body weight in 
relation to age and physical activity. Dieticians recommend between 1200 calories 
to 2000 calories. A daily caloric decrease of 500 Kcal/day causes an average 
weight loss of 0.5 kg/week, and a caloric decrease of 1000 kcal/day causes an 
average weight loss of1 kg/week. 
Fat intake 
Fat is the most energetic dense macronutrient with 9 kcal/g compared to 4 kcal/g 
for proteins and carbohydrates. Hyperinsulinemic individuals have higher capacity 
to store fat in their body. Not all kinds of fat have the same effect. When consumed 
instead of carbohydrates or unsaturated fats (commonly found in non-hydrogenated 
vegetable oils), trans-unsaturated fats (commonly found in commercially fried and 
baked products) increase the risk of ovulatory infertility. The consumption of trans-
fats instead of other macronutrients has been associated with greater insulin 
resistance, and risk of type 2 diabetes (Chavarro et al, 2007). Several studies have 
shown that excess fat intake is linked to insulin resistance (Vessby et al.,2001). 
Subjects with less than 37% of fat intake, and those with moderate consumption of 
unsaturated fatty acids, have improved insulin sensitivity (Riccardi and Rivellesse, 
2000).  
Although many studies showed the beneficial effects of polyunsaturated fatty acids 
(eicosapentaenoic acid and docosahexaeonic acid are present mainly in fish oil) on 
diabetic patients, no evidence is found about their effect on PCOS patients 
(McAuley et al, 2005). 
Overall, dietary fat should account for no more than 30% of the calorie content of 
the diet, with a maximum of 10% of calories coming from saturated fat. The 
remainder of the fat content should be as a balanced mixture of unsaturated fat 
including cooking oils and spreads (Norman et al, 2004). 
Carbohydrate intake 
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Excluding carbohydrates is not efficient, but consuming limited quantities and 
replacing white carbohydrates sources (as white bread) with multi-cereals bread can 
cause an excellent shift to a healthy regimen as fibers inclusion is beneficial. 
A low glycemic index (GI) diet may provide the greatest benefit for women with PCOS 
(Kennedy et al, 2005) where it is linked to enhanced insulin sensitivity, reduced 
postprandial hyperglycemia, increased HDL, and decreased triglycerides. Increased 
glycemic load (amount of carbohydrates taken multiplied by GI), caused by high GI 
food, and increases the risk for type 2 diabetes (Kennedy et al, 2005). Glycemic load 
can be reduced by following an isocaloric diet that replaces high GI foods with low 
ones. Following a low carbohydrate diet up to 6 months, people who have or are at 
risk of type 2 diabetes have shown to lose weight (Samaha et al, 2003). At the 
beginning, a carbohydrate restricted diet is essentially helpful but not effective if 
severe restriction is followed. On the long term, low-carbohydrate diet is associated 
with harmful effects on the lipid profile and should be used for short-term for better 
weight loss achievement (Moran et al, 2003).In general, carbohydrates should be 
50% of the daily caloric intake. 
Protein intake 
Recent controversial studies have shown that high intake of protein leads to 
improved glucose and insulin responses. Proteins increase satiety and postprandial 
thermogenesis and lowers abdominal fat (Vessby et al, 2001). Moderate protein 
intake is essential to protect lean body tissue. Proteins should account for 20% of a 
diet’s calories (Moran et al, 2003) consumed from lean meat sources and 
vegetarian sources such as beans which provide the patient with extra benefit from 
fiber contents. 
Note that a high protein low carbohydrates diet is a type of weight loss plan that 
emphasizes consumption of high-protein-containing food. High-protein low-
carbohydrate diet (for 1 month) was compared to low-protein high-carbohydrate diet 
(for 3 months) in PCOS patients. The comparison reported no significant 
differences in term of weight loss(Brehm et al, 2003).Another study showed that 
high protein diet resulted in minor differential improvements for high density 
lipoprotein (HDL-C, TC/HDL-C), AUC for glucose, and Femoro-AcetabularImp 
ingement (FAI) (Moran et al, 2003). 
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Eating behavior 
Eating behavior is an important issue that is generally not well addressed, and 
more irregular eating behavior was noticed with more consumption of energy dense 
food. Studies have shown that regular meal consumption increases the 
postprandial energy expenditure, decreases calorie intake, and develops insulin 
sensitivity (Harnack et al, 2000). 
Breakfast consumption is associated with less energy intake and improved insulin 
sensitivity (Kerver et al, 2006). It is also linked to weight gain and obesity. In 
general, low frequency of major eating meals is linked to high fat mass and leptin 
levels (Farshchi et al, 2004). Yet, no detailed studies regarding eating behavior in 
PCOS patients were noted.  
In addition, a high intake of fruits, vegetables and whole grains shown to protect 
against CVD, diabetes and cancer. 
Physical activity 
Patients who exercise have increased lean body tissue and lower body fat; thus 
they have increased resting energetic expenditure which causes a higher metabolic 
function in women with PCOS (Jakcic et al, 2003).The recommendation for a 
healthy lifestyle is a 30 min of physical activity for at least 5 days weekly (Jeffery et 
al, 2003). Some studies showed that moderate-to-high intensity exercise for 60-75 
min has a long-term greater effect on weight loss. Several exercise options could 
be taken into consideration such as aerobic exercise, endurance exercise, and 
resistance training (increases muscle and influence body mass and composition 
leading to an increase in the metabolic rate). 
In conclusion, the best nutritional recommendation for PCOS patients is to follow a 
low caloric diet including all the macronutrients with emphasis on healthy choice 
and increasing physical activity. A combination of moderately calorie restriction with 
limited fat intake in parallel with physical activity is the best for achieving weight 
loss (Stern et al, 2004) 
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2.17 Rationale: The benefits of nutritional education in treating PCOS in 
Lebanon. 
Several studies have been carried out  to assess the benefits of LSM and the 
intervention of nutrition  program on PCOS outcomes that include IR, ovulation 
induction, hyperandrogenism, fertility, menstrual frequency, and lipid profile 
(Karimzadeh et al.,2010 ; Hoeger et al.,2008 ; Tang et al.,2006). Furthermore, 
studies conducted on overweight and obese PCOS women have shown that weight 
loss, exercise and LSM are effective treatment methods (Legro et al., 2013 ; Vause 
et al.,2010). 
Despite the fact that several studies have shown the role of adequate nutrition and 
exercise in enhancing the success of PCOS treatment, such methods of treatment 
are still far from application in Lebanon due to the heavy reliance of physicians in 
this field on medications. 
It is fairly common in Lebanon to find that women who suffer from PCOS are also 
obese (BMI over 30 Kg/m2). However, the nutritional approach in treating these 
patients is barely in action in Lebanon. A large study is needed to shed light on the 
vitality of introducing the nutritional aspect of PCOS treatment, and to study the 
influence of diet modification and nutritional counseling/education on PCOS 
outcomes. There is a limited literature in Lebanon about PCOS assessing the effect 
of short-term and long-term nutritional interventions on their metabolic ad endocrine 
features. 
 
2.18 Research variables 
• Nutritional investigations included FFQ and 24-hour recall (two 24-hours 
recall). Nutritional counseling was documented to exhibit operative 
commitment to study. Nutritional screening was carried out in a simple and 
non-invasive way primarily to evaluate the nutritional status. A range of both 
subjective and objective nutritional screening tools such as 24 hour dietary 
recall, food frequency questionnaire (FFQ) will be used. FFQ survey 
provides detailed data regarding eating patterns and history (DeBruyne et 
al., 2011). 
	
	
67	
	
• Physical activity was assessed using the IMS- physical activity survey that 
permitted the study of the change in physical activity and behavior in PCOS 
patients. 
• The anthropometric measurements taken were mainly weight, height, waist 
circumference, hip circumference and body composition analysis using ELG 
3rd generation. This provides information on body analysis and obesity level 
information from which an individual plan of nutritional care can be devised 
and monitored. 
• Hypertension measurements were taken to monitor the effect of healthy food 
choices on pre-hypertensive patients in PCOS women participant, for 
hypertension is a PCOS feature. 
• Biochemical indicators: (Vitamin D, insulin resistance, blood glucose FBS, 
HDL-C, LDL-C, total cholesterol, triglyceride level, total testosterone, insulin 
resistance) in order to study the benefit and efficiency of the nutritional 
education/counseling on PCOS biochemical indicators. Refer to table 4 
about the biochemical parameters and their cut-offs. 
• Other PCOS conditions reported: regularities of menstrual cycle (seen by 
pregnancy onset, ovulation, and fertility rate) 
• Hirsutism was measured using the Ferriman-Gallewey score. 
• Psychological assessment using BDI-II. This is a very widely used scale and 
it is one of the oldest containing 21 item self-report measure of cognitive, 
behavioral, affective, and somatic components of depression, developed 
based on DSM-IV criteria of depression. Items on the BDI are rated on a 4 
point type scale ranging from 0 to 3. Total scores are obtained by summing 
the highest ratings on each of the 21 items and may range from 0 to 69 with 
higher scores indicating symptom severity. The BDI has excellent 1 week 
test-retest reliability (r=0.93, P<0.001) and internal consistency (α=0.91). 
Convergent validity for the BDI is satisfactory and was established through 
examining the correlation of its’ scores with scores on the Revised Hamilton 
Psychiatric Rating Scale for Depression (r=0.71) (Beck et al., 1996).GAD-7 
is another scale that will be used to score for anxiety in PCOS patient, a 
short screening tool and validated. 
	
	
68	
	
Each of the discussed variables was monitored and studied during the pilot and 
larger scale project at the beginning of the intervention, 3 months and 6 months 
after the intervention. 
Table 4 : Research parameters and their cut- offs  
Parameter Unit Normal 
Ranges 
Rationale 
Vitamin D   ng/ml 30-74 (1) 
 
“Vitamin D plays a physiologic role in 
reproduction including ovarian follicular 
development and luteinization. Low 
Vitamin D levels may exacerbate the 
symptoms of PCOS, including insulin 
resistance, ovulatory, menstrual 
irregularities, infertility, hyper-
androgenism, obesity and elevate the risk 
of cardiovascular diseases”( Lin et 
al.,2015). 
Insulin μU/mL < 25 
μU/mL 
Women with polycystic ovary syndrome 
(PCOS) are profoundly insulin resistant, 
and the resultant hyperinsulinemia 
exacerbates the reproductive 
abnormalities of the syndrome. Agents 
that ameliorate insulin resistance and 
reduce circulating insulin levels could 
provide a new therapeutic modality for 
PCOS (Legro et al.,1998).  
Blood glucose mg/dL 126(4) Women with polycystic ovary syndrome 
(PCOS) often develop type 2 diabetes 
mellitus (T2DM) (Boudreaux et al., 2006).    
FBS mg/dL 70 to Fasting blood glucose, along with insulin 
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99(1)  levels can be used to assess insulin 
resistance which is common in PCOS 
women (Carmina et al.,2004). 
HDL-C  mg/dL 50-60(1) Usually, women with PCOS, lower HDL-
cholesterol than their non-PCOS 
counterparts even if they are not obese 
(Wild et al.,2012).  
LDL-C mg/dL <130(1) PCOS patients had very low LDL 
compared to non-PCOS patients (Wild et 
al., 1985).  
Total Cholesterol mg/dL <200(1) Commonly, women with PCOS 
dyslipidemia which leads to abnormal 
Total Cholesterol levels (Wild et al., 
2012). .  
Triglyceride  mg/dL 40-160(1)  On average, women with PCOS were 
higher triglyceride than their non-PCOS 
counterparts even if they are not obese.  
Testosterone 
(female) 
  ng/dL  15 to 
70(9)  
PCOS patient have higher testosterone 
levels compared to non-PCOS patients. 
 
 
2.19 Originality of the study 
Being a developing country, Lebanon still lacks a rich peer reviewed research 
concerning PCOS. The data available about the knowledge and awareness of 
Lebanese PCOS patients on the important role of the adequate nutrition and 
physical activity in the PCOS treatment is still very scarce. Unfortunately, up until 
now, no research has been conducted in Lebanon concerning the public adopting 
healthy food choices under the influence of educational sessions that enhance LSM 
and weight loss although this issue might be the beneficial to many women seeking 
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PCOS treatment. Consequently, this study was the first to assess the benefits of 
non-pharmacological treatment of PCOS in Lebanon. What was therefore new 
about this project was to revisit the efficiency of balanced food choice and adequate 
nutritional framework in PCOS treatment in Lebanon. It is important to mention that 
an intervention was established and directed to discern the efficiency of this 
approach prior to proceeding to a final large scaled up intervention. 
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Chapter 3 
Subjects, Materials and Methods 
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3.1 Introduction 
The intervention is divided into three phases; planning, implementation and 
evaluation. 
This chapter (3) will illustrate the major steps of the planning phase and these 
include: Sampling methods, Sample size calculation, Inclusion, exclusion criteria 
and confounding factors 
However, to our knowledge no studies have assessed the lifestyle modification of 
PCOS on our target population. 
 
3.2 The design and methodology of the study 
The study that was conducted is a prospective public health interventional study 
specifically designed for the culture of Lebanese population, and fitted to study the 
influence of educational session’s intervention in enhancing each of healthy eating 
choice and LSM on PCOS outcomes and health status of PCOS patients. Patients 
in this study included both obese and lean PCOS patients who attended the 
obstetrics and gynecology clinic of the American University of Beirut - Medical 
Center in Beirut, Lebanon. Institutional Review Board (IRB) at the American 
University of Beirut is responsible to give the ethical approval. Based on both the 
PCOS status and the physical and nutritional status of the PCOS patients, the 
development of an intervention was assessed. A primary pilot study was conducted 
on a small sample population size (N=76) that will to a great extent advance, 
enhance and assess the impact of nutritional counseling/education on PCOS 
patients but also to assess the acceptability of the program among PCOS patients. 
The results of the pilot study were used to plan a large scale up intervention 
program (N=294 PCOS women versus 294 non-PCOS women) that can be rolled 
out nationally in answer to the escalation in PCOS sufferers in the region. Please 
refer to figure 2 that illustrates the study process. 
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Figure 2 Flowchart showing the project stepwise process 
3.2.1 Sampling Methods 
Randomized control trials (RCTs) was used to test the efficacy of a public health 
nutrition intervention to enhance health eating and lifestyle modification among 
Lebanese PCOS women. 
The 2003 Rotterdam in the Netherlands addressed new diagnostic criteria which 
states that at least two of the following three features must exist: 
oligomenorrhea/amenorrhea, clinical and biochemical evidence of 
hyperandrogenemia, and/or polycystic ovaries documented on ultrasonography. 
Women diagnosed with PCOS were approached by the physician first and then the 
researcher. Demographic characteristics such as age, gender, job status, education 
level, yearly income, past medical history, food intake, menstrual and ovulation 
dates were assessed. 
Based on the sample size calculation, inclusion and exclusion criteria, patients 
(Pilot N=76; Scale-up N=588) were selected through simple randomization. During 
the pilot study PCOS women were recruited. During the scale up intervention 
PCOS and non-PCOS women were recruited from the Obstetrics and gynecology 
clinics. The purpose of recruiting non-PCOS women is to later compare PCOS data 
versus non-PCOS data. Patients were grouped according to their weight groups 
Start
•Assessment	of	obese	and	lean
•Different	variables	used	(anthropometric	measurment,	biochemical	indices,		
hypertension,	nutritional	assessment,	physical	assessment	and	medical	status)
Intervention
•Nutritional	sessions	and	weight	loss	program
•Physical	activity	promotion
•Measuring	indicators	at	3	months	from	baseline
Post	
intervention
•Assessment	of	obese	and	lean
•Indicators		used	at	the	begining	will	be	assessed	at	the	end	(6	months	)	of	the	
study
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(Group A-B: Overweight/obese (BMI> 24.9 kg/.m2); Group C-D: Lean (BMI< 24, 9 
kg/m2)). The enrolled patients were randomly allocated into controls or 
interventions. Enrolled patients signed a consent form and were given the right to 
drop out of the study at any time. Patients diagnosed with PCOS were verbally 
informed by the gynecologist. The researcher provided patients, who participated, 
with an informed consent form including the name and address of the research 
facility and the investigators, the research topic and its purpose, the criteria of 
eligibility. A brief description of the procedure involved, benefits /risks, the time of 
participation required (6 months), the location of the research, the contact person 
for retrieval of further information, and an invitation for participation. Patients were 
asked to sign the consent form after having read all the terms and conditions for 
participation. 
The grouping procedure: Each patient had a code (randomization) used on each 
assessment form in order to ensure the anonymity of each subject involved in this 
study. To identify each patient, the code of each patient along with her name will be 
listed on a separate paper identifying their contact details in order to call them for 
follow-up. This list was placed in a locked closet that the researcher of this study 
has access to it. 
1- The pilot study included 76 patients where the recruited population was 
divided into 2 groups: 38 patients in the overweight/obese group, and 38 
patients in the lean group (each according to the BMI measured).Then each 
group was divided into subgroups receiving different treatments (Intervention 
or control) (Refer to Figure 3). 
Each study participant had 3 sessions, divided into 2 sections: assessment and 
education. 
An assessment form was filled by the candidate at each visit that include: medical 
assessment, nutritional assessment(measuring body analysis in term of weight, 
height, BMI, BMR, hip circumference, waist circumference and body fat), 
biochemical assessment (FBS, fasting insulin, total cholesterol, triglyceride, 
LDL,HDL,CRP, and total testosterone),hypertension, hirsutism score and 
psychological assessment (using BDI-II and GAD-7).Moreover, each patient filled in 
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questionnaires at each visit: food frequency questionnaire, 24 hour recall, physical 
activity questionnaire. 
Qualitative data were collected from the study patients through:  
 Informal individual interviews on life style, adherence to the weight loss or weight 
maintenance programs and guidelines 
 
- Continuous observation of patients ‘ response to the interventions 
-  Direct involvement of the researcher in ensuring that the study procedure is 
not compromised.  
 
Sample size 
The population of interest in this study included PCOS patients aged from 18 to 45 
years (reproductive age). 
Simple random sampling strategy was used in the selection of the different groups 
of the study patients according to the study design.  
The outcomes which either decrease weight in obese PCOS or maintain weight in 
lean PCOS patients was assessed to be 76% although it is used for both groups. 
We took 76%, assuming there was no study before on weight maintenance in lean 
PCOS patients, never the less it is considerable to be 5% in the study to assess a 
difference of 14% between control and intervention to achieve the outcome. 
For the pilot study and based on a previous study on obese PCOS patients we 
needed 76 PCOS patients (Hoeger et al.,2006). 
This sample size calculation was used to determine the number of PCOS patients 
interviewed and assessed in order to get results reflecting the target population as 
needed. It also shows the level of accuracy in this sample size . 
 
SS = Z2 x (p) x (1 – p) 
C2 
Z = Z-value (1.96 for a 95 percent confidence level) 
P = Percentage of population expressed as decimal, in the case of this study we 
are using 76% = 0.76 (this value was based on previous studies on the weight loss 
percentage of PCOS patients) (Palomba et al.,2008). 
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C = Confidence interval, expressed as decimal (0.05 = +/- 5 percentage points) 
Z-values (Cumulative normal probability table)= represent the probability that a 
sample will fall within a certain distribution. The Z-values for confidence levels in 
this case is 1.96 (guided by the cumulative normal probability table). 
SS =1.962 x 0.76 x 0.24 
0.52 
SS =3.8416 x 0 .76 x 0.24 
0.0025 
SS = 280 
5% attrition will be added = (5/100 x 280) + 280 
SS = 294  
For the pilot study, 25% of the SS was considered = 25/100 x 294 = 73.5 = 76 
Sample size (NSS) for pilot study =76  
Thus sample size (NSS) for larger scale intervention = 294 
The justification for the sample size was based on the 95 % confidence interval and 
a precision limit of 0.05 for the study. 
In the scale-up intervention Two hundred nighty four PCOS and Two hundred 
nighty four non-PCOS women were recruited age and weight matched . Patients 
were approached, and those eight and age matched were accepted to participate in 
the study. Thirty PCOS women continued the study intervention from the  
study phase to the scale up phase. Non-PCOS women were recruited during the 
scale –up intervention. However, due to fall outs and some incomplete results 
during follow up, the total number of research patients that completed the six 
months scale – up intervention was five hundred eighty (580) (Refer to figures 3 
and 4).The justification of the sample size is based on the 95% confidence interval 
and a precision limit of 0.05 for the study.  
However, the prevalence of PCOS in Lebanon in this study was not conducted. 
76	
	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 Consort 2010 flow diagram for Pilot study process 
 
Enrolment,	and	informed	consent	–	102	Women	with	PCOS	
Exclusion	of	24	
Ethics	approval	sought	and	obtained	
Allocation	into	Lean	and	Obese
Group	C	Lean	PCOS	–	Intervention	(n	
=	19)	
Group	A	Obese	PCOS	–	Intervention	(n	=	
19)	
Group	B	Obese	PCOS	–	No	intervention	
(n	=	19)	
Group	D	Lean	PCOS	no	intervention	
(n	=	19)	
None	lost	to	follow	up	
+	 +	
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Figure 4 Consort 2010 flow diagram for scale-up process
Enrolment,	and	informed	consent	–	760	Women	with	PCOS	
Exclusion	of	172	
Ethics	approval	sought	and	obtained	
Allocation	into	Lean	and	Obese
Allocated to PCOS (n= 294) 
¨	Received allocated obese group  
(n= 147)  
A :Obese Intervention=74 
B:Obese Control :n=73  
Allocated to non-PCOS (n= 294) 
¨	Received allocated obese group  
 (n= 147)  
A :Obese Intervention=74 
B:Obese Control :n=73  
	
Allocated to PCOS (n= 294) 
¨	Received allocated lean  (n= 147)  
C : Lean Intervention=74 
D:Lean Control :n=73	
	
Allocated to PCOS (n= 294) 
¨	Received allocated lean  (n= 147)  
C : Lean Intervention=74 
D:Lean Control :n=73	
	 Lost	to	follow	up	
	(	N=8)	
+	 +	
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3.2.2 Inclusion, exclusion criteria and confounding factors 
The study was conducted in two phases (pilot and scale-up) employing the 
following criteria: Prospective study patients were briefed and selected using the 
inclusion criteria listed below as a prerequisite. 
The eligibility criteria 
• Patients must be aged between 18 years or above and below 45 years  
• Diagnosed with PCOS according to the Rotterdam ESHRE/ASRM 
sponsored PCOS consensus workshop group, 2003. 
Exclusion criteria 
• Patients with Cushing’s syndrome, thyroid disease, cancer, kidney or liver 
disease 
• Patients following a structural weight loss program 
• Women with history of daily physical activity more than 30 minutes 5 days 
weekly (in order to have matched controls and intervention groups). 
• Patients on metformin medication (note that patients on metformin are 
excluded because metformin can cause weight loss which will give us false 
positive results). 
3.2.3 Randomization of study patients 
Life science researches need randomization. RCTs are planned experiment tailored 
to assess the efficacy of an intervention conducted on human beings by comparing 
intervention and control groups.  Biases are reduced by randomization. In our study 
there was a specific plan to identify and enroll study patients. First patients are 
screened for PCOS and then the eligibility criteria is applied and thus who met 
these criteria were enrolled in the study. 
The grouping procedure: Each patient had a code (randomization) used on each 
assessment form in order to ensure the anonymity of each subject involved in this 
study. To identify each patient, the code of each patient along with her name was 
listed on a separate paper identifying their contact details in order to call them for 
follow-up. This list was placed in a locked closet that the researcher of this study 
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has access to it. The purpose of this randomization was to eliminate any bias and 
make both groups equally distributed. 
The two groups (weight loss or weight maintenance and controls) were randomly 
selected from the same population of PCOS diagnosed, receiving treatment and 
support at the OBS clinics at AUBMC, Beirut, Lebanon. They were not only 
statistically equivalent to the larger group; they were also statistically equivalent to 
each other. One group received weight loss intervention another group received 
weight maintenance intervention and the other 2 groups did not receive it and 
remained on the gynecologist usual health care. Simple randomized evaluation 
(with two groups) was that one group received the program that is being evaluated 
(Nutritional and guidelines intervention) and the other did not. 
The design of this study ensures that the variables used are possible to use in 
order to determine the efficacy of this intervention on the PCOS women. The 
hypothesis was stated, the inclusion and exclusion criteria were different and the 3 
follow-ups for assessment with the PCOS women were achieved, thus the study 
outcomes are accurate results to be discussed in chapter 4 and 5. 
Randomization- Pilot study 
The pilot study included 76 patients where the recruited population was divided into 
2 groups: 38 patients in the overweight/obese group, and 38 patients in the lean 
group (each according to the BMI measured). Then each group was divided into 
subgroups receiving different treatments. 
To explore more, the total of the pilot study was a 4 groups study where subjects 
(n=76 PCOS patients) were grouped into 2 groups: lean versus overweight/obese: 
A. Lean group was sub grouped into 2 subgroups with equal number of patients:  
1- The intervention group (n=19): receiving an intervention by the researcher 
which include nutritional counseling/education, cooking sessions about 
healthy food, and the gynecologist treatment. Please refer to Appendix 8 
2- The control sub group (n=19): receiving the gynecologist treatment (drugs) 
with no nutritional intervention. 
Indicators were measured at 0, 3 and 6 months 
B. Overweight/Obese group was sub grouped into 2 subgroups: 
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1- The intervention group (n=19): receiving the tailored diet and weight loss 
nutritional intervention taking into consideration diabetes, high lipid profile 
and hypertension nutritional information. Please refer to Appendix 9. 
2- The control sub group (n=19): receiving the gynecologist treatment (drugs) 
with no nutritional intervention. 
 
Randomization- scale- up intervention 
The pilot study included 588 women where the recruited population were divided 
into 8 groups:  
The PCOS women group:  
147 patients in the overweight/obese group, and 147 patients in the lean group 
(each according to the BMI measured).  
Then each group was divided into subgroups receiving different treatments. 
A. Lean group was sub grouped into 2 subgroups with equal number of patients:  
1- The intervention group (n=147): receiving an intervention by the 
researcher which include nutritional counseling/education, cooking 
sessions about healthy food, and the gynecologist treatment. Please refer 
to Appendix 8. 
2- The control sub group (n=147): receiving the gynecologist treatment 
(drugs) with no nutritional intervention. 
Indicators were measured at 0, 3 and 6 months. 
B. Overweight/Obese group was sub grouped into 2 subgroups: 
1- The intervention group (n=147): receiving the tailored diet and weight loss 
nutritional intervention taking into consideration diabetes, high lipid profile and 
hypertension nutritional information. Please refer to Appendix 4. 
2- The control sub-group (n=147): receiving the gynecologist treatment (drugs) 
with no nutritional intervention. Please refers to Appendix 9. 
The non- PCOS women group:  
294 patients in the overweight/obese group, and 294 patients in the lean group 
(each according to the BMI measured).  
Then each group was divided into subgroups receiving different treatments. 
C. Lean group was sub grouped into 2 subgroups with equal number of patients:  
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3- The intervention group (n=147): receiving an intervention by the 
researcher which include nutritional counseling/education, cooking 
sessions about healthy food. Please refer to Appendix 8. 
4- The control sub group (n=147): did not receive any intervention. 
Indicators were measured at 0, 3 and 6 months. 
D. Overweight/Obese group was sub grouped into 2 subgroups: 
3- The intervention group (n=147): receiving the tailored diet and weight loss 
nutritional intervention taking into consideration diabetes, high lipid profile and 
hypertension nutritional information. Please refer to Appendix 9. 
4- The control sub-group (n=147): did not receive anything.  
Figure 5 illustrates the distribution of the recruited population. 
Indicators were measured at 0, 3 and 6 months. 
 
 
Figure 5 the study population group division  
 
3.2.4 Confounding factors  
Random assignment, as a result of confounding by indication, does not affect 
randomized trials (Johnston, 2001). Since the control characteristics (inclusion 
588
PCOS
294
Obese	
147
A:	intervention	
74
B:	Control	
73
Lean
147
C:	intervention	
74
D:	Control	
73
NON_PCOS
294
Obese	
147
E:	intervention	
74
F:	control	
73
Lean
147
G:	intervention	
74
H:	Control	
73
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criteria) of the various groups (overweight/obese Interventions and controls, lean 
interventions and controls) and subgroups (intervention versus Control) were the 
same, the probability of confounding was smaller in this study. By expanding the 
types and values of analogies performed in the analysis, devaluation in the 
possibility for the occurrence and confounding factors was obtained, such that 
these confounding variables can be classified by their origin. The choice of 
measurement instrument (operational confound), situational characteristics 
(procedural confound), or inter-individual differences (person confound). By 
augmenting the figures of comparisons executed in the proximate analysis, a 
contraction in the probability of happening and results of operational confounding 
factors were realized in this study. Equivalently, to guarantee the strength and 
validity of the findings and a reduction in the potential for operational confound, the 
data from anthropometric, 24 hour recall , and general assessment  measurements 
were repeated twice and attested by another medical staff. To diminish situations of 
confounding, either before the study implementation or after the analysis, a peer 
review in the advancement of the theoretical scheme and at the end of the pilot 
intervention was used. The peer review likewise, depended on cumulative ability 
within medical colleagues in the care and support program for PCOS, to recognize 
possible shortcomings in the study design and analysis, containing methods where 
the data may depend on confounding. To lessen the incident of self-selection by 
patients or prejudice by the study planner, the people under study were randomly 
split after brief instructions, using the Randomized Control Trial (RCT) design. This 
methodology divides the members into groups (overweight/obese and lean) and 
subgroups (interventions versus control) significant to the criteria that match the 
research question.  
 
3.3 Recruitment, study subjects and procedure 
In this study, the patients were women who are in a range of age of 18 to 45 years 
old who were diagnosed with PCOS by the obstetrics and gynecology clinic of the 
AUB-MC. 
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3. 3.1 The eligibility criteria 
• The patient’s age must be included in the range of 18 to 45 years old. 
• The patient must be diagnosed with PCOS according to the Rotterdam 
ESHRE/ASRM sponsored PCOS consensus workshop group, 2003. 
 
3.3.2 Exclusion criteria 
• Patients that have Cushing’s syndrome, thyroid disease, cancer, kidney or 
liver disease 
• Patients who are following a structural weight loss program 
• Women with history of daily physical activity more than 30 minutes 5 days 
weekly (in order to have matched controls and intervention groups). 
• Patients on metformin medication (this exclusion is done to avoid false 
positive result, for metformin may also lead to weight loss). 
 
3. 4 Pilot study method 
The gynecologist verbally notified patients of their diagnosis with PCOS. Prior to 
participation, the researcher provided patients, who wish to volunteer as a 
participant in the study, with an informed consent form composed of the following: 
the name and address of the research facility and the investigators, the research 
topic and its purpose, the criteria of eligibility, a brief description of the procedure 
involved, benefits /risks, the time of participation required (6 months), the place in 
which the study is conducted, the contact person for recovering further information, 
and an invitation for participation. After having read and discussed all the terms and 
conditions that relate to their participation in this study, patients were kindly 
requested to sign the consent form.  
The method of grouping patients is as follows: For the sake of randomization, each 
patient had a code used on each assessment form in order to ensure the anonymity 
of each subject included in this study. To be able to call patients for follow up, the 
code of each patient along with her name were listed on a separate paper 
identifying their contact details. This list was be accessed by the researcher of the 
study and will be locked up in a closet. 
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Seventy six patients participated in the pilot study and were divided 2 groups: 
obese group containing 38 patients as well as a lean group including 38 patients 
(each according to the BMI measured). After that, each of the lean and obese 
groups was further divided into subgroups receiving different treatments. 
In other words, the pilot study was a 4-group-study (n=76) PCOS patients: 
A. Lean group consisted of 2 sub-groups each containing equal number of 
patients:  
1- The intervention group(n=19): receiving an intervention by the researcher 
which include nutritional counseling/education, cooking sessions about 
healthy food,  informing about lycopene containing food and the significance 
of enhancing their lycopene containing food intake, as well as the 
gynecologist treatment.  
2- The control sub group (n=19): receiving the gynecologist treatment (drugs) 
with no nutritional intervention. 
Indicators were measured at 0, 3 and 6 months. 
B. Obese group  were sub grouped into 2 subgroups: 
1- The intervention group (n=19): receiving the specially designed diet and 
weight loss nutritional intervention taking into account diabetes, high lipid 
profile and hypertension nutritional information. 
2- The control sub-group (n=19): receiving the gynecologist treatment (drugs). 
No nutritional intervention was present. 
Indicators were measured at 0, 3 and 6 months. 
The reason why the 2 main groups were divided into 2 subgroups was to study the 
significance of dietary treatment nutraceutical food component on PCOS outcomes. 
This aided the assessment of the effect of diet on both obese and lean PCOS 
patients after being subjected to nutritional education sessions focusing on 
promoting healthy food choice suitable for their condition, weight loss if needed and 
promoting physical activity. 
 
Process of the study (pilot and scale up) 
Every participant in the study had 3 sessions, divided into 2 sections: assessment 
and education. 
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At each visit, the candidate filled an assessment form including: medical 
assessment, nutritional assessment(measuring body analysis in term of weight, 
height, BMI, BMR, hip circumference, waist circumference and body fat), 
biochemical assessment (vitamin D(25)OH ,FBS, fasting insulin, total cholesterol, 
triglyceride, LDL,HDL,CRP, and serum testosterone),hypertension, hirsutism score 
and psychological assessment (using BDI-II and GAD-7). Moreover, each patient 
filled in questionnaires at each visit: food frequency questionnaire, 24 hour recall, 
physical activity questionnaire. 
Patients who were in the intervention groups were then subject to nutritional 
education/counseling (following the proposed guidelines) as well as the structural 
weight loss program for obese patients.  
The researcher, who is a licensed dietitian, proposed a weight loss diet guideline to 
the obese. This weight loss diet guideline is proposed by using 1200 -1500 calories 
daily menu plan calculated according to the obese patients BMR. Calories are 
assigned after calculating patient’s daily recommended intake and subtracting 500 
calories from their daily energy requirements. Lean patients; however, followed a 
weight maintenance diet proposed by the researcher after calculating their BMR, 
and proposing a daily diet menu according to their allowed calorie intake. Both 
obese and lean PCOS patients were advised to do physical activity of a minimum of 
30 min per day, 3 times weekly. 
After 3 and 6 months from the first sessions, each patient was asked to follow-up 
with the same questionnaires and assessments used. Consequently, there was a 
total of 3 blood samples taken over a period of 6 months (one 3 ml sample at each 
follow-up visit) for biochemical analysis [vitamin D(25)OH ,FBS, fasting insulin, total 
cholesterol, triglyceride, LDL,HDL,CRP, and total testosterone ] in which the patient 
was required to fast before the blood test. Knowing that the food frequency 
questionnaire includes lycopene containing food choices, the lycopene servings 
consumed by the patient was counted at each visit (baseline, 3 and 6 months after 
education sessions) and then compared at the end of the study with the changes in 
testosterone levels. Moreover, obese patients were subjected to monthly follow-up 
with their diet and weight change.  
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Dropouts were also included in the research results in order to assess the 
compliance of the patients in the study. 
After completing the pilot study successfully, (during MPhil) the intervention 
outcomes were assessed. More patients were included to undertake for a larger 
sample population to participate in the intervention clinical trial (for PhD). 
 
Approach of the intervention 
Food frequency questionnaire were developed using a valid FFQ but modified to 
suit the Lebanese culture and were used during the study to assess the nutritional 
intake of PCOS patients before and after intervention. 
The plan was evaluated using statistical analysis. The characteristics of patients 
who had an improvement in PCOS outcomes and those who had unsuccessful 
outcome were compared in the 2 groups (obese versus lean). An independent 
sample t-test was used for the continuous variables and a chi-square was used for 
the categorical variables. 
Differences in anthropometric assessment, nutritional assessment, physical activity 
questionnaire, hypertension measures, biochemical analysis, reproductive 
questions, hirsutism score and psychological assessment were measured at 
baseline, 3 months and 6 months from the beginning of the study. 
A multivariate logistic regression analysis was carried out in order to study the 
association between the characteristics of the study patients and nutrition 
education/counseling and to check the statistical significance of an association 
between lycopene intake and testosterone levels. A two-sided value of P< 0.05 is 
considered statistically significant.   
 
3.5 Intervention Setting, Assessment tools and Ethical consideration  
3.5.1 Intervention Setting 
The study was conducted at the American University of Beirut Medical Centre, 
Beirut, Lebanon. AUBMC is one of the leading medical institutions in the Arab 
region. The women's health center at the AUBMC is well known with the quality of 
care given to the women. Other research projects are being conducted in the same 
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center such as the periodontal disease and the in vitro fertilization outcomes, the 
Vitamin D status during pregnancy and bariatric surgery in PCOS women. 
3.5.2 Measurements of research variables 
Anthropometric, biochemical, nutritional, medical and psychological assessment 
and the nutritional counseling and education were undertaken at the Department of 
Obstetrics and Gynecology of the American University of Beirut Medical Centre, 
Beirut, Lebanon. Refer to table 5. 
Table 5 The variables used and their frequency 
Variable type Variables  Frequency 
Nutritional assessment  FFQ and 24-hour recall( 
two 24-hours recall 
At baseline , after 3 
and 6 months from 
baseline  
Physical activity IMS- physical activity 
survey 
At baseline , after 3 
and 6 months from 
baseline 
anthropometric 
measurements 
weight, height, waist 
circumference, hip 
circumference and body 
composition analysis 
At baseline , after 3 
and 6 months from 
baseline 
Hypertension  
measurements 
DP and SP At baseline , after 3 
and 6 months from 
baseline 
Biochemical indicators Vitamin D, insulin 
resistance, blood glucose 
FBS, HDL-C, LDL-C, total 
cholesterol, triglyceride 
level, serum testosterone, 
insulin resistance 
At baseline , after 3 
and 6 months from 
baseline 
Fertility and gynecological 
assessment  
regularities of menstrual 
cycle (seen by pregnancy 
At baseline , after 3 
and 6 months from 
baseline 
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onset, ovulation, and 
fertility rate) 
Clinical hyperadrogenemia  Hirsutism score At baseline , after 3 
and 6 months from 
baseline 
Psychological assessment BDI-II and GAD-7 At baseline , after 3 
and 6 months from 
baseline 
 
 
3.5.3 Research assessment tool 
The assessment of the PCOS patients was formulated to target the aim of the study 
and achieve a high quality of research. The different used tools are designed to 
insure correct reporting and deep analysis. After the pilot study (N=76) a critical 
evaluation was conducted for the tools used ensuring the quality of research and 
reporting in the scale up (N=588). 
Critical appraisal of the assessment tool was ensured after the pilot study (n=76) to 
ensure adequacy of reporting detail on the data sampling, data collection and 
analysis in the scale- up (n=588).  
 
3.5.4. Research indicators and their cut off  
 
The cut off points of biochemical analysis are referred to in table 6. 
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Table 6 The different biochemical parameters and their cutt off values 
Parameter Unit Normal Ranges 
Vitamin D   ng/ml 30-74 (1) 
 
Insulin μU/mL < 25 μU/mL 
Blood glucose mg/dL 126(4) 
FBS mg/dL 70 to 99(1)  
HDL-C  mg/dL 50-60(1) 
LDL-C mg/dL <130(1) 
Total Cholesterol mg/dL <200(1) 
Triglyceride  mg/dL 40-160(1)  
Testosterone 
(female) 
  ng/dL  15 to 70(9)  
 
 
3.5.5 Statistical analysis 
All data was collected and analyzed using SPPS statistical software version 20. 
Descriptive statistics was performed using means and standard deviation for 
continuous variables, frequency and percentage for categorical variables. 
Baseline characteristics were compared according PCOS using chi-squared test for 
categorical variables and student t-test for continuous variables. 
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Differences between baseline and 6 months for anthropometric assessment, 
nutritional assessment, physical activity questionnaire, hypertension measures, 
biochemical analysis, reproductive questions, hirsutism score and psychological 
assessment were tested using paired t-test after checking normality of the 
difference between the 2 periods (baseline and 6 months ). 
A multivariate logistic regression analysis was carried out in order to assess the 
association between the characteristics of the study patients and nutrition 
education/counseling. A two-sided value of P< 0.05 is considered statistically 
significant.   
 
3.5.6 Training of the research team 
The training for the research team involved in this study was designed to orient staff 
about the project implemented. The training involved the gynecologist at the 
Obstetrics and gynecology clinics and the nurses involved in the diagnostic 
procedure. The training included definition of the syndrome and diagnostic criteria 
used, and patient approach. The training has been organized to allow the team to 
know their tasks during this study. 
 
3.6 Ethical consideration 
Human studies project need a formal procedure of ethical consideration and 
approval. This project required ethical consideration from the University of 
Westminster and the collaborating institution in Lebanon where PCOS patient were 
recruited. Our research involves recruiting human beings, intervene with them and 
obtain sensitive and deep data, collecting blood 3 times and measuring the study 
variable outcomes at the end point (after 6 months from baseline). This study ensured 
decreasing the relative weights of the study’s risks which involves the blood 
withdrawal where a skin discoloration could have caused on the site of withdrawal. 
The recruiting physicians have the right to withdraw any patients from study if they 
evaluated a high risk on the patients. All information about the patient from this 
research project was kept in a locked office.  Unless required by law, only the study 
doctor and designee, the ethics committee and inspectors from governmental 
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agencies have direct access to the medical records which may be audited without 
violating confidentiality , the name of the patients is never used. 
 
Basic principles of ethical practice  
1. Informed consent  
After being diagnosed with PCOS patients were approached about the study 
and an information sheet was given to every patient to provide them with all 
the needed information and details. The information sheet stated guarantee 
of collected data and its compliance with the Data protection Act and the 
University of Westminster's data Protection Code. 
2. Patient's full volunteer and no pressure for participation 
3. Confidentiality assurance  
4. No risk of taking part of the study  
5. Patient's option to stop at any time of the study. 
Ethical approvals for this study were submitted to the Institutional review board the 
American University of Beirut on June 25, 2014 and the ethics committee at the 
University of Westminster on July 24, 2015. Both approvals were received before the 
initiation of the study. 
 
Risks and discomforts  
Polycystic ovarian syndrome patient on treatment visit the Women's health center 
every 6 months for blood tests and abdominal ultrasound. Blood withdrawal may 
cause a discomfort or blue discoloration at the site of blood withdrawal. Other risk 
such as the feeling of being forced to lose weight will cause an additional risk. 
Following a daily nutritional guidelines and weight loss or weight maintenance plan 
may put the PCOS women under pressure to follow it and be a source of stress to 
abide by the guidelines on a daily manner. 
Measure to reduce risks and discomforts 
PCOS women who already had blood sample collected were asked to return on a 
couple of day in order to decrease any discomforts cause by blood withdrawal. The 
Medical laboratory team at the American University of Beirut Medical Center was 
responsible of blood withdrawal and analysis. 
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Regarding the compliance of nutritional guidelines PCOS women were informed 
and educated about the importance and benefits of adhering to these guidelines in 
order to improve their overall health status.  
The research team was trained and always on reminder to approach diagnosed 
PCOS women. 
 
Legal rights 
Any women who participated in this study have not given up any of her legal rights 
by singing the informed consent form
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3.7 Intervention, strategy-planning, implementation and evaluation phases 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
• 3	-scale	up	intervention	(	N=294	PCOS	
and	N=294	non-PCOS)	
• Duration	(6month)	
• Nutritional	assessment	;	FFQ	and	24	h	
recall	questionnaire,	dietary		beliefs	and	
attitudes		
• Body	analysis	assessment,	biochemical	
analysis	,hypertension	
• Psychological	assessment:	BDI-II,	GAD-7	
• Administration	of	educational	
sessions(6	month/3	sessions)	
• Checkpoint	of	variables	0,	3	and	6	
months		from	baseline	
• Scale	up	intervention	results	analysis	
and	interpretation		
• Outcome	evaluation	
IMPLEMENTATION PHASE	
PLANNING PHASE	 Pilot study intervention	 Scale up intervention	
EVALUATION 
PHASE 
SPREADING	
1	-Preliminary	requirement	
(administrative)	
• Registration	with	School	
• Research	ethical	approval	from	
Westminster	UK	and	AUMC	
Beirut		
• Development	of	project	
documents	and	evaluate	
logistic/inputs	needed	
• Get	ethical	approval	from	UoW	
• Get	ethical	approval	from	
AUBMC	IRB	
• Patients	recruitment	according	
to	the	criteria	
• Patients	grouping	(	g1	vs	g2	)	
• 2	-Pilot	study	(	N=76)	
• Duration	(	6	months)	
• Nutritional	assessment;	FFQ	and	24	h	
recall	questionnaire	
• Body	analysis	assessment	,biochemical	
analysis,	hypertension	
• Psychological	assessment	:BDI-II,	GAD-7	
• Administration	of	educational	sessions	
(6	months/3	sessions)	
• Checkpoint	of	variables	0,	3	and	6	
months	from	baseline	
• Pilot	study	results	analysis	and	
interpretation		
• MPhil	to	PhD	transfer	report	
submission	
	
• Thesis	writing	
Thesis	
presentation	
at	UoW	and	
AUBMC	
• Oral	
presentation	
• Viva	exam	
and	AUBMC	
	• Present	the	
nutritional	
framework	for	
PCOS	patients		
• Start	working	in	
the	different	
Lebanese	
regions	in	order	
to	address	the	
PCOS	
recommendatio
ns	to	the	large	
population	of	
Lebanon	
	
6	months	 6	months	6	months	 12	months	 1	month	
Start	of	the	study	 End	of	the	study	
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3.7.1. Planning phase 
This phase was mainly focused on planning the research project, procedures and 
paper work. The aim was to create a plan for the timeline of the project and the 
activities included. 
1- Administrative work 
An approval is needed before conducting any human being research and the 
documents need for the approval were prepared and submitted before the 
study initiation such as registering the at the UoW ,Registration document at 
the UoW , Ethical approval from the research ethics at Uow  and IRB at 
AUBMC and the study details ( sample size , recruitment and research team 
training). 
2- Collaboration between the institutions in this phase included visiting the 
University of Westminster, and the American University of Beirut, Medical 
Center, Beirut, Lebanon. Then University of Westminster provided the 
workshop for PhD process and registration. The American University of Beirut, 
Beirut, Lebanon offers the facility to recruit patients, intervene with them and 
the Medical Laboratory analysis for blood samples. The Obstetrics and 
Gynecology department at the AUBMC offered a research course on how to 
undergo a research at the institution.
3.8.2 Intervention strategy –Implementation phase 
Pilot study (N=76) 
Pilot studies are normally carried out before scale-up interventions in quantitative 
research as a trial to evaluate the research and avoid any further investigation due 
to inadequacy in the designed project. 
The pilot study population (n=76) were part of the scale up intervention population 
size.  The pilot study is of valued vision because any missing detail from pilot study 
was added to the scale up intervention and thus improved the quality of outcomes. 
 
Pre-intervention assessment – Pilot study 
The following assessment were used 
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1. An assessment form approved by the IRB at AUBMC adapted to the aim and 
objectives of this research in a form of assessment tool (Appendix 3). 
2. Medical and physical assessment; anthropometric measurement, medical 
history and demographic questions recorded in the appropriate section of the 
assessment form at baseline for all patients (Please refer to appendix 3). 
3. Physical activity questionnaire (Please refer to appendix 4), Psychological 
questionnaires GAD-7 and BDI-II (Please refer to appendix 5), Hypertensive 
measurements, Food frequency questionnaire (Please refer to appendix 10), 
and biochemical assessment carried by the Medical Laboratory at the 
American University of Beirut medical center at baseline (Please refer to 
tables 4 and 5). 
4. A 24 hour recall was conducted by phone call to the patient's one on a 
weekday and another one on a weekend and calories were calculated 
(Please refer to appendix 11). 
 
3.8.3 Intervention phase: 6 months 
The intervention phases included the following steps: 
1: Randomization 
Randomization of the PCOS women, and starting the nutritional intervention for 
overweight/obese group and the lean group for a period of 6 months. 
2. Process checking to confirm that the project is following the ethical principles 
through the correct approach of the PCOS women, continuous feedback from the 
PCOS women to ensure their adherence to the allocated intervention and 
guidelines.  
Weekly phone calls to the study patients to monitor their progress through the 
dietary intervention.  
Follow-up calls to the patients to ensure their presence at the follow-up 
appointments and avoid any disturbance during the research timeline. 
Routine checkup to the blood samples results to add them to the PCOS women 
data sheet. 
3. Post-intervention assessment – Pilot study. 
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Assessments were conducted at baseline, after 3 months from baseline and after 6 
months from baseline. Each assessment included all the variables used at baseline 
to ensure adequate data has been collected. Assessments were done to all groups 
(Interventions and controls). 
Interventions groups were monitored every 2- 3 weeks at the hospital as a follow-up 
appointment to ensure their adherence to the guidelines and for any further 
questions. 
4. Evaluation phase 
The information collected before the intervention at baseline and after the 
intervention were compared. Data were entered after each assessment and after 6 
months a statistical analysis was carried on. 
Between pilot study and scale up intervention 
After the pilot study the study patients progressed to the scale up intervention 
sample size.  A number of study patients (N=30) of the pilot study patients 
continued their adherence to the guidelines for an extra 6 months which consisted a 
1 year intervention. 
 
Scale up intervention (N=588) 
The pilot study results are evidence based and this determined by the scale up 
intervention were a larger sample size was used. During the scale up intervention 
non-PCOS women were recruited.  
Pre-intervention assessment – Sale up 
• A numerous of assessments were carried out  at baseline  
An assessment form approved by the IRB at AUBMC adapted to the aim and 
objectives of this research in a form of assessment tool ( Please refer to 
appendix3 ) 
• Medical and physical assessment; anthropometric measurement, medical 
history and demographic questions recorded in the appropriate section of the 
assessment form at baseline for all patients. 
• Physical activity questionnaire, Psychological questionnaires  GAD-7 and 
BDI-II, Hypertensive measurements , Food frequency questionnaire , and 
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biochemical assessment carried by the Medical laboratory at the American 
University of Beirut medical center  at baseline. 
• A 24 hour recall was conducted by phone call to the patient's one on a 
weekday and another one on a weekend and calories were calculated. 
• Biochemical indicators: (Vitamin D, insulin resistance, blood glucose FBS, 
HDL-C, LDL-C, total cholesterol, triglyceride level, total testosterone, insulin 
resistance) in order to assess the effectiveness of the nutritional 
education/counseling on COS biochemical indicators. 
• Other PCOS conditions reported: regularities of menstrual cycle (seen by 
pregnancy onset, ovulation, and fertility) 
• Hirsutism will be measured using the Ferriman-Gallewey score. 
• Psychological assessment using BDI-II. This is a very widely used scale and 
it is one of the oldest consisting of 21 items self-report measure of cognitive, 
behavioral, affective, and somatic components of depression. Items on the 
BDI are rated on a 4 point type scale ranging from 0 to 3. Total scores are 
obtained by summing the highest ratings on each of the 21 items and may 
range from 0 to 69 with higher scores indicating symptom severity. The BDI 
has excellent 1 week test-retest reliability (r=0.93, P<0.001) and internal 
consistency (α=0.91). Convergent validity for the BDI is satisfactory and was 
established through examining the correlation of its’ scores with scores on 
the Revised Hamilton Psychiatric Rating Scale for Depression (r=0.71) (Beck 
et al., 1996a).GAD-7 is another scale that will be used to score for anxiety in 
PCOS patient, a short screening tool and validated (there is an Arabic 
version of it too). 
Intervention phase – 6 months  
The evaluation phase included randomization of the study patients for PCOS and 
non-PCOS women (weight matched), nutritional counseling and education using 
the dietary intervention and the proposed guidelines. This phase also included 
monitoring the scale up intervention groups for a period of 6 months. 
 
Intervention strategy – Evaluation phase 
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Since scale up initiation evaluation was ongoing and study patients were called to 
ensure their attendance to the follow-ups appointments and assessment during the 
study timeline. 
Non-PCOS women followed these proposed guidelines and results were compared 
to PCOS outcomes. After each data collection appointment, the data were entered. 
After the end of the scale up intervention assessment appointment data were 
analyzed and reported to MPhil report and Thesis. 
 
Sustainability plan 
Sustainability plan was intended after analyzing the outcome of the pilot study. The 
sustainability plan proposed is to blend the nutritional intervention program and 
guidelines after analyzing the outcome and finalizing the research.  
The sustainability plan is to refer the PCOS diagnosed women at the Obstetrics and 
Gynecology clinics at the American University of Beirut Medical Centre, Beirut, 
Lebanon to be referred to the dietitian for counseling and assessment as part of 
their treatment along with any subscribed drugs.
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Chapter 4 
Pilot study results 
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4.1 Introduction 
It allowed the researcher to adjust the aspects faced during the pilot study to be 
fully implanted in the scale up intervention. The pilot study allowed adjusting the 
project design, to meet the challenges faced in the field from patients’ recruitment, 
to clinics.  
 
4.2. Summary of Materials and Methods 
There is no study up to date in Lebanon about the nutritional status for PCOS 
women and thus the need to map their intake and control it is crucial for their health 
status Patients prior to enrollment were subject to assessment (Appendix 3) using 
parameters such as personal and family medical history, anthropometric 
measurements, biochemical markers, menstrual cycle date marker, obstetrics and 
gynecology, medical history and socio-economic data. The patients were grouped 
according to their weight (normal weight and overweight/obese PCOS) and each 
group was divided into 2 subgroups the first was given nutritional intervention 
(nutritional counseling and intervention) and the second no intervention (controls) 
for a period of six months.  The pilot study assessments were carried out three 
times (at baseline, after 3 and after 6 months) as mentioned in the study method.  
 
4.3 Pilot study results at baseline, three months and six months follow up 
4.3.1 Pilot study baseline characteristics: socio-demographic: 
The pilot study included 76 PCOS patients divided equally between 4 groups, 
obese intervention , obese control , lean control ,and lean intervention (25%), 
having a mean age of 25.3 years. About 40% were married, with 31% were 
smokers, and 51% had a high-school educational level. Ninety six percent had 
irregular menstrual cycle, with a mean age at menarche of 12.4 years. Fifty percent 
were on oral contraceptives, and 72 % had acne. All baseline characteristics are 
summarized in table 7. 
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Table 7 Baseline characteristics of the recruited population 
Character Frequency(n=76) 
Epidemiology of the 
disease among 
recruited PCOS patients  
Age, mean (±SD) 25.3 (±5) 
Group, n(%) 
A (obese intervention) 
B (obese control) 
C (lean control) 
D (lean intervention) 
 
19 (25%) 
19 (25%) 
19 (25%) 
19 (25%) 
Marital state, n(%) 
Single 
Married 
 
46 (60.3%) 
30 (39.7%) 
Smoker, n(%) 24 (30.8%) 
Education, n(%) 
˂ High school 
High school 
University-BS 
Higher degrees 
 
13 (17.10%) 
41 (59.94%) 
19 (25%) 
3 (3.8%) 
Home type, n(%) 
Owned 
Rented 
 
66 (85.9%) 
10 (14.1) 
People living at home, 
mean (± SD) 
4.2 (±1.3) 
Working, n(%) 37 (47.4%) 
Yearly income in $, mean 
(±SD) 
44,835 (±20,791) 
Medical payment, n(%) 
Private 
NSSF 
Insurance 
HIP 
 
40 (52.6%) 
10 (13.1%) 
17 (22.3%) 
9 (11.8%) 
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Gynecologic  Gravida, n(%) 
0 
1 
2 
3 
 
58 (76.3%) 
8 (10.5%) 
7 (9.2%) 
3 (3.9%) 
Para, n(%) 
0 
1 
2 
3 
 
66 (86.8%) 
7 (9.2%) 
3 (3.9%) 
2 (2.6%) 
Age at menarche, mean (± 
SD) 
12.4 (±1) 
Period, n(%) 
Irregular  
Regular 
 
74 (96.2%) 
2 (3.8%) 
Sexually active, n(%) 27 (34.6%) 
Contraception, n(%) 39 (50%) 
Hormonal therapy, n(%) 8 (10.3%) 
Acne, n(%) 56 (71.8%) 
 
 
4.3.2 Pilot study anthropometric measurements 
Anthropometric measures are shown in tables 8 in comparison between 
interventions and controls and their subgroups (overweight/obese and lean) 
between baseline and 6 months. The mean change in body weight after 6 months 
differed between the 2 groups where patients receiving intervention lost an average 
of 7.7Kg for overweight/obese patients and 0.5 for lean patients while controls 
gained about 3.6 kg for overweight/obese patients and 0.3 for lean patients with 
p˂0.001 which corresponded to an average 9.4 % loss in body weight with 
overweight/obese  interventions ,1 % with lean patients  and 3.6% gain in body 
weight with overweight/obese controls and 1.3 % lean controls  (p˂0.001), noting 
that 19% of overweight/obese patients receiving intervention met the primary goal 
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of at least 5% loss in body weight compared to none of the controls (p˂0.001). 
When comparing the subgroups of overweight/obese and lean patients, it was 
found that overweight/obese patients who took intervention lost an average of 7.7 
Kg while controls gained an average of 3.1 Kg at the end of the study (p ˂0.001), 
whereas lean patients had no significant change in their weights whether they took 
intervention or not (p=0.084). Concerning BMI change, a significant difference 
occurred between interventions and controls where interventions had a decrease of 
an average 2.4 kg/m 2 of their BMI compared to controls who had an increase of 0.9 
kg/m 2  in their BMI (p ˂0.001). This difference remained significant in subgroups of 
overweight/obese patients where interventions had an average decrease of 3.2 in 
their BMI (p ˂0.001) and in subgroups of lean patients the change was negligible. 
Also there existed a significant difference in waist and hip circumference between 
general interventions and controls and in overweight/obese subgroup patients (P 
˂0.001) where overweight/ obese patients receiving intervention were having a 
significant decrease in these measures (-7.2 Kg and -5.1 Kg respectively) 
compared to those with no intervention (+2.0 and +1.3 respectively), but this 
change was not significant in lean patients. In addition, a significant difference 
occurred between interventions and controls regarding EBF (3.6% decrease in 
interventions compared to 1.1% increase in controls, p=0.002). 
 
4.3.3 Pilot study gynecology results 
Time to ovulation was measured at the time of intervention, as shown in table 8, 
and showed to be faster in overweight/obese patients receiving intervention (47.2 
days) compared to overweight/obese controls (50 days). While lean interventions 
time to ovulation 42.5 days and lean controls 49 days. This difference was not 
significant statistically (p=0.648) between the 4 groups. 
 
4.3.4 Pilot study biochemical markers results: 
It was noted that no significant difference occurred between interventions and 
controls regarding the change in their biomedical markers, as shown in table 9, nor 
between the subgroups compared, however; testosterone showed to be in high 
levels (43 ng/dL), and Vitamin D in low levels (12.2-13.5 ng/dL).Moreover, it was 
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noted a higher mean decrease in LDL-C in obese control group compared to obese 
intervention (-22 vs -13 mg/dl). 
4.3.5 Pilot study psychological status results: 
Regarding the 3 scores used to measure psychological and physical activity (BDI-II, 
GAD-7, and PA), as shown in table 9 a significant difference occurred after 
providing the nutritional intervention (p=0.014, p ˂0.001, p ˂0.001 respectively). 
When taking obese patients separately, high depression and anxiety scores 
occurred, with a significant change when providing intervention (p=0.002 for 
GAD7), however for lean patients no significant difference occurred between 
interventions and controls with normal depression and anxiety scores. 
  
4.3.6 Pilot study physical activity status results: 
Regarding physical activity, obese patients receiving intervention had an average of 
3.6 increase in their PA score, which was significantly different than controls (p 
˂0.001), whereas lean patients had a borderline significant change (p=0.056) 
between interventions and controls.  
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Table 8 Variation in weight and reproductive characteristics between 
interventions and controls 
Variable Overweight/ 
Obese 
Interventions 
(n=19) 
Overweight/ 
Obese 
Controls 
(n=19) 
Lean 
Interventions 
(n=19)  
Lean 
Controls 
(n=19) 
p-
value 
Weight at 
baseline, mean 
(± SD) 
81.2(±13) 84.5(±13 
 
52.8(±3.3) 58.5(±5.9) 0.002 
Individuals who 
lost weight, n(%) 
19 ( 25 %) 0 ( 0 %) 12( 15.7 %)  6 ( 7.9%) ˂0.001 
Individuals who 
gained weight, 
n(%) 
0 14(18.4%) 0 5(6.5 %) ˂0.001 
Change in body 
weight(Kg),mean 
(± SD) 
-7.7 kg 
(±5.5) 
3.1 (±3.8) -0.5 (±0.6) 0.8(± 2.3) ˂0.001 
% change in 
body weight, 
mean (± SD) 
-9.4(±6.2) + 3.6 (±4.8) -1 (± 5.5) + 1.3 (± 
4.2) 
˂0.001 
Achieved  5% 
loss in body 
weight,n(%) 
19 ( 25 % ) 0 ( 0 %) 0 ( 6.5% ) 0 ( 0 %) ˂0.001 
Time to 
ovulation ( 
number of days), 
mean (± SD)Kg 
47.2 (±32.1) 50(±31.6) 42.5 (±33.4) 49 (± 32) 0.648 
  
 
Statistically significant results are shown in boldface.  
Student-t-test was done for continuous variables to get the mean and Chi 2 for 
binary variables to get percentages.
	
	
106	
	
Table 9 Variation in anthropometric, biochemical, psychological and physical activity parameters between 
the study population groups 
 
Factor A 
Overweight/Obese 
intervention (n=19) 
B 
Overweight/Obese 
control (n=19) 
p-value C 
Lean control (n=19) 
D 
Lean intervention (n= 
19) 
p-value 
 Mean at 
baseline 
Average 
change 
after 6 
months  
Mean at 
baseline 
Average 
change after 
6 months 
 Mean at 
baseline 
Average 
change 
after 6 
months 
Mean at 
baseline 
Average 
change 
after 6 
months 
 
Weight (kg) 
81.2(±13) -7.7(±5.5) 84.5(±13) 3.1(±3.8) ˂0.001 
58.5(±5.9
) 
0.8(±2.3) 52.8(±3.3) -0.5(±0.6) 0.084 
BMI (kg/m 2 ) 31.7(±6.1
) 
-3.2(±2.4) 32.6(±5.1) 1.2(±1.5) ˂0.001 
22.2(±1.7
) 
0.4(±1.1) 20.3(±1.5) -0.3(±0.5) 0.044 
Waist 
circumference  
(cm) 
103(±11) -7.2(±5.4) 106(±12) 2.0(±2.5) ˂0.001 
85.5(±7.8
) 
0.6(±1.2) 82.2(±5.1) 
0.25(±1.1
) 
0.459 
Hip 
circumference  
(cm) 
116(±13) -5.1(±3.3) 115(±10) 1.3(±1.4) ˂0.001 99.2(±7) 0.4(±1.1) 92.4(±3.8) -0.1(±0.3) 0.221 
CRP (mg/L) 8.3(±8.6) -3.6(±6.6) 6.5(±5.9) -0.7(±3.4) 0.154 1.4(±1.9) -0.2(±1.0) 1.5(±2.2) -0.6(±1.4) 0.466 
LDL (mg/dl) 108(±38) -13(±34) 127(±37) -22(±39) 0.505 96.1(±54) -12(±27) 94.7(±23) -20(±40) 0.600 
HDL(mg/dl) 52.2(±13) 1.0(±4.7) 50.9(±13) 1.0(±4.5) 0.978 61.0(±15) -0.8(±14) 59.9(±13) -4.0(±7.2) 0.586 
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TG (mg/dl) 75.2(±28) -2.0(±9.1) 120(±53) -9.1(±33) 0.375 69.4(±30) -6.5(±22) 99.6(±44) 
-
25.0(±56) 
0.405 
T Chol(mg/dl) 176(±44) -12(±31) 202(±38) -23(±40) 0.441 171(±64) -14(±30) 174(±34) -29(±51) 0.432 
Testosterone 
(ng/dL) 
          
Vitamin D            
BDI-II 
3.08(±0.9
) 
-0.9(±1.1) 3.5(±0.8) -0.1(±0.6) 0.062 
2.57(±1.0
) 
-0.2(±0.6) 3.22(±0.8) -0.6(±0.5) 0.152 
GAD7 
2.92(±0.5
) 
-1.1(±0.8) 2.79(±0.6) 0.1(±0.5) 0.002 
2.14(±0.9
) 
0.0(±0.4) 2.50(±0.7) -0.4(±0.5) 0.062 
PA ( hours) 
0.23(±0.5
) 
3.6(±1.7) 0.23(±1.0) 0.07(±0.3) ˂0.001 
0.64(±0.8
) 
0.9(±2.1) 1.5(±2.7) 2.5(±1.0) 0.056 
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- Statistically significant results are shown in boldface.  
- The p value refers to comparison of mean change between baseline and 6 
months. 
- BMI: Body Mass Index, CRP: C - Reactive Protein, LDL: Low Density 
Lipoprotein, HDL: High Density Lipoprotein, TG: Triglycerides, T. Chol: Total 
Cholesterol, BDI-II: Beck Depression Inventory-II, GAD-7: Generalized 
Anxiety Disorder 7, PA: Physical Activity.  
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4.3.7. Food Frequency Questionnaire and 24 hour recall: 
Food intake was measured by FFQ at 0, 3, and 6 months in order to study effect of 
nutritional intervention on food intake, and these are shown in table 10.FFQ was 
analyzed by calculating the serving sizes. Average caloric intake via 24 hour recall 
was analyzed using NutriPro software. Patients who received intervention in the 
overweight/obese had a significant decrease in number of portions of most high 
calorie food items including bread and carbohydrate portions (p<0.001), fruit 
portions (p=0.027), fats and oils whether saturated or unsaturated (p=0.040 and 
0.028respectively), high fat meat (p=0.030), and sweets (p=0.010), and an increase 
in lean meat and vegetables. However, overweight/obese controls had no change 
in most types of food items except for an increase in bread portions by 3 portions), 
in saturated fat (+ 1), high fat meat (+ 2) and in sweets .The difference between 
overweight/obese interventions and controls is significant in bread intake. 
In the lean intervention groups there was a decrease in portion size in bread (- 1), 
fruits (- 1), saturated fat (- 2) and sweets. The lean controls group had an increase 
in portion in the bread (+1), high fat meat (+1), saturated fat (+1) and sweets (+1). 
There was no statistical significance between the lean intervention and control 
groups. 
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Table 10 Variation in food serving size between the study groups employing 
FFQ 
 
 
 
Statistically significant results are shown in boldface.  
Student-t-test was done to get the mean number of serving (rounded to the nearest 
ones). 
 
Food items Overweight/obese 
(n=38)  
p-
value 
Lean (n=38) p-value 
Interventions Controls Interventions Controls 
Breads (30g) - 3 + 3 < 
0.001 
- 1 + 1 0.025 
Dairy products 
(30g) 
0 0 0.890 0 0  0.890 
Fruits ( 1 
serving) 
- 3 0 0.027 - 1 0  0.035 
Fats/Oils 
MUFA/PUFA 
Saturated 
 
 +2 
- 2 
 
0 
+1 
 
0.070 
0.028 
 
0 
 -2 
 
0 
+1 
 
0.950 
0.035 
Meat(90 g) 
High fat 
Medium fat 
Lean 
 
- 2 
0 
 +2 
 
+ 2 
0 
0 
 
0.030 
0.790 
0.045 
 
0 
0 
+1 
 
+1 
0 
0 
 
0.047 
0.920 
0.043 
Vegetables( 
1cup) 
 +3 0 0.025 +1 0 0.038 
Sweets - 3 + 3 0.010 -1 +1 0.029 
Beverages 0 0 0.910 0 0 0.880 
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4.4 Discussion 
The justification of recruiting non-PCOS women was to assess the effect of the 
researcher intervention on non –PCOS women and compare the outcomes with 
PCOS women. This helped us determining the effect of diet on both overweigh/obese 
and lean PCOS patients after being subjected to nutritional education sessions 
focusing on promoting healthy food choice suitable for their condition, weight loss if 
needed and promoting physical activity and the effect of this intervention on non –
PCOS women. 
 
Weight management among interventions 
 A significant number of studies have investigated the effect of weight loss programs 
in synchronization with pharmaceutical agents rather than weight loss/maintenance 
unaided.  
In this pilot study, the weight loss seen among the overweight/obese intervention 
group who followed weight management sessions was higher (7.7Kg (±5.5) ) than 
the lean weight maintenance group (0.5 Kg(±0.6)) . On the other side, 
overweight/obese control group had more weight gain (3.1 Kg (±3.8)) than the lean 
control group (0.8 Kg (±2.3)). 
The changes seen between the four groups were due to the obedience of the 
intervention groups to the nutritional intervention (a tailored weight management 
plan) and the weight gain amongst control groups who did not follow any dietary 
intervention. Consequently, the dietary intervention was potentially dynamic in term 
of weight loss/management for a period of time (6 months) to endorse a targeted 5-
10 % weight loss of initial body weight. A recent study on overweight/obese PCOS 
patients following a low carbohydrates/low dairy diet for eight weeks showed a weight 
loss higher than the weight loss seen in our study (Phy et al.,2015).  
By linking these results to the pilot study results, the low carbohydrates/low dairy diet 
was more effective in the short term (8 weeks) than the hypocaloric diet followed in 
the pilot study.  However, in the long run to preserve a sustainable weight loss, the 
six months hypocaloric diet seemed effective for PCOS patients who were vulnerable 
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to weight gain. During the scale-up intervention, the-pilot-study-overweight/obese -
intervention-group will be followed for an extended period to confirm the maintenance 
efficiency of the hypocaloric six months weight loss diet. 
 Another study by Moran et al in 2006 indicated a similar average weight loss of 5.7 
Kg, but on a shorter period of intervention (8 weeks) (Moran et al.,2006). This is due 
to the difference in type of diet management (meal replacement versus hypocaloric 
–pilot study), where the caloric intake is controlled by meal replacement, while the 
hypocaloric diet is  not controlled  due to differentiation in meal preparation among 
the PCOS patients. So practically on the long term, hypocaloric diet is more efficient, 
which will be tested further in the scale-up intervention.  
 
Anthropometric changes pre- and post-intervention 
A significant reduction was seen in waist circumference (P˂0.001) amongst the 
overweight/obese intervention group, which was comparatively equal to the low 
starch/low diary 8 weeks diet (Phy et al., 2015) (P < 0.0001). A variation in the 
anthropometric indices like waist circumference can be seen in low starch/low diary 
weight loss group due to the exclusion of carbohydrates and simple sugars from the 
regime (Phy et al., 2015). This is why a quicker modification in waist circumference 
was seen in association to the pilot study results.  
Low starch/low diary diet management is effective in reducing waist circumference 
and abdominal obesity amongst PCOS patients. This pilot study gives evidence that 
a non-elimination diet with hypocaloric dietary management can offer similar results 
even for a longer period of time (6 months). The intervention patients in the lean 
group gained fewer centimeters in waist circumference compared to control group 
This pilot study demonstrates that a six months dietary intervention gives an 
improvement in the body composition of overweight/obese PCOS patients and 
decrease the progress towards obesity in lean PCOS patients.  
The BMI in intervention overweight/obese PCOS patients decreased and in 
control patients increased by significantly  (P < 0.001) and this is due to the weight 
loss accomplished after the intervention. In the weight loss group, the BMI decrease 
is clinically significant in reducing diabetes and metabolic syndrome in the global non-
PCOS population, which improves fertility issues in the PCOS population (Moran et 
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al., 2006). The change seen in BMI pre and post-intervention is similar to other 
studies, but on a shorter period of time (8 weeks) (Phy et al., 2015), which is due to 
the low starch/low diary diet followed by fast weight loss after weight management in 
relation to biochemical changes. 
The 7% weight loss via nutritional intervention showed non-significant 
changes in biochemical markers (Fasting blood glucose; LDL-C, HDL-C, TC, TG, 
total testosterone, CRP and fasting insulin levels) with P values (0.40, 0.50, 0.55, 
0.47, 0.74, 0.837, 0.13 and 0.64) respectively. These results are similar to Moran’s 
et al. (2007) study outcomes, where no reduction in CRP levels was seen after 4% 
weight loss. This pilot study adds to the scientific data that a 7 % weight loss shows 
non-statistically change in CRP levels (P= 0.13). Even though former literature 
demonstrates that weight loss decreases CRP levels (Moran et al., 2007), it is not 
perceived in women with PCOS. 
The lipid profile factors (total cholesterol, LDL-C, HDL-C, and triglyceride) also 
showed a non-statistically significant P-value reduction amongst overweight/obese 
group with P values (0.60, 0.59, 0.43 and 0.4) respectively. The outcomes after the 
study accomplishment indicated that a 7% weight loss was not adequate to alter the 
lipid profile parameters in PCOS patients after a hypocaloric weight loss diet. 
However, a 7.7 Kg weight loss in this pilot study was seen too minor to employ 
beneficial effects on the metabolic profile. In comparison, Phy’s et al. (2015) research 
outcome presented that low starch/low dairy eight weeks diet statistically reduced 
total testosterone (p =0.008) and fasting insulin (P <0.001). 
Consequently, insulin sensitivity is affected by reducing carbohydrate intake in PCOS 
patients in a short period of time (8 weeks) even though, with the comparatively 
equivalent weight loss compared to this pilot study. PCOS patients are at increased 
risk of cardiovascular disease and raised inflammatory indicators, and this requires 
an additional weight loss to exert metabolic benefits. A higher mean reduction in LDL-
C was noted in the overweight/obese control group compared to the obese 
intervention, who were on LSM, due to high statins medication intake in this group 
(45.5 % of the total population) (Refer to appendix 14; figure 7).  
Additionally, HDL-C was seen to be higher in obese control and this is due to 
reduction in LDL-C caused by statin intake. This might be the event for a longer 
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period of intervention need to improve the metabolic syndrome parameters in 
overweight, obese PCOS women. However, non- significant change in lipid profile 
except in HDL-C (P< 0.001) was seen after a 1-year lifestyle intervention for PCOS 
adolescents, which is due to altered population age range (adolescents PCOS girls) 
(Lass et al., 2001). 
Hirsutism is clearly related to hyperandrogenism, and results recommend that total 
testosterone and SHBG are critical parameters in PCOS. Total testosterone is linked 
to hyperinsulinemia according to Lass et al. (2011). The alteration in weight seen in 
overweight/obese intervention group was not seen to be associated to the equivalent 
change in insulin and total testosterone level. The hypothesis stating that obesity and 
PCOS are linked to insulin resistance is supported in the pilot study outcomes. These 
effects will be evaluated further on the scale-up intervention. Long term suitability 
(long period weight loss plan and lifestyle change with promoting physical activity) 
and obedience are required to be examined in the scale-up intervention when a sub-
population of the pilot population will continue for an extra 6 months on the weight 
management intervention and later compared to the population who follow a 6 
months intervention.  
 
Menstrual Regularity post intervention 
In overweight/ obese group nutritional education and weight loss/maintenance have 
revealed a cost-effective intervention in terms of time to ovulation between 
intervention and controls.  The time to ovulation in this study has confirmed to be 
different between intervention (overweight/obese and lean) and controls with no 
statistically significant difference and a P =0.648. 
Time for ovulation was less in the intervention groups (overweight/obese and lean) 
due to the weight loss and increased physical activity while a longer time for ovulation 
was seen in controls. Lass et al. (2011) has shown equal results over a longer period 
(1 year) where amenorrhea reduced by 42% (P< 0.001) in the weight loss group. The 
study results are biased by the fact  of ovulation induction medications intake by some 
PCOS women as part of the usual care have biased this factor, thus, an extra variable 
(number of menstrual period during the study duration) will  be counted in the scale-
up intervention. The pilot study results propose that a hypocaloric weight loss diet 
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with physical activity promotion and a 7.7 Kg average weight loss can reestablish 
menstrual cycle in overweight/obese women. 
Many PCOS women in the population studied were looking to conceive following the 
intervention proposed, but obesity, and insulin resistance can alter their pregnancy 
outcomes and cause adverse effects such as preeclampsia. Consequently, a weight 
loss before pregnancy plan is desirable in order to conceive in a healthy BMI range. 
Deviation to a healthy lifestyle 
Significant results appeared in the overweight/obese intervention groups with an 
increased consumption of vegetables lean meat MUFA and PUFA when comparing 
the food frequency questionnaire before and after intervention. Major decrease 
seemed in saturated fat  as well as sweets, in fruits, bread, high fat meat, causing a  
decrease in the weights of the patients. The lean intervention group results showed 
a decrease in high caloric food such as bread, saturated fat and sweets. This 
decrease has prevented them from proceeding to gaining weight by excess caloric 
intake compared to the lean control group who showed increase in unhealthy food 
consumption. 
The intervention (Lean or Obese) groups were educated to consume healthy food 
items such as fruits and vegetables, lean proteins and MUFA/PUFA fats that can limit 
the likelihood of nutritional deficiencies, which may stop them from conception or 
adverse effects. This is the first study to offer a balanced nutritional weight loss plan. 
Thus, women who are concerned about their reproductive health can follow the 
proposed nutritional guidelines for the PCOS (overweight/obese and lean). The 
originality of this study is diverse from education on healthy lifestyle, food options, to 
physical activity promotion and tools to be used in the long term and not just for 
interventional purposes. 
All PCOS population can use the proposed nutritional guidelines as tools in the future. 
The compliance of the PCOS patients to the pilot study’s nutritional guidelines was 
seen in the changes seen in their food items intake suggested. 
On the other hand, a significant increase of bread (P=0.025) and sweets intake  
due to their uncontrolled eating plan was seen amongst  the control groups. These 
results are vital to promoting the awareness of the implication of nutritional 
guidelines and dietary behaviors for the PCOS patients.  
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In addition, menstrual regularity was altered by the significant increase in total 
physical activity among the overweight/obese intervention. A significant 
improvement was seen in psychological status between both intervention groups 
and both control groups with a P value 0.014 and a BDI-II with a P value < 0.001. 
This is the first study to assess the physiological state changes among all PCOS 
patients and to compare those following a weight loss/ maintenance diet. After 
study completion , it was lifestyle modification (weight loss/maintenance and 
physical activity) can improve the psychological status (anxiety, depression, and 
mood swings) amongst intervention groups (overweight/obese and lean PCOS).  
Considerably weight loss/maintenance is an important factor for PCOS patients in 
self-esteem restoration. The psychological scores were improved as a result of their 
compliance and in the future a possible sustainability indicator. Thus, this pilot study 
highlights the positive effects of physical activity and weight loss nutritional 
interventional programs in PCOS patients with psychological status disturbances, 
(anxiety and depression). 
 
Pilot study results improving scale up design 
This pilot study is a potential stage towards preventing or limiting obesity among 
PCOS population. The outcomes highlighted the inconvenience faced during body 
temperatures measurement at the different menstrual cycle stages to indicate the 
ovulation dates. Therefore, data collection in the scale up was changed to dates 
recording and life birth rate recording. It is suggested to count the number of cycles 
rather than the body temperature measurement in the scale up intervention. Another 
limitation seen in the pilot study is the single centered study population recruitment 
(one medical center as a setting of the study) at the capital of Lebanon. A single 
center study does not include different socio-economic and cultural status patients 
with. So in the scale up intervention four centers in different socio-economic settings 
and areas were included. 
• All research assessment tools were refined to adapt to the higher population 
size in the scale up intervention. The monitoring plan was developed during 
the pilot study. 
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• The research team including the gynecologists were trained about the 
patient approach, data collection and diagnosis. The purpose of re-training 
them is to ensure good data collection with minimum bias. 
• Data was reviewed following after each patient visit at the study site by the 
doctoral researcher and the gynecologist to assure completeness of data. 
• Continuity of field check-ups by the researcher for monitoring purposes and 
detection of any potential hazards that may affect the flow of the study. 
• Monitoring the effect of nutritional guidelines on patients' adherence and its 
results on anthropometric measurements and biochemical analysis.  
• Sustainability plan (from outcome of conclusion and discussion) and 
guidelines follow-up by all gynecologists in order to guide their PCOS 
patients on the importance of nutritional intervention and lifestyle medication 
in AUBMC and another women’s health center in Lebanon.  
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Chapter 5 
Results: Scale-up intervention 
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5.1 Introduction 
The scale up intervention (n=588) outcomes involve the recruitment of pilot study 
patients (n=76) in the scale up intervention with an additional four hundred twenty-
two patients. Patients are recruited based on the calculation method used. A sub-
sample (n=30) of the pilot study patients were monitored for a total of 12 months’ 
period of time. The scale up intervention was well organized to monitor the changes 
and sustainability plan involving the research team consisting of the researcher, the 
hospital staff team and the patients involved for a period of six months. Data 
collection was collected over this scale up period of time. 
 
Objectives 
i. To evaluate the effectiveness of public health nutrition through the pre-
intervention versus the post-intervention assessment employing the study 
indicators (positive deviation to healthy life style, adequate/balance dietary 
intake, healthy body weight, optimum physical activity, optimum blood 
pressure, improved biochemical indicators) via pilot/scale up intervention. 
ii. To design and optimize educational sessions tailored to PCOS patients in 
order to raise their nutritional awareness, enable informed healthy food 
choice and engage them in physical activity. 
iii. To assess the rates of regularities of menses (examined by pregnancy onset 
and ovulation) in the participant groups and in matched control PCOS 
population receiving no intervention. 
iv. To evaluate the efficacy of public health nutrition through the pre-intervention 
versus the post-intervention assessment employing the study indicators 
(positive deviation to healthy life style, adequate/balance dietary intake, 
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healthy body weight, optimum physical activity, optimum blood pressure, 
improved biochemical indicators) via pilot/scale up intervention. 
v. To develop and optimize the nutrition framework for people living with PCOS 
in Lebanon. 
 
Diagnosed women with PCOS (n=76) were approached about the study and invited 
to participate in the research at the clinics of Obstetrics and Gynecology of the 
American University of Beirut Medical Center, Beirut, Lebanon(during 2016-2017). 
Upon the applied sample size calculation, inclusion and exclusion criteria, 588 
patients were designated over simple randomization. Patients diagnosed with 
PCOS and accepted to participate in the study were subject to an assessment form 
including medical history, obstetrical and gynecological history, anthropometric 
measures, menstrual regularity diary, biochemical parameters and socio-
demographic indices. Patients who participated in the study were PCOS and non- 
PCOS. Each women group was subdivided into lean and over/obese group. PCOS 
women recruited were weight-matched with non-PCOS women. Study patients 
were grouped into interventions and controls according to their randomization 
number. Study patients received a nutritional assessment, counseling and 
education. Patients over 6 months were subject to a total of 3 educational sessions. 
Assessment was carried on at baseline, 3 months and 6 months after baseline as 
mentioned in the study methodology (details in Chapter 3). 
The following data are presented for study after 6 months and then after 12 months. 
 
5.2 Results 
I. Baseline characteristics 
a. Socio-demographics  
b. Gynecology  
II. Changes after 6 months  
a. Anthropometric measurements  
b. Gynecology 
c. Biomedical markers 
d. Psychological status and physical activity 
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e. 24-hour recall 
f. Comparison between obese and lean patients  
g. FFQ changes  
III. Changes after 12 months  
a. Gynecology 
b. Anthropometric measurements  
c. Biomedical markers 
d. Psychological status and physical activity 
e. FFQ Changes after 12 months for PCOS patients  
 
5.2.1 Baseline characteristics  
Socio-demographics  
The study included 588 patients, half of which had PCOS (294). Table 11 
summarizes the socio-demographic baseline characteristics. Most patients in this 
study were in the middle age group (20-30 years) (80.4%), patients were matched 
in age and weight between PCOS and non-PCOS groups, where similar 
percentages occurred in the 2 groups with a non-significant p-value. More than 60% 
of the patients were single, and this distribution occurred similarly between the 2 
groups with a non-significant p-value. About 13.9% of the females in general were 
smokers, but there was a significant difference between the 2 groups where 20% of 
PCOS patients were smokers compared to only 2.4% of the non-PCOS patients. 
About quarter of the patients were alcoholics and no difference between whether 
they had PCOS or not. Most of the patients had high school or university 
educational levels, and lived in owned homes with an average of 4 people living at 
home. About half of the patients were working (53%), with an average yearly 
income of about 40,501$ (44,770 for PCOS patients and 34,168$ for non-PCOS 
patients), and most paying privately their medical payments followed by health 
insurance plan payments.  
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Table 11 Baseline characteristics of all baseline scale up patients 
 
Character 
Total 
(N=588) 
PCOS 
(n=294) 
Non-PCOS 
(n=294) 
p-value 
Age, n(%) 
18-20 
20-25 
25-30 
30-35 
 
56 (9.6%) 
247 (42%) 
226 (38.4%) 
59 (10%) 
 
27 (9.2%) 
106 (36%) 
126 (42.8%) 
35 (11.9%) 
 
29 (9.8%) 
110 (37.4%) 
123 (41.8%) 
32 (10.8%) 
0.677 
Marital state, n(%) 
Single 
Married 
 
393 (66.8%) 
195 (33.2%) 
 
202 (68.7%) 
92 (31.3%) 
 
186 (63.3%) 
108 (36.7%) 
0.380 
Smoker, n(%) 82 (13.9%) 59 (20.1%) 7 (2.4%) **<0.00
1 
Alcoholic, n(%) 152 (25.9%) 75 (25.5%) 78 (26.5%) 0.887 
Education, n(%) 
˂ High school 
High school 
University-BS 
Higher degrees 
 
45 (7.7%) 
240 (40.8%) 
199 (33.8%) 
104 (17.7%) 
 
33 (11.2%) 
110 (37.4%) 
90 (30.6%) 
61 (20.7%) 
 
0 (0%) 
139 (47.2%) 
118 (40.1%) 
37 (12.6%) 
*0.002 
Home type, n(%) 
Owned 
Rented 
Family 
 
431 (73.3%) 
99 (16.8%) 
58 (9.9%) 
 
263 (89.4%) 
29 (9.9%) 
2 (0.7%) 
 
128 (43.5%) 
87 (29.6%) 
79 (26.9%) 
**<0.00
1 
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People at home, mean 
(± SD) 
4.0 (±1.4) 4.47 (±1.3) 3.14 (±1.1) **<0.00
1 
Working, n(%) 312 (53.0%) 142 (48.3%) 183 (62.2%) 0.036 
Yearly income in $, 
mean (±SD) 
40,501 
(±17,526) 
44,770 
(±17,209) 
34,168 
(±16,106) 
**<0.00
1 
Medical payment, n(%) 
Private 
NSSF 
Insurance 
HIP 
 
240 (40.8%) 
110 (18.7%) 
55 (9.3%) 
183 (31.2%) 
 
106 (36.0%) 
60 (20.4%) 
40 (13.6%) 
88 (30.0%) 
 
39 (51.3%) 
11 (14.5%) 
0 (0%) 
26 (34.2%) 
*0.002 
 
Gynecology 
As shown in table 12, more than 90% of patients had nulliparous, lower menarche 
age for PCOS patients (Mean age of 12.1 years for PCOS compared to 13.9 for 
non-PCOS patients). Fifty-three percent had irregular cycle (53.2%), however when 
comparing between the 2 groups, seventy-two percent most PCOS patients 
(79.2%) had irregular cycle compared to none in non-PCOS patients. Patients 
having PCOS were more sexually active (19%) compared to non-PCOS patients 
(6.1%)PCOS patients had more acne (81.6%) compared to non-PCOS patients 
(6.4%), lower average number of cycles (3.78 compared to 5.67) and longer time to 
ovulation (43.9 days compared to 12.6 days for non-PCOS patients).  
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Table 12 Gynecological baseline characteristics for all baseline scale-up 
patients 
 
Character Total (N=588) 
PCOS 
(n=294) 
Non-PCOS 
(n=294) 
p-value 
Gravida, n(%) 
0 
1 
2 
3 
 
540 (91.8%) 
19 (3.2%) 
22 (3.7%) 
7 (1.2%) 
 
258 (87.8%) 
14 (4.8%) 
16 (5.4%) 
6 (2.0%) 
 
294 (100%) 
0 
0 
0 
*0.005 
Para, n(%) 
0 
1 
2 
3 
 
561 (95.4%) 
15 (2.5%) 
8 (1.4%) 
4 (0.7%) 
 
267 (90.8%) 
15 (5.1%) 
8 (2.7%) 
4 (1.3%) 
 
294 (100%) 
0 
0 
0 
0.062 
Age at menarche, 
mean (± SD) 
12.7 (±1.4) 12.1 (±1.0) 13.9 (±1.3) **<0.001 
Period, n(%) 
Regular  
Irregular 
 
275 (46.8%) 
313 (53.2%) 
 
61 (20.8%) 
233 (79.2%) 
 
294 (100%) 
0 (0%) 
**<0.001 
Sexually active, n(%) 87 (14.8%) 56 (19.0%) 18 (6.1%) *0.007 
Contraception, n(%) 176 (30.0%) 92 (31.3%) 84 (28.6%) 0.872 
Acne, n(%) 335 (57%) 240 (81.6%) 19 (6.4%) **<0.001 
Number of cycles, 
mean (±SD) 
4.99 (±2.7) 3.78 (±1.1) 5.67 (±1.0) **<0.001 
Time to ovulation in 
days, mean (±SD) 
32.3 (±28.2) 43.9 (±28.8) 12.6 (±11.8) **<0.001 
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I. Changes after 6 months 
5.2.2 Improved anthropometric indices  
Initially patients were weight and age matched for the different groups and for 
PCOS and non-PCOS patients. In the PCOS group, the average initial weight was 
86.4(±2.7) for intervention and 81.7(±6.4) for controls in the overweight/obese 
group. As for the average initial weight for in the intervention group was 53.5(±3.4) 
and 56.8(±3.9) for controls in the lean group. The difference between these groups 
was statistically significant with P= 0.001. In the non- PCOS group, the average   
initial weight was 87.1(±8.2) for intervention and 82.6(±9.1) for controls in the 
overweight/obese group. As for the average initial weight for in the intervention 
group was 54.4(±6.5) and 51.0(±2.0)) for controls in the lean group. 
However, when studying the change in the body weight after the 6 months between 
the different groups, as shown in tables 13 & 14 there was a low statistical 
significance in this change whether in the PCOS group or the non-PCOS group ( 
P=0.002 and P=0.005). PCOS patients who got the intervention lost about 8.2 Kg in 
the overweight/obese group and 1.5Kg in the lean group .Whereas, the control 
ones in the PCOS overweight/obese group gained about 4.96 Kg and the lean 3.13 
Kg. As shown in tables 13 & 14  there was a statistical significance between the 
PCOS groups (P= 0.001).In the non-PCOS group patients who got the intervention 
lost about 11.6 Kg in the overweight/obese group and 0.81  Kg in the lean group. 
Whereas, the control ones in the PCOS overweight/obese group gained about 1.22 
Kg and the lean 0.23 Kg. The difference was statistically significant in both PCOS 
and non-PCOS groups (P=0.001; P=0.001). 
When studying the % change in the body weight, PCOS patients who got the 
intervention lost an average of 10 .03% in the overweight/obese group and 2.8 % in 
the lean group of their body weight. In the PCOS controls groups 90% of PCOS 
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overweight/obese and 16.3% of lean interventions met the primary goal of 5% loss 
in body weight. In comparison to the controls PCOS group patients gained an 
average of 5.74 % in the overweight/obese groups and 5.5 % in the lean group with 
no patients in the control groups meeting the 5 % loss in their weights (P-value 
significant in all cases). Whereas non-PCOS patients who got the intervention lost a 
slightly higher percentage of their weights than PCOS ones (13.3 Kg for 
overweight/obese group and 1.48 Kg for lean group) and 100 % of the 
overweight/obese group met the 5 % loss in body weight while only 16.7% in the 
lean maintenance group. Note that the intervention patients met the 5 % loss in 
body weight in more than. 50% of cases whether they had PCOS or not, with a 
statistical significance (P =0.001; P=0.001). 
Most body composition parameters decreased significantly with intervention 
patients but stayed the same or increased with the control patients in both PCOS 
and non -PCOS groups. 
PCOS overweight/obese patients who got the intervention showed a decrease in 
waist circumference of 4.5 cm (compared to an increase 2.0 cm for controls). Non-
PCOS overweight/obese patients who got the intervention showed a decrease in 
waist circumference of 6.7 cm (compared to no change for controls). As for the 
PCOS lean patient who got the intervention showed a decrease in waist 
circumference of 0.3 cm (compared to an increase of 4.2 cm for controls).  The 
difference between these group is statistically significant with P=0.001. While the 
non PCOS lean had a decrease in waist circumference of 0.3 compared to no 
change for controls with no statistical significance between the non-PCOS group.\ 
Note that the non-PCOS patient who got the intervention had a bigger decrease in 
most parameters more than PCOS ones but the difference was no statistically 
significant. 
 
 
5.2.3 Improved reproductive profile 
As shown in tables 13 & 14 , there no significant difference between the 
intervention and control groups in the change in hirsutism score for both PCOS and 
non-PCOS patients where the score decreased slightly in the intervention groups 
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(by 0.14 for overweight/obese PCOS, 0.30 for lean PCOS, 0.01 for 
overweight/obese non-PCOS and 0.1 for lean non -PCOS) slightly decreased for 
PCOS groups and didn’t change for non-CPS group. 
On the other hand, time to ovulation and number of cycles changed significantly 
between groups in the PCOS and non - PCOS patients. 
Time to ovulation was longer PCOS overweight/obese and lean control groups in 
comparison to non-PCOS patients and overweight/obese intervention groups. 
PCOS patients who got the intervention had a shorter time to ovulation (34.6 days 
for overweight/obese groups and 38.1 for lean group), than those who didn’t with 
(52, 4 days to overweight/obese group and 53.6 days for lean group). The 
difference between the PCOS groups is statistically significant with P < 0.001. As 
for the non-PCOS who got the intervention time to ovulation different in the 4 
groups with 17.4 days for overweight/obese intervention and 10.1 for controls , 
while the lean groups had 9.6 days for intervention and 13.1 for controls. The 
difference between the groups was statistically significant with P<0.001. 
Similarly PCOS patients who got the intervention had more average number of 
cycles during the 6 months study duration (4.3 cycles) for overweight/obese group 
and ( 4.1 cycles) for lean group in comparison to the control groups  with average 
(3.1 cycles for overweight/obese group and 3.6 for lean group). The difference 
between the PCOS groups is statistically significant with P< 0.001. On the other 
hand, the non -PCOS who received the intervention or not had an equal number of 
cycles with non -statistical significance between the groups (P= 0.0.3). 
Regarding the pregnancy rate for PCOS patients , it was shown that it increased 
significantly with intervention patients in all groups compared to controls (from 0% 
to  70% compared from 0% to 15 % respectively )as shown in figure 6 below. 
 
 
 
5.2.4 Biomedical and metabolic profile changes 
The CRP decreased slightly for both intervention and control patients who had 
PCOS or not, but the most decrease was for the PCOS patients in the 
overweight/obese group who got the intervention where CRP decreased by 1.7 mg/l 
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(Refer to tables 15 & 16). However, FBS decreased for PCOS significantly in the 
overweight/obese and lean by 5.5 mg/dl and 3 mg/dl respectively compared to an 
increase in the FBS in the control groups by 7.4 mg/dl and 3.7 mg/dl for 
overweight/obese and lean groups respectively. The difference between PCOS 
gross was statistically significant with P<0.001. In comparison to non-PCOS 
patients FBS decreased for both interventions in the overweight/obese and lean 
groups by 5.5 mg/dl and 3.2 mg/dl respectively while controls showed an increase 
with significant P-value of <0.001. 
Regarding the lipid profile, PCOS patients who got the intervention had a decrease 
in all lipid parameters ( LDL, HDL, TG and total cholesterol) more than the control 
patients, but this difference was significant for LDL where P<0.001. Total 
cholesterol decreased by 13.5 and 19.7 for overweight/obese and lean PCOS 
intervention respectively compared to overweight/obese and lean controls with a 
decrease in 10.9 and an increase for lean control by 1,6. The difference was 
statistically significant with P<0.001 ( Refer to table 15). Similarly non-PCOS 
patients who got the intervention had a decrease in lipid profile more than controls 
who had a slight increase in most lipid parameters, with a significant difference 
between intervention and controls for Total cholesterol that decreased by 6.2 for 
overweight/obese intervention and 0.6 for lean intervention and decreased by 0.6 
and increase by 1 for overweight/obese and lean groups respectively(Refer to table 
16). 
Testosterone as indicator of hyperandrogenemia, decreased for PCOS by 3.2 ng/dL 
for overweight/obese group and 2 ng/dL for lean groups who got the intervention 
but increased by 1.9 ng/dL and 1.5 ng/dL respectively for overweight/obese and 
lean groups who didn’t receive the intervention. The difference is statistical non-
significant with P=0,120. However, non-PCOS patients had a slight decrease 
whether they got intervention or not (-0.01 for overweight/obese group, -0.03 ng/dL 
for lean group; and -0.06 ng/dL for control in the overweight/obese group and -0.04 
ng/dL for lean controls). 
Looking for insulin levels, PCOS patients who got the intervention had more 
decrease than controls (- 1.3 µu/mL for overweight/obese group and -0.6 µu/mL for 
lean group) and an increase for controls overweight/obese group by 0.5 µu/mL). 
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Whereas, non-PCOS patients who got the intervention had higher decrease than 
PCOS ones (- 3.8 µu/mL for overweight/obese group and -1.2 µu/mL for lean group 
compared to slight change for controls. The difference was not statistically 
significant.  
Vitamin D levels improved slightly in PCOS patients whether they got the 
intervention or not (+0.71 for overweight/obese intervention group, +0.92 for 
overweight/obese controls, +0.59 for leas intervention and +0.80 for lean controls). 
Whereas, the change in non-PCOS patients was negligible. 
 
5.2.5 Enhancement of psychological status and physical activity  
Studying psychological status, 2 tests were used; first the BDI-II which decreased 
significantly between intervention and controls in the PCOS groups (P<0.001)(Refer 
to table 15), but the change was not significant between the non-PCOS patients 
(P=0.006)(Refer to table 16). 
PCOS who got the intervention showed a decrease in BDI-II by 1.2 for 
overweight/obese intervention and 0.69 for lean intervention compared to an 
increase of 0.16 for overweight/obese controls and 0.08 for lean controls. Whereas, 
the non-PCOS groups who got the intervention showed a decrease by 1.6 for the 
overweight/obese group and 0.45 for lean group and an increase by 0.56 for the 
overweight/.obese control group and no change for lean control groups. The 
second score, GAD-7, showed a decrease by 0.9 units for overweight/obese 
intervention and by 0.2 units for lean intervention in the PCOS groups while controls 
showed an increase by 0.08 for overweight/obese controls and 0.06 units for lean 
controls. The difference was statistically non-significant (P= 0.027). Whereas, non-
PCOS patients showed a decrease in score by 2.1 units for overweight/obese and a 
decrease of 0.5 units for lean intervention group, however, an increase for 
overweight/obese group was seen by 0.08 units and 0.45 units for lean. The 
difference was statistically non-significant (P=0.039). 
A third score studied being the physical activity showed a significant increase for 
patients who got the intervention in general and for PCOS in specific. PCOS 
patients who got the intervention showed an increase in their physical activity by 3 
hours for overweight/obese group and 2.22 hours or lean group compared to 
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controls who showed only 0.06 hours for overweight/obese and lean controls with 
P=0.001. Similarly, non-PCOS patients who got the intervention showed an 
increase in their physical activity (2.5 hours for overweight/obese group and 0.6 for 
lean group) compared to controls (0.08 hours for overweight/obese groups and 0.45 
for lean group). 
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Table 13 Average changes in anthropometricand reproductive  parameters  
among the 4 groups from baseline to 6 months in PCOS women  
 
 
 
Factor 
PCOS 
p-value 
Obese  Lean  
Intervention 
A (n=147) 
Control  
B(n=147) 
Intervention 
C(n=147) 
Control 
D(n=147) 
Initial Wt (kg) 81.7(±6.4) 86.4(±2.7) 53.5(±3.4) 56.8(±3.9) <0.001 
Weight change -8.2(±7.1) 4.96(±3.9) -1.5(±2.1) 4.73(±3.45) 0.001 
% change in 
weight -10.03(±6.7) 5.74(±4.8) -2.8(±3.6) 5.5(±6.4) <0.001 
Met 5% weight 
loss, n(%) 90% 0% 16.3% 0% <0.001 
BMI -3.7(±3.01) 1.1 (±1.5) -0.3(±0.5) 1.9 (±1.2) 0.025 
Waist circumf.  
(cm) -6.7 (±5.8) 2.0 (±2.5) -0.08(±1.0) 4.2 (±2.5) <0.001 
Hip circumf.  
(cm) -4.5 (±3.3) 1.3 (±1.5) -0.3(±0.9) 2.8 (±2.0) 0.015 
Hirsutism -0.14(±1.1) -0.06(±1.9) -0.30(±1.6) -0.03(±1.7) 0.13 
Time to ovulation 34.6(±26.1) 52.4(±26.0) 38.1(±28.6) 53.6(±24.1) <0.001 
Number of cycles 4.3(±0.8) 3.1(±0.7) 4.1(±1.2) 3.6(±1.9) <0.001 
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Table 14 Average changes in anthropometricand reproductive  parameters  among 
the 4 groups from baseline to 6 months in non –PCOS PCOS women 
 
 
 
 
 
 
Factor Non-PCOS 
p-value 
 Obese  Lean  
 Intervention  
E(n=147) 
Control  
F(n=147) 
Intervention  
G(n=147) 
Control 
H(n=147) 
Initial Wt (kg) 87.1(±8.2) 82.6(±9.1) 54.4(±6.5) 51.0(±2.0) 0.001 
Weight 
change -11.6(±3.6) 1.01(±0.3) -0.81(±3.4) 0.12(±1.0) 0.005 
% change in 
weight -13.3(±2.3) 1.22(±0.5) -1.48(±3.9) 0.23(±2.0) 0.001 
Met 5% 
weight loss, 
n(%) 
100% 0% 16.7% 0% 0.001 
BMI -3.5 (±0.5) 2.9 (±0) -0.5 (±0.8) 0.8 (±0) 0.020 
Waist 
circumf.  
(cm) 
-4.5 (±1.5) 0.0 (±0) -0.3 (±2.0) 0.0 (±0) 0.008 
Hip circumf.  
(cm) -4.4 (±1.0) 0.0 (±0) -0.4 (±0.7) 0.0 (±0) 0.025 
Hirsutism -0.01(±0.4) 0(±0.8) -0.1(±0.0) 0(±0.0) 0.16(±1.1) 
Time to 
ovulation 17.4(±14.2) 17.4(±12.3) 9.6(±3.2) 13.1(±3.4) <0.001 
Number of 
cycles 5.6(±1.4) 5.6(±1.9) 6.0(±0.0) 6.0(±0.0) 0.003 
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Table 15 Average changes in biochemical, psychological and nutritional 
parameters  among the 4 groups from baseline to 6 months in PCOS  
 
Factor 
PCOS 
p-value 
Obese  Lean  
Intervention 
A (n=147) 
Control  
B(n=147) 
Intervention 
C(n=147) 
Control 
D(n=147) 
CRP (mg/L) -1.7 (±4.9) -1.0 (±4.0) -0.9(±1.6) -0.08(±0.5) <0.001 
FBS ( mg/dl) -5.5 (±1.2) +7.4(±3.1) -3.0(±1.4) +3.7(±0.3) <0.001 
Insulin (µu/mL) -1.3(±0.2) +0.5(±0.01) -0.9(±0.02) -1.2(±0.1) 0.033 
Testosterone 
(ng/dL) -3.2(±1.3) +1.9(±0.4) -2.0(±0.4) +1.5(±0.7) 0.001 
Vitamin D 
(ng/mL) +0.71(±1.5) +0.92(±0.1) +0.59(±2.3) +0.80(±1.7) 0.120 
LDL (mg/dl) -16.5 (±22) -10.5 (±41) -4.5(±17) 1.7 (±20.1) <0.001 
HDL (mg/dl) 0.61 (±3.4) 1.26 (±4.4) -0.95(±5.0) -0.13(±8.6) 0.071 
TG (mg/dl) -7.5 (±7.0) -4.8 (±7.8) -8.8(±7) 0.02(±1.6) 0.023 
T-Cholesterol -13.5 (±2) -10.9 (±4) -19.7 (±3) 1.6 (±1) <0.001 
BDI-II -1.2 (±1.1) 0.16(±0.6) -0.69(±0.4) 0.08(±0.3) <0.001 
GAD7 -0.9 (±0.8) 0.08 (±0.5) -0.2(±1.6) 0.2 (±0.2) <0.001 
PA ( hours) 3.0 (±1.5) 0.06 (±0.3) 2.22(±0.9) 0.06 (±1.3) 0.038 
24 hour recall 1 -579(±319) -55(±288) -314(±157) 165(±141) <0.001 
24 hour recall 2 -688(±312) -60(±219) -421(±140) 0.5(±128) <0.001 
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Table 16 Average changes in biochemical, psychological and nutritional 
parameters  among the 4 groups from baseline to 6 months in PCOS 
Factor Non-PCOS 
p-value 
 Obese  Lean  
 Intervention  
E(n=147) 
Control  
F(n=147) 
Intervention  
G(n=147) 
Control 
H(n=147) 
CRP (mg/L) -0.25(±0.25) 0.0 (±0) 0.0 (±0) -0.05(±0.0) 0.056 
FBS ( mg/dl) -5.5(±2.5 +3.2(±3.2) -3.2(±1.4 +2.2(±0.5) 0.001 
Insulin (µu/mL) -3.8(±0.8) +0.2(±0.0) -1.2(±0.3) +0.1(±0.0) 0.024 
Testosterone 
(ng/dL) 
-0.01(±0.0) -0.06(±1.2) -0.03(±0.8) -0.04(±0.5) 0.186 
Vitamin D (ng/mL) -0.002(±1.8) 0.003(±1.5) -0.001(±2.3) 0.003(±1.8) 0.132 
LDL (mg/dl) -0.2 (±0.2) -0.4 (±1.3) -2.0 (±3.4) -1.0 (±0) 0.034 
HDL (mg/dl) 0 (±0) 0 (±0) -0.45 (±1.1) 2.0 (±0) 0.536 
TG (mg/dl) -7.5(±5.1) 2.08(±2.2) -1.8 (±4.3) 0.0 (±0) 0.002 
T-Cholesterol -6.2 (±0.8) -0.6 (±1.6) -1.5 (±4.0) 1.0 (±0.0) <0.001 
BDI-II -1.6 (±0) 0.56 (±0.5) -0.45 (±0.9) 0.0(±0) 0.006 
GAD7 -2.1 (±0) 0.0 (±0) -0.5 (±0.6) 0.0 (±0) 0.039 
PA ( hours) 2.5 (±0.5) -0.08 (±0.2) 0.6 (±1.3) 0.45(±0.5) 0.021 
24 hour recall 1 -461(±108) -178(±85) -210(±427) 116(±0) <0.001 
24 hour recall 2 -714(±183) -31 (±144) -204(±486) -107(±0) <0.001 
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All values represented as mean (±SD), except for met 5% loss in body weight as 
percentage 
 
*p-values of comparison between PCOS groups and non-PCOS groups patients.
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Figure 6 The graph depicts pregnancy rate in intervention and control group at 
baseline and after intervention 
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Table 17 Average change in values between baseline, 6 and 12 months for a subpopulation of PCOS 
Factor 
Between 0-6 (n=30) 
p-value 
Between 6-12 (n=30) 
p-value p-value* Intervention Control Total Intervention Control Total 
Hirsutism  score -2.1 (±0.2) 0.3 (±0.7) -0.8 (±0.3) **<0.001 -2.0 (±0.2) 
0.0 
(±0.1) -1.0 (±0.2) **<0.001 0.089 
Number of 
cycles 2(±0.3) 1(±0.4) 3(±0.7) **<0.001 3(±0.2) 1(±0.5) 3(±0.7) **<0.001 **<0.001 
Waist 
circumference -1.0 (±2.0) 1.5 (±2.5) 
0.25 
(±2.6) *0.003 -4.0 (±4.1) 5.5 (±3.6) 0.75 (±6.1) **<0.001 *0.034 
Hip circumference -3.0 (±3.0) 2.0 (±2.0) -0.5 (±3.6) **<0.001 -3.0 (±3.0) 5.5 (±1.5) 1.2 (±4.9) **<0.001 **<0.001 
Waist/Hip ratio 0.010 (±0.00) 
-0.009 
(±0.009) 
0.0003 
(±0.01) **<0.001 
-0.005 
(±0.015) 
0.010 
(±0.03) 0.0025(±0.02) 0.074 **<0.001 
% Body fat 0.0 (±0.0) 0.5 (±0.5) 0.25 (±0.4) **<0.001 -0.05 (±0.5) 
1.1 
(±1.1) 0.55 (±1.0) *0.001 **<0.001 
% EBF -3.0 (±3.0) 0.9 (±0.9) -1.02 (±3.0) **<0.001 0.0 (±0.0) 
0.2 
(±0.2) 0.10 (±0.1) *0.001 **<0.001 
% BM 0.1 (±0.1) 0.4 (±0.4) 0.25 (±0.3) *0.007 0.4 (±0.3) 
0.2 
(±0.2) 0.30 (±0.2) *0.030 0.518 
BMI -2.3 (±0.5) 0.7 (±0.7) -0.8 (±1.6) **<0.001 -2.8 (±2.9) 
1.3 
(±0.3) -0.7 (±2.9) **<0.001 **<0.001 
BMR 10.0 (±13.3) 3.0 (±4.1) 6.5 (±10.3) *0.046 4.5 (±4.6) 
-5.0 
(±6.1) -0.2 (±7.2) **<0.001 *0.004 
Change in 
weight (kg) -3.5 (±3.6) 2.0 (±2.0) 
-0.75 (± 
4.0) **<0.001 -7.0 (±7.2) 
4.0 
(±1.0) -1.5 (±7.5) **<0.001 **<0.001 
% change in 
weight -3.6 (±3.7) 2.5 (±2.5) 
-0.59 
(±4.4) **<0.001 -7.9 (±8.1) 
6.5 
(±3.1) -0.68 (±9.5) **<0.001 **<0.001 
CRP (mg/L) -0.8 (±0.0) 0.2 (±0.0) -0.13 (±0.4) **<0.001 -0.3 (±0.0) 
0.1 
(±0.1) 0.0 (±0.2) **<0.001 **<0.001 
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FBS (mg/dl) -7.5 (±1.5) -2.0 (±4.1) 
-5.7 
(±4.8) **<0.001 -3.0 (±2.0) 
2.5 
(±2.5) -0.2 (±3.6) **<0.001 **<0.001 
LDL(mg/dl) -7.5 (±3.6) -10.5 (±12.8) 
-9.0 
(±9.4) 0.347 -11.0 (±0.0) 
12.5 
(±0.5) 0.7 (±11.9) **<0.001 0.268 
HDL (mg/dl) 0.0 (±1.0) 2.5 (±1.5) 1.2 (±1.8) **<0.001 0.0 (±0.0) 
0.0 
(±0.0) 0.0 (±0.0) - - 
TG (mg/dl) -3.0 (±3.0) 0.5 (±2.5) -1.2 (±3.3) *0.001 -9.0 (±11.3) 
3.0 
(±2.0) -5.5 (±12.5) **<0.001 0.707 
Testosterone 
(ng/dL) -0.8 (±0.1) 
-1.1 
(±1.0) 
-0.9 
(±0.7) 0.189 -3.2 (±0.4) 
-1.9 
(±2.0) -2.5 (±1.6) *0.014 **<0.001 
Insulin (μU/mL) -0.9 (±0.7) -0.3 (±0.4) 
-0.6 
(±0.5) *0.013 -1.4 (±0.3) 
-0.1 
(±0.0) -0.4 (±0.0) *0.004 *0.034 
Vitamin D 
(ng/mL) 2.2 (±0.0) 0.3 (±0.3) 
0.96 
(±0.93) **<0.001 0.06 (±0.04) 
0.00 
(±0.10) 0.03 (±0.09) *0.031 0.304 
BDI-II -0.5 (±0.5) 1.0 (±0.0) 0.5 (±0.5) **<0.001 -2.0 (±0.0) 
1.0 
(±0.0) -0.5 (±1.5) <0.001 **<0.001 
GAD-7 -2.0 (±0.0) 0.5 (±0.5) -0.7 (±1.3) **<0.001 -0.01 (±0.0) 
-0.08 
(±0.0) -0.04 (±0.0) <0.001 **<0.001 
Physical activity 
( hours/week) 3.0 (±0.7) 0.0 (±0.0) 
1.5 
(±1.6) **<0.001 1.2 (±0.4) 
0.0 
(±0.0) 0.6 (±0.7) <0.001 **<0.001 
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5.2.6 24-hour recall 
Final factor studied was the 24-hour recall that showed a significant change 
between intervention and control patients whether they had PCOS or not, however 
no significant difference occurred between PCOS and non-PCOS patients. Patients 
who got the intervention had a significant decrease in the 24-hour recall during 
weekdays (579 calories for PCOS overweight/obese intervention and 461 calories 
for non-PCOS patients overweight/obese intervention) and during weekends (688 
calories for PCOS overweight/obese interventions and 714 calories for non-PCOS 
patients overweight/obese intervention) whereas patients who didn’t get the 
intervention showed an increase in their calorie intake. These are shown in table 
10.  
 
Food Frequency Questionnaire 
After the 6 months duration, it was noted that PCOS patients had a significant 
change in the number of portions of all food types where number of portions 
improved after the intervention for all food types. On the other hand, non-PCOS 
patients had some food types that didn’t change significantly with the intervention 
such as potato, squash, organ meat, luncheon meat, and Arabic sweets. Changes 
in portions of all food types after 6 months are shown in table 18. Similarly, Patients 
who were followed for 12 months showed also a significant improvement in all food 
types after getting the intervention compared to those who didn’t get the 
intervention where all high calorie food decreased in number of portions while low 
calorie food increased in their number of portions, as shown in table 21  ( Refer to 
Appendix 12-14). 
 
5.3 Comparison between obese and lean patients  
Table 18 shows comparison in weight between obese and lean subgroups after the 
6 months follow up. It was noted that PCOS patients who were obese lost more 
weight than lean patients when receiving the intervention (-8.2 and -1.5 kg 
respectively), and as a result 90% of those obese patients met the 5% loss in body 
weight compared to only 16.3% of lean PCOS patients. Note that obese non-PCOS 
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patients who got the intervention lost more weight than PCOS ones (-11.6 kg 
compared to -8.2 kg, making -13.3% compared to -10.03% body weight loss). 
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Table 18: Average change in weight after 6 months between the 8 study 
groups 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 PCOS Non-PCOS p-
val
ue 
Obese  Lean  Obese  Lean  
Interve
ntion 
(A) 
Contr
ol 
(B) 
Interv
entio
n 
(C) 
Contr
ol 
(D) 
Interve
ntion 
(E) 
Cont
rol 
(F) 
Interve
ntion 
(G) 
Contr
ol 
(H) 
Initial 
Weight 
(kg) 
81.7(
±16.
4) 
86.4(
±12.7
) 
53.5(
±3.4) 
56.8(
±3.9) 
87.1(
±8.2) 
82.6
(±9.
1) 
54.4(
±16.5
) 
51.0(
±2.0) 
*0.
001 
Weight 
change 
(kg) 
-
8.2(±
7.1) 
4.96(
±3.9) 
-
1.5(±
2.1) 
3.13(
±3.45
) 
-
11.6(
±3.6) 
1.01
(±0.
3) 
-
0.81(
±3.4) 
0.12(
±1.0) 
**<
0.0
01 
Weight 
change 
(%) 
-
10.0
3(±6.
7) 
5.74(
±4.8) 
-
2.8(±
3.6) 
5.5(±
6.4) 
-
13.3(
±2.3) 
1.22
(±0.
5) 
-
1.48(
±3.9) 
0.23(
±2.0) 
**<
0.0
01 
Percentage 
of the 
group that 
achieved 
minimum of 
5% weight 
loss 
90% 0% 16.3% 0% 
100
% 0% 
16.7
% 0% 
**<
0.0
01 
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5.4 Changes after 12 months
Table 19 12-months changes between intervention and control PCOS patients 
Factor Intervention Control p-value 
Clinical 
Hyperandrogeni
sm 
Hirsutism  score -3.5 (±0.8) 0.4 (±0.2) **<0.001 
Time to ovulation 49.5 (±2.5) 38.5 (±10.8) **<0.001 
Number of cycles 3.0 (±0.1) 2.0 (±0.3) *0.032 
Body 
composition 
Waist 
circumference -5.0 (±6.1) 7.0 (±1.0) **<0.001 
Hip circumference -6.0 (±6.1) 7.5 (±0.5) **<0.001 
Waist/Hip ratio 0.005 (±0.01) 0.0005 (±0.02) 0.470 
% Body fat -0.05 (±0.5) 1.6 (±1.6) **<0.001 
% EBF -3.0 (±3.0) 1.1 (±1.1) **<0.001 
% BM 0.5 (±0.2) 0.6 (±0.6)  0.522 
BMI -5.1 (±3.4) 2.0 (±0.3) **<0.001 
BMR 14.5 (±18.0) -2.0 (±2.0) **<0.001 
Change in weight 
(kg) -10.5 (±10.8) 6.0 (±1.0) **<0.001 
% change in 
weight -11.0 (±11.3) 9.1 (±0.4) **<0.001 
Biomedical 
markers 
CRP (mg/L) -1.1 (±0) 0.3 (±0.1) **<0.001 
FBS (mg/dl) -12.5 (±3.6) 0.5 (±6.6) **<0.001 
LDL(mg/dl) -18.5 (±3.6) 2.0 (±12.3) **<0.001 
HDL (mg/dl) 0.0 (±1.0) 2.5 (±1.5) **<0.001 
TG (mg/dl) -19.0 (±8.2) 3.5 (±4.6) **<0.001 
Testosterone 
(ng/dL) -3.05 (±0.3) -2.05 (±3.1) 0.196 
Insulin (μU/mL) -2.3 (± 0.3) -0.4 (±0.7) *0.004 
Vitamin D 
(ng/mL) 2.3 (±0.0) 0.3 (±0.2) **<0.001 
Scores of 
psychological 
assessment 
BDI-II -2.0 (±0) 1.0 (± 1.0) **<0.001 
GAD-7 -2.0 (±0) 0.5 (±0.5) **<0.001 
Physical activity 4.2 (±0.2) 0.0 (±0) **<0.001 
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5.4.1 Anthropometric measurements 
A significant difference occurred in weight change between interventions and 
controls where intervention patients lost about 10.5 kg making about 11% loss in 
their body weights while controls gained about 6 kg after the 12 months making 
about 9.1% gain in their body weights. Most body composition parameters had a 
significant improvement in the intervention group more than the control group 
except for waist/hip ratio and % body mass where a null change occurred similarly 
in both groups. The intervention patients had a 5 cm decrease in their waist 
circumference within 12 months period (compared to 7 cm increase with controls), 6 
cm decrease in their hip circumference (7.5 increase with controls), 0.05% 
decrease in body fat (1.6% increase with controls), 3% decrease in EBF (1.1% 
increase with controls), 5.1 decrease in their BMI (2 kg/m2 increase with controls), 
and 14.5 units improvement in BMR (decrease in 2 units with controls)( Refer to 
table 19). 
5.4.2 Gynecology of 12 months follow-up 
Table 16 summarizes all factors studied for PCOS patients who were followed up to 
a period of 12 months. Hirsutism score decreased significantly by 3.5 units for 
intervention group compared to an increase of 0.4 units in the control group. 
Similarly, time to ovulation increased more in the intervention group (by 49.5 days) 
than the control group (increased by 38.5 days), and number of cycles also 
increased more in the intervention group than the control one (increased by 3 
cycles and 2 cycles respectively).  
 
5.4.3 Biomedical markers 
All biomarkers except testosterone changed significantly between intervention and 
control PCOS patients who were followed for 12 months. CRP decreased by 1.1 
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mg/L in the intervention group compared to an increase by 0.3 mg/L in the control 
group. Similarly FBS decreased by 12.5 mg/dl in the intervention group compared 
to 0.5 mg/dl increase in control group. LDL decreased by 18.5 mg/dl compared to 
2mg/dl increase with controls, TG decreased by 19 mg/dl compared to 3.5 mg/dl 
increase with controls, but HDL didn’t change with intervention patients and 
increased by 2.5 mg/dl with controls. Testosterone decreased by 3.05 ng/dl 
compared to 2.05 ng/dl decrease with controls (but this difference was not 
significant), insulin decreased by 2.3 μU/mL compared to 0.4 μU/mL decrease for 
controls, and finally vitamin D improved by 2.3 ng/ml compared to only 0.3 ng/ml 
improvement with controls.  
 
5.4.4 Psychological status (n=30) 
Also scores of psychological status and physical activity changed significantly 
between intervention and control patients after 12 months follow up. The 2 
psychological status scores (BDI-II and GAD-7) decreased by 2 units for 
intervention patients after 12 months, compared to a small increase in the control 
group (by 1 and 0.5 units respectively).  
 
5.4.5 Physical activity 
Physical activity improved by 4.2 units with intervention patients and didn’t change 
for controls (p<0.001 for the 3 scores).  
 
5.4.6 FFQ showed significant results 
FFQ has shown statistically significant improvements in all food items. Results are 
shown in table 22 (Appendix 13). 
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A number of studies (please refer to appendix 7) have focused on the impact of diets 
adopted by women suffering from PCOS on the medical intervention periods and the 
weight loss; however, few have addressed the effect of nutritional guidelines and 
counseling on PCOS overweight or obese versus lean women and compared these 
results with non-PCOS women in their reproductive stages of life. This study 
demonstrates that nutritional guidelines and weight management provided to 
overweight and lean PCOS patients result in significant weight loss, improvement in 
reproductive capacity, biochemical and nutritional levels or states in women with 
PCOS. 
The aim of the study was to assess the efficacy and effectiveness of public health 
nutrition intervention designed to create, enhance, and sustain healthy lifestyles and 
LSM among PCOS patients attending the Obstetrics and Gynecology Clinic at the 
American University of Beirut Medical Centre (AUB-MC) in Lebanon. This aim was 
based on the observation that some women with PCOS suffer from obesity, which 
has been shown that the disorder in some cases was developed due to weight gain 
(Moran et al., 2006).  
 
To translate our aim into a quantitative well developed and controlled research study, 
the research was seeking to achieve a primary weight loss (from 5-10% of initial body 
weight) among overweight or obese PCOS, and weight maintenance among lean 
PCOS patient as well as measure the impact of such a dietary plan on the 
biochemical, psychological, and nutritional status . As such, a weight loss ranging 
between 5 to 10 percent of the initial body weight considered optimal to see 
improvements in both the mild symptoms of PCOS, the risk factors of metabolic 
syndrome and to tackle the insulin problem (Norman et al.,2004). 
Turner-McGrievy et al., 2014 published a randomized pilot to assess the effect of 
weight loss on women with PCOS comparing vegan to low-calorie diet. Vegan 
women lost more weight at 3 months but both groups had no difference at 6 months 
intervention. This conclusion shows that low-calorie diet over a longer term (6 
months) has a similar effect to any exclusion diet.  
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During the study, women involved had high adherence to the guidelines and this is 
due to the regular telephonic communication with them. The peer society pressure 
for the married women to get pregnant played a major role to their compliance in 
order to reach the favorable end results of getting pregnant. The applied nutritional 
guidelines proposed have shown successful results in PCOS treatment. Our 
employed guidelines involved dietetic intervention lacking psychological focuses on 
the implementation of healthy eating principles in addition to physical activity 
promotion as a combined treatment. The results of the study offer good proof that 
the use of these guidelines over a long-term upon diagnosis can help improve the 
symptoms of PCOS. They also provided strong evidence on the long term adoption 
improving the anthropometric and reproductive profile. 
The metabolic syndrome parameters are still not widely used upon diagnosis for 
PCOS. In Lebanon, PCOS women showed prevalence of metabolic syndrome seen 
upon the laboratory tests conducted in this study. Women with PCOS have 
presented with underlying metabolic syndrome traits. 
As such, this study discusses several interrelated topics in light of the pilot study 
followed by the scale up intervention conducted over a period of 6 months each. 
Below, we present the major topics that form the scope of the research study: 
6.1 Baseline characteristics 
6.2 Anthropometric measurements 
6.3 Gynecology characteristics 
6.4 Biomedical markers 
6.5 Psychological status and physical activity 
6.6 Nutritional assessment: 24-hour recall and FFQ 
6.7 Twelve months follow-up for a subpopulation 
6.8 Comparison PCOS versus non-PCOS women 
6.9 Strengths and limitations  
 
6.1 Scale up baseline characteristics: 
During the pilot study (n=76) and scale up intervention (n=588) women attending the 
Obstetrics and Gynecology clinics at the AUBMC were recruited and followed up 
Most patients recruited fell in the age groups 2 and 3, i.e. age ranges between 20 to 
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25 and 25 to 30 years respectively. The age ranges show that most women suffering 
infertility and reproductive concerns fall in these two groups. Furthermore, it is 
important to note that most of the recruited population is of good educational standard     
(Bachelor and master levels). As a good educational background is important to raise 
awareness within the PCOS community regarding the disorder and the importance 
of adopting and adhering to lifestyle modification, this is of extreme significance to 
the aim of the research. 
 
6.2 Scale up anthropometric measurements: 
During the pilot study and scale up intervention, women suffering PCOS managed 
their weight by losing 7.7 Kg (±5.5) and 8.2 Kg (±7.1) respectively during pilot and 
scale up phases among overweight and obese intervention groups. On the other 
hand, the controls groups had no improvement in their weight status but portrayed 
an increase in their weight. As such, the percentage change in body weight during 
scale up intervention for PCOS women in comparison to PCOS women who did not 
receive any intervention lies within the set expectations. 
The difference between the two groups is statistically significant. The patients met 
the primary goal of 5% loss in body weight compared to control patients who gained 
weight. These results are higher than the pilot study results where % change in body 
weight was -10.03% (±6.7) for PCOS overweight/obese interventions and 5.74 
%(±4.8) for controls. The difference in results between pilot and scale up is due to 
recruiting a higher population size, which gives us a higher statistical power and 
accuracy of details. 
In light of our findings, a previous study reported the effect of adopting a weight loss 
plan by employing the DASH diet employing healthy food advices in overweight and 
obese PCOS women (Asemi et al., 2014). The results of Asemi et al., (2014) showed 
a decrease in body weight of while this study results showed a greater reduction 
average body weight of interventions groups. The present data showed that a 
consumption of the proposed nutritional guidelines led to a significant reduction in 
weight in comparison to other studies. 
In our research conducted on PCOS women within the intervention group, we noted 
that the study group managed to achieve weight loss of 5%-10% of their initial body 
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weight after 6 months of intervention. This is due to the compliance of the intervention 
groups to the professional nutritional counseling and follow up provided by the 
researcher. These results confirm the potential of the intervention for a period of 6 
months in comparison to other studies.  
Furthermore, the study demonstrates that a 6 -months nutrition intervention results 
in significant (P<0.001) weight loss in PCOS women, with no exclusion of any food 
groups or elements. By comparing these results to Turner-McGrievy et al.(2014) who 
employed low glycemic index vegan diet, this study proposed more improvement in 
term of weight loss (-9.5 Kg ) with detriment to the research subjects over 6 months. 
We highlight the fact that since no food groups are being excluded from the diet, it is 
expected to facilitate for the research subjects in general to adhere to the diet. This 
raises the probability of adopting such dietary plans as part of the research subjects’ 
lifestyles in the long run. 
Furthermore, a study by Phy et al. (2015) employed a shorter period of intervention 
while measuring the weight loss in light of dietary management period lasting 8 
weeks. The mentioned study adopted a low carbohydrates and a low dairy diet, which 
resulted in a weight loss of 8.6 Kg (± 2.3). Comparing these results to ours, the Phy 
et al. (2015) study has shown a more effective weight loss over a shorter period. The 
limitations in Phy’s study is the dietary restriction used (lowering carbohydrates and 
dairy product) which may further decrease many minerals such as calcium in the first 
place.  The dietary restriction can't be employed on the long term as a lifestyle 
modification for PCOS women. The dietary intervention is for research purposes and 
rather can’t be used a nutritional guidelines for PCOS women on the long run.  
Yet, as discussed earlier, the objective is to enable women suffering from PCOS to 
maintain nutritional balance for the longest periods possible as well as help them 
integrate into a healthier lifestyle especially those susceptible to weight gain. As such, 
the proposed diet along with the intervention time, do not fall short with the results 
delivered in light of those provided by Phy (2015). 
In light of the above, Moran et al. in 2006 studied weight loss in PCOS women over 
8 weeks period of time by promoting meal replacement and showed an average 
weight loss which falls below the results provided by our research study. The 
limitations of Moran et al.’s study in 2006 are the short term employment for this 
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study. Short term assessment cannot confirm the effect of such a nutritional 
intervention on the long term use by PCOS women. In addition, many PCOS women 
when being studied, meal replacement can cause a financial concerns for them, 
some can afford while others don’t. The sample size used is too small (n=43).Yet 
again, providing PCOS women with meals is not potentially effective on the long run, 
which highlights the importance of incorporating a lifestyle modification that is long 
term, well planned, and affordable to all PCOS cannot be achieved by simple meal 
replacement and rather a combination of weight loss plan, nutritional education and 
guidelines to improve their lifestyle. 
In our study, a significant decrease was seen in waist circumference (P<0.001) 
among the overweight or obese and lean intervention groups in comparison to the 
control groups who gained centimeters. Our findings were relatively lower in 
comparison to the low starch/low diary 8 weeks diet (Phy et al., 2015) which showed 
a significant decrease in waist circumference (P < 0.0001).  As waist circumference 
is an indicator of abdominal obesity and linked to insulin resistance, a change in the 
anthropometric indexes such as waist circumference is interpreted in the case of the 
low starch/low diary weight loss group, due to the elimination of carbohydrates and 
simple sugars from the diet (Phy et al., 2015). This justifies that a shorter period of 
dietary intervention (8 weeks) can decrease abdominal obesity and waist 
circumference rather than longer period of time (6 months) in the study. Low 
carbohydrates dietary intervention has shown to decrease abdominal obesity and 
this is clearly shown in the results of Phy et al., (2015). Macronutrient limitation as 
part of research intervention can be employed over a short period of time (8 weeks) 
given significant results. Abiding for macronutrient restriction on the long term can be 
hard to PCOS women. 
This scale-up study presents evidence that a non-elimination diet employing hypo-
caloric dietary management can produce relatively similar results to the type of diets 
over shorter period. In the control groups, PCOS patients gained fewer centimeters 
in waist circumference due to their non-adherence to any nutritional intervention and 
thus progression to weight gain manifested by a change in anthropometric 
measurements.  
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Furthermore, in the scale-up intervention a decrease in percentage body fat was seen 
among interventions versus controls with P <0.001. These results were higher than 
the pilot study results (interventions versus -controls) (with P= 0.064). The difference 
in results is due to the recruiting of a higher population size in the scale up 
intervention (n=588) in comparison to the pilot study (n=76). As the decrease in body 
fat is essential to induce ovulation and improve the reproductive hormonal profile in 
PCOS women confirming improvement in their reproductive status.  
Furthermore, a higher BMI decrease in the scale up study than pilot study for 
interventions groups. While controls had an increase in weight and thus BMI over 6 
months period of time. The study results are higher than those reported in Asemi et 
al., (2014). The reason of the higher decrease in the study is the employment of a 
higher population size (n=147) in comparison to Asemi et al., (2014) study (n=24) 
and the longer period of dietary intervention (6 months versus 8 weeks). This 
suggests the need of a longer period of nutritional intervention such as 6 months to 
properly quantify and assess the improvements and impacts on the BMI indexes. 
As such, we conclude that in relation to BMI, this study clearly reflects that over a 6-
months period of dietary intervention improvement in the composition of PCOS 
patients and decrease the progression towards obesity in susceptible PCOS patients 
can be noted. 
 
6.3 Scale up gynecology results: 
Hirsutism score is utilized to assess the hair pattern distribution in PCOS women. 
According to the scale-up, study results both PCOS and non-PCOS women in the 
intervention groups had slight decrease in the hirsutism score with no statistical 
significance. The scale up results are similar to the pilot study results for interventions 
and controls with P =0.13 for PCOS groups in comparison to controls in scale-up for 
PCOS. 
The results of this study are not in agreement with Naderpoor et al., ( 2015) study 
where hirsutism score decreased by 2.4 employing a sample size of 114  but not 
following weight loss through nutritional guidelines and counseling and rather 
metformin (insulin-sensitizing hormone) treatment. This concludes that metformin 
can induce a higher decrease in clinical hyperandrogenism in PCOS women than 
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nutritional guidelines. This conclusion cannot be followed on all PCOS women, as 
metformin is not prescribed to all PCOS women where no insulin resistance is 
diagnosed. Thus, the proposed nutritional guidelines for weight management for 
PCOS exhibit potential first line treatment in the long run and can be used for all the 
PCOS population and not just a selection. 
In addition, the study demonstrated that weight loss using nutritional guidelines 
improves pregnancy rate among women trying to conceive and live birth rates in 
interventions groups with infertility. Seventy percent of the women trying to conceive 
(n=165) were able to conceive spontaneously noting that this study only included 
patient with PCOS etiology only for infertility. This suggests that the guidelines 
proposed may be used as well for PCOS women aiming to conceive. Hence, adopting 
a balanced dietary plan with no exclusions to food groups can result in positive 
outcomes in patients trying to conceive. 
The results of the scale up study are in parallel with the findings provided by Kort et 
al., (2014). This demonstrates that in this case of a 10% weight loss of initial body 
weight ovulatory pattern in PCOS women can be restored following these guidelines. 
Intervention groups (overweight/obese and lean) had less time for due to the weight 
loss and increased physical activity while controls have a longer time for ovulation. 
Other findings such as those provided by Lass et al. (2011) showed similar results 
over a longer period (1 year) where amenorrhea significantly  decreased (P< 0.001) 
in the weight loss group.  
Before ending with a conclusion to this point, the scale up results are biased with the 
fact that ovulation induction medication are part of the usual care of PCOS 
pharmaceutical treatment. Hence, weight loss dietary intervention promotes 
ovulation induction agents in PCOS women and reproductive profile improvements 
cannot be achieved without weight loss in overweight/obese PCOS women. 
As such, the number of cycles increased from baseline and after 6 months for 
interventions and slightly increased in controls with P <0.001 and this is due to 
ovulation induction drugs. This study revealed that the proposed guidelines and 
consequent weight management in intervention groups with PCOS lead to significant 
weight loss and thus increase in menstrual episodes. These findings are aligned with 
the finds provided by other studies such as Orstein et al ., 2011 who proved 
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improvement in menses regularity in overweight/obese women with PCOS after 
weight loss over 12 weeks period of time. 
 
6.4 Scale up biochemical markers: 
The percentage weight loss of 10 % in the overweight/obese intervention group 
showed significant changes in some of the biochemical markers (total cholesterol 
FBS, CRP, LDL, and testosterone) with P values < 0.001. These results do not fall in 
parallel with the pilot study results where non-statistical significant changes were 
noted.  The C-reactive protein marker showed no statistical significance change in 
pilot study and this is due to the lower percentage of weight loss of initial body weight. 
The results are opposite to the findings of Moran et al., (2007) who found that CRP 
levels are not significantly changing by weight loss in PCOS women in a shorter 
period of time dietary intervention (8 weeks). In light of the different findings (ours vs 
Moran), our findings demonstrated the need for a longer period of testing ( 6-12 
months) in order to detect an improvement in CRP levels change. 
This scale up study proves that weight loss can cause significant ( P<0.001)changes 
induced by weight to CRP and thus adds to the literature a new finding to be further 
looked at in the future in treating PCOS women who are at risk of metabolic 
syndrome. 
On another note, the study over the 6 months period noted improvements in lipid 
profile of concerned patients under the intervention group, which was reflected by a 
decrease in LDL and total cholesterol in comparison to control groups with a P  values 
( 0.001 and 0.001 ) respectively.  
Previous studies tackling the same aspect demonstrated significant decrease in total 
cholesterol and LDL after 1 month intervention employing a high protein diet ( protein 
40% )( Stamets et al .,2004). Yet, a high protein (protein > 30 %) diet cannot be used 
over a long period of time due to the side effects that can cause to the body and 
excess load on kidneys, and thus cannot be incorporated within a lifestyle 
modification plan as PCOS women need a “attainable” lifestyle modification plan 
which will help improve and maintain the quality of life over the long run. 
In light of the above, the nutritional intervention proposed and its 10 % weight loss 
showed a statistically significant difference in FBS reduction between intervention 
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and controls with a P value< 0.001. During scale up intervention FBS had a higher 
decrease in FBS than the pilot study intervention. The greater decrease in scale up 
is due to the high population size.   Phy et al., (2015) showed that low starch/low 
dairy diet for 8 weeks can significantly decrease fasting insulin and this is justified by 
the low starch intake. Decreasing one food group showed efficient results in the 
metabolic parameters such as FBS and insulin resistance (Phy et al., 2015) but fitting 
this type of diet into a lifestyle can be hard especially for PCOS women who face 
episodes of carbohydrates cravings. As such, this adds up to the collected evidence 
that in order to promote a healthy well-balanced lifestyle, PCOS women must be 
provided with attainable dietary plans that are both efficient and effective on different 
metabolic levels. 
Hirsutism is evidently linked to hyperandrogenism, and results propose that total 
testosterone is a critical parameter in PCOS. On the endocrine level, testosterone 
decreased for intervention groups and increased for controls. This difference in 
change is statistically significant with a P = 0.001.  
According to a study conducted by Lass et al., in 2011 testosterone and 
hyperinsulinemia are positively correlated. The change in weight seen in this study 
among intervention groups showed that increased weight loss can decrease total 
testosterone level among intervention PCOS women with a significant difference 
(p=0.001)in comparison to control groups who gained weight and thus testosterone. 
This suggests that weight loss is attributed to a decrease in total testosterone and 
thus any further endocrine disorders among PCOS women. As previously seen in the 
pilot study, the change in weight seen in overweight/obese intervention group was 
not seen to be related to the parallel change in insulin and total testosterone level. 
The pilot study results support the hypothesis that obesity and PCOS are linked to 
insulin resistance. This was further assessed in the scale-up confirming that weight 
loss in the intervention groups is seen to be related to insulin resistance and total 
testosterone level. The high population size used in the scale up intervention in 
comparison to the pilot study allowed us to reveal important correlation to be 
considered in the future. A further discussion is done about the compliance over a 
longer period of time and its effect on the metabolic, endocrine and anthropometric 
measurement comparing 6 months versus 12 months intervention study. 
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6.5 Scale up psychological status: 
The pilot study showed that a moderate caloric-restricted diet in overweight and 
obese PCOS women improved depression and anxiety scores significantly (P = 
<0.001 for BDI-II and P< 0.001 for GAD-7) after providing them with the nutritional 
counseling. During the scale up study, we demonstrated that the nutritional 
intervention with higher percentage of weight loss has similar effect with statistical 
significance between intervention and control groups in the PCOS groups with 
P<0.001. Other researchers suggest that exercise and psychological results are 
independent( Byrne et al ., 1993) ( La Fontaine et al .,1992).We demonstrated that 
the addition of exercise to the nutritional intervention as part of lifestyle modification 
results in improvements in the psychological assessments among PCOS women 
facing depression and anxiety, which is seen in the results of BDI-II and GAD-7.  At 
the end of the intervention, the intervention groups appeared less psychologically 
disturbed that could point the statistical significance. In addition, the scale-up group’s 
results are in parallel with the pilot study results. As such, we can conclude that 
physical activity(defined by 30 min daily medium intensity exercise ; light jog, 
swimming, cycling, etc..) in combination with nutritional intervention leading for 
weight loss restored the self-esteem and body image among PCOS women and 
decreased their anxiety related to reproductive concerns and this is clearly seen 
among women specially trying to conceive. A group of forty-nine obese PCOS 
women enrolled in a study assessing the effect of diet alone, combined with exercise 
or diet and combined aerobic –resistance exercise on their depression level. In this 
study, patients reported improvement in their in depression and demonstrated that 
dietary restriction combined with exercise have a significant improvement on the 
depression scores on overweight and obese PCOS women (P<0.001) (Thomson et 
al., 2010). These results are in line with this study findings. For example, in both 
studies PCOS overweight and obese women followed a caloric restriction diet 
combined with physical activity. Overweight and obese PCOS women following low-
protein high-carbohydrate (LPHC) diet versus a high-protein low-carbohydrate 
(HPLC) diet  reported a significant reduction in depression score among The HPLC 
diet group with no change for the LPHC diet group(Galletly et al.,2004).The findings 
of this study are in agreement with the scale-up study results. The type of diet 
	
	
156	
	
followed by the overweight and obese women in PCOS in the proposed nutrition 
guidelines is hypo-caloric while Galletly et al., (2004) study compared two different 
diets on depression score. The limitation of the study was to assess the effect of 
different type of diets on the psychological profile in PCOS women. 
 
6.6 Scale up physical activity results 
PCOS women reported improved psychological states in parallel with increased 
physical activity along with improvement on the metabolic level (fasting insulin and 
FBS). The key factor for psychological status in the intervention groups is the addition 
to the physical activity status, this is clearly seen during the pilot study, and the scale 
up intervention where increased PA levels 3.0(±1.5) for PCOS overweight/obese 
intervention at the end of the study period is strongly associated with improved 
metabolic, anthropometric and psychological status (especially in the PCOS 
intervention groups) 
 
6.7 Scale up nutritional assessment: 24-hour recall and FFQ results  
The objective of the study was to assess the effectiveness of the nutritional 
counseling on the improvement of PCOS women well-being and design educational 
sessions tailored to PCOS women raising their nutritional awareness pertaining 
healthy food options and developing the latter into a lifestyle. Researches showed 
that PCOS progression is linked to obesity (Sedighi et al.,2014 , Moran et al., 
2015). Therefore, the caloric restriction of obese women leads to weight loss. The 
food intake of PCOS women was assessed at baseline and after the intervention for 
both overweight/obese and lean PCOS women. The lean PCOS women showed 
lower intake in comparison to overweight and obese PCOS women. The nutritional 
guidelines and counseling proposed healthy food options including complex 
carbohydrates , fat ( PUFA and MUFA), fruits and vegetables consumption  
employing caloric range between 1200 and 1500 calories for weight loss and 1800 
calories for weight maintenance. The major finding was that dietary intervention 
showed significant effect on weight loss and fasting insulin level. As such, the 
reduction in insulin level is thought to improve the endocrine abnormalities in 
PCOS. 
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Furthermore, adherence to the nutritional guidelines (Please refer to appendix 8 and 
appendix 9) in both intervention groups for a period of 6 months affected FBS and 
fasting insulin level. The food intake of the patients was assessed using food 
frequency questionnaire adapted to the Lebanese population and two 24 hour recalls 
reporting weekday intake and weekend intake. When comparing the FFQ between 
the pilot study and scale up intervention, many results have changed. An increased 
number of food options showed significant changes before and after the intervention 
specifically in the intervention groups. The change in intake between intervention 
groups and controls was statistically significant among all food items with a P <0.001 
except for fresh fish, orange and kiwi with P=0.003, P= 0.002 and P=0.003 
respectively and this is due to their widespread use among Lebanese women as 
detected in the FFQ. The FFQ also showed high carbohydrates intake among all 
PCOS women but the nutritional assessment by FFQ showed their adherence and 
compliance to the guidelines provided during counseling. As such, this is the first 
study assessing food intake among PCOS women in the Middle East region, and 
their changes after a nutritional dietary intervention.  
 
6.8 Twelve months follow-up 
A subpopulation from the pilot phase was selected to continue an extra 6 months 
follow-up with a total of 12 months intervention and control phase(N=30). The 
results showed an improvement in the hirsutism score with an extra decrease 
among interventions during the 6-12 months phase and no change among controls. 
This change is linked to decrease in testosterone. Hirsutism pattern is a clinical 
justification of the biochemical change in the testosterone level. In comparison to 
the pilot study the results are similar in the hirsutism score but on the biochemical 
level testosterone decreased more. Lass et al., 2011 showed a less decrease in 
testosterone level L in comparison to the study. The reason of their outcome is the 
population recruited consisting of adolescents with PCOS.  Adolescents' 
compliance can be less in comparison to adults who have high compliance due to 
their reproductive concerns. Anthropometric measurements decreased in extra 
values during the extra phase of interventions. Waist circumference decreased by 
an extra of 4 cm (±4.1) and this change is statistically significant with P< 0.001 in 
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comparison to controls who gained 5.5 cm (±3.6). The decrease in waist 
circumference is an improvement in the abdominal obesity which exposes the 
PCOS women to anovulation (Aubuchon et al., 2012). The number of cycles 
changed as well and an extra number of cycles were seen during the additional 
phase. This demonstrated that a lifestyle modification among PCOS women is 
potential to help them restore their ovulation. Weight decreased by an additional 
amount in the extra phase. During the second phase (pilot study) a higher weight 
loss reduction was seen than the first phase .Controls showed an increase in the 
total body weight and the change was statistically significant between control and 
interventions and between 6 and 12 months with a P< 0.001.  The aim of this study 
was met during the additional phase where around 7.8 % of weight was reduced 
from initial body weight. 
On the biochemical level, C-reactive protein as inflammatory marker showed  a 
slight decrease in the additional 6 months phase and we report that this reduction is 
statistically significant between interventions and controls with a P< 0.001. We 
conclude that the weight loss in the intervention groups has decreased CRP among 
PCOS women and the study findings are not in line with Moran et al., 2007. This 
conclusion is due to the large sample size population used during this study. 
Women with PCOS are at high risk of metabolic syndrome and thus weight loss can 
improve the metabolic considerations by decreasing the inflammatory marker CRP.  
During the pilot study we suggested an extra amount of weight loss to assess the 
effect of the increased reduction on the metabolic syndrome parameters and the 
outcome of the 12 months follow-up has justified the need of a longer period of time 
for intervention. Furthermore, the metabolic effects of PCOS with their biochemical 
presentations have shown many improvements in this extra phase with reduction in 
FBS, LDL and TG with a P values <0.001. The lipid parameters showed 
improvements after an extra 7 Kg weight loss. The results demonstrated that 
lifestyle modification through continuous weight loss for obese PCOS women and 
weight maintenance for lean PCOS women can give significant results. Fasting 
insulin and total testosterone showed a reduction that was not statistically 
significant and the results are not in parallel to Phy et al., (2015) who showed that 
reducing starch and dairy from the diet can reduce significantly fasting insulin. 
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Therefore, insulin is affected by the carbohydrate intake in PCOS patients. The 
number of cycles has increased from 2 to 3 cycles among interventions PCOS 
women (P< 0.001) and this is linked to a decrease in weight that has improved 
ovulatory function and restored menses. 
For PCOS women weight loss/ maintenance plays a key role in restoring self-image 
and esteem. It is noted that the depression and anxiety score showed 
improvements in BDI-II and GAD-7) with P<0.001 for both scores, after this second 
phase of weight loss. Noting an improvement in their physical activity (+1.2 h/w 
(±0.4)) duration was a result of their educational sessions about physical activity as 
part of lifestyle modification. We conclude then that weight loss combined with 
physical activity possesses a positive impact on PCOS women who presented with 
depression and anxiety state. 
As a conclusion, a twelve months nutritional education employing a range of 1200-
1500 calories per day for weight reduction, and 1800 calories per day for weight 
maintenance for PCOS women resulted in weight loss for the intervention groups 
and weight maintenance for lean intervention groups. On the other hand control 
groups showed an increase in their total weight. 
The employed nutritional guidelines outcomes showed a positive deviation to a 
healthy lifestyle among PCOS women. This suggests the need for nutritional 
intervention for all PCOS women to prevent any further complications, decrease the 
present metabolic presentations and make it a lifestyle and not just a short period of 
intervention. 
 
6.9 Comparison PCOS versus non-PCOS 
6.9.1 Anthropometric measurements 
In this study, non-PCOS women were weight and age matched to the PCOS 
women in order not to bias the study results. Only very few studies have 
investigated the effect of weight between PCOS and non-PCOS recruiting 
overweight/obese and lean women. 
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6.9.2 Gynecology 
When comparing women with PCOS and women without PCOS we observe non-
equivalent weight loss where non-PCOS women lost more and this is due to the 
less insulin resistance among non-PCOS women (Moran et al., 2007). The weight 
reduction is needed to be greater among overweight/obese PCOS women to 
observe metabolic improvements among them. The weight loss manifested by a 
reduction in waist circumference was an improvement for abdominal obesity 
especially for those who are insulin resistant. Overweight/obese women with PCOS 
had less reduction in waist circumference in comparison to overweight/obese non-
PCOS women (Moran et al.,2007).The excess body weight reduction was greater in 
non-PCOS women than in PCOS women justifying that non-PCOS women are able 
to lose more weight than PCOS women reflecting metabolic considerations at the 
molecular level of PCOS women. The limitations of Moran et al., (2007) study were 
the low population size recruited and the low duration of time employed for this 
study (8 weeks). 
Women with PCOS face menstrual irregularities while women without PCOS don’t 
experience any. Thus weight loss is required for PCOS women in order to regulate 
their menses and less likely for non-PCOS (Moran et al., 2007). The difference 
between PCOS and non PCOS is statistically significant with P<0.001 in number of 
cycles. Women with PCOS had 4.3 as number of cycles while women without 
PCOS had higher number of cycle and this is due to their regularity of menses (5.6 
cycles) .This doesn’t abandon the fact that overweight/obese women without PCOS 
should lose weight as prevention of progression to further reproductive 
abnormalities such as PCOS (Franks et al., 2002).  
 
6.9.3 Biochemical markers 
The change in IR in PCOS women was contingent to the weight loss seen in the 
abdominal area. In the same work we did we report that a greater reduction in IR 
was found among non PCOS women associated to greater weight loss. This 
confirms that women with PCOS have significantly higher insulin resistance than 
non-PCOS women and these results are in line with Moran et al., study in 2007.  
Changes in weight are associated with insulin resistance where high insulin 
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resistant women are less likely to lose more weight than normal insulin level. 
Women with less insulin resistance require less reduction in weight to benefit 
metabolically (Moran et al., 2007). In weight loss surgeries, women with less IR at 
baseline demonstrated more reduction in CRP after weight loss (Moran et al., 
2007). In the study, weight loss of 8.2 Kg in overweight/obese with PCOS is 
associated with 1.7 mg/L CRP reduction while overweight/obese non-PCOS women 
experienced less CRP reduction due to the lower baseline value between both 
PCOS and non-PCOS. Weight loss exerts more beneficial effect on PCOS women 
due to their higher inflammatory states based on higher CRP level compared to 
non-PCOS. The conclusion to this point is limited due to the lack of further 
investigation using extra inflammatory marker such as IL-6 and TNF –a(Moran et 
al,2007) .This confirms that weight loss is more beneficial for insulin resistant 
women regardless of PCOS status. This is a strong reason for the need of 
guidelines to weight loss or weight maintenance in order to manage weight, 
improve insulin resistance and thus CRP level.  Furthermore, weight management 
benefits conferred by the proposed guidelines can prevent or treat from one side 
high inflammatory state and type 2 diabetes among PCOS women. The FBS 
reduction observed among overweight/obese PCOS women was less than the non-
PCOS women and this is associated to the greater insulin resistance among PCOS 
women. The weight loss effect showed statistical significance between PCOS and 
non PCOS overweight/obese women on the lipid profile. The results of this study 
are similar to other studies (Moran et al., 2007). Women without PCOS showed less 
decrease in LDL level than PCOS women following weight loss. This is justified by 
the fact that PCOS women are under statin medications which justifies the 
increased reduction in LDL, total cholesterol and TG. To conclude this point, weight 
loss is needed more in PCOS women to exert beneficial effect on the lipid profile as 
risk factor to metabolic syndrome. 
Metabolic syndrome parameters   
 Diastolic and systolic pressure showed greater decrease among PCOS women 
and slight increase among controls) and this is exerted by the weight loss effect 
induced by the proposed guidelines. Decreasing the diastolic and systolic pressures 
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are one the major keys to metabolic syndrome and thus preventing any further 
cardiovascular disorders such as hypertension. 
Weight reduction is known to affect positively the psychological abnormalities 
among women especially PCOS women (Conte et al., 2015). 
 
6.9.4 Psychological status 
 This is one of the very few studies to have investigated the effect of weight loss on 
PCOS and non –PCOS women following weight loss or maintenance. The 
depression score decreased slightly more in non-PCOS interventions women. In 
this study, women showed to have higher score of psychological disturbances 
assessed by BDI-II and GAD-7 before the treatment. The BDI-II score decreased 
between both interventions PCOS and non-PCOS are slightly similar. The similarity 
in reduction between both groups constitutes a great point confirming that both type 
of women can benefit equivalently from the proposed guidelines and thus weight 
loss/maintenance. The control groups for both PCOS and non-PCOS have shown 
slight increase in BDI-II score. The GAD-7 score reduction was greater in non-
PCOS intervention groups than PCOS intervention group’s .This demonstrates that 
non-PCOS women benefit the most at this level from PCOS women. This can draw 
a conclusion that the anxiety level among PCOS is high enough to be affected by 
weight loss / maintenance due to the different hormonal treatment taken by PCOS 
women.  
 
6.9.5 Physical activity  
The physical activity improvement was greater among PCOS women than non-
PCOS) and this is oppositely seen in weight reduction where increased physical 
activity did not affect increased weight reduction among PCOS women. This should 
be further investigated with controlled environment on both PCOS and non-PCOS 
where equal physical activity should be practiced to assess the exerted benefits on 
the different groups of women. To conclude weight reduction is affected mainly by 
insulin level even when combined with physical activity.   
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6.9.6 Food Frequency Questionnaire 
The food frequency questionnaire showed significant change and improvement in 
food choice with P<0.001 and this is justified by the reduction in caloric intake 
calculated in the 24 hour recall. Note that this is the first study assessing the food 
intake of POCS women using this FFQ adapted to the Lebanese population. When 
comparing these results with pilot study results the single items analysis showed 
similar results with an increase in the fruits and vegetables intake per week and a 
reduction of simple carbohydrates intake among all intervention groups. Significant 
results have been seen with an increased consumption of green salad (5 serving 
sizes) among intervention groups and decrease in white bread intake, pasta and 
rice. The intervention groups PCOS and non-PCOS were receiving educational 
sessions about health food consumption such as increasing fruits and vegetables 
intake, lean cut proteins and limited number of healthy fat intake, decrease full fat 
dairy products and excess caloric intake. This strategy exerts beneficial effects 
such as preventing any deficiencies among women in minerals and vitamins that 
are needed for their reproductive health. The novelty of this study is the healthy 
lifestyle education such as consuming healthy options, decrease excess caloric 
intake, increase moderately physical activity level and not just for the purpose of 
interventional study instead for a lifestyle modification over lifetime. The conclusion 
drawn is similar to the pilot study where intervention groups showed compliance to 
the nutritional guidelines. In conclusion, these guidelines present a powerful tool to 
be used in the future for PCOS and non-PCOS women in order to give healthy 
habits. 
Six months nutritional intervention employing nutritional guidelines exerts greater 
beneficial effect on non-PCOS women rather than PCOS women. This is due to the 
comparatively higher weight reduction among non-PCOS women. Additionally a 12-
months nutritional intervention has shown cumulative improvements on the 
endocrine and metabolic levels for PCOS women, concluding that lifestyle 
modification over a one-year period is required to lose weight for overweight/obese 
subjects with PCOS and thereby exert improvements in nutritional, biochemical, 
psychological and reproductive status. 
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Chapter 7 
Author's critical analysis 
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7.1 Author’s critical analysis on the intervention 
This study is not only concerned with nutritional status in PCOS but sits within the 
broad finding of public health nutrition. Because of this data presented are very 
broad. The strengths of nutritional support intervention overweight pharmaceutical 
interventions as seen by the findings. 
The overall results of this project validate the author discussion to use non-
elimination diet to support the nutritional status of the patients. The author 
recommends studies of this kind employing non-elimination diet. 
During this study patient drop-out was in low rate. Based on the regular phone calls 
with the patients women followed the guidelines but some faced some financial 
constraints for those coming from low socio-economic background. Confidentially is 
commonly seen in Lebanon among women attending the obstetrics and gynecology 
clinics for menses irregularity and infertility. Women with absence of menses and 
infertility were facing social fear from inability to fit the cultural norms. Absence of 
menses can be due to pregnancy via non-marital sexual relation, and infertility 
would restraint them from getting kids and building a family after marriage.  
Abdominal ultrasound for the PCOS diagnosis is available at the clinics but due to 
some financial restraints to low socio-economic women scans were done rarely. 
Women diagnosed with PCOS during this study were assessed using an abdominal 
ultrasound for the ovaries to confirm the syndrome. For these type of women if 
ultrasound was done at early stage of PCOS phase the treatment can be easier 
and they would have not gained weight. On the other side, obese women with 
undiagnosed PCOS could have treated obesity at early stage and decrease the 
complications faced. This justifies the lack of knowledge about the important of 
nutritional support and obesity management for women in general and PCOS in 
specific. Wrong dietary practices and CAM use followed by PCOS women were 
seen during this study. Women used to follow strict and elimination diets brought 
from non-qualified sources to lose weight in a short period of time such as a week 
or two but this end up in regaining the weight and in excess which caused a sharp 
increase in obesity.  Women failing to conceive or women with irregular menses 
suffer from disturbed mental health issues like depression, anxiety and irritability 
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leading to excess eating and obesity. The regular follow-ups and phone calls done 
during the study have a great impact on the patients following the intervention to 
increase the support and encourage them on deviating into healthy lifestyle. The 
lean intervention group had a great maintenance on their weight and a better 
insight over their dietary practices with the follow-ups tools. This adds to the 
literature that regular support by phone calls and close follow-up sessions give a 
better result for PCOS women.  
During the first stages of planning for this study a literature review was conducted in 
order to propose nutritional guidelines including a food plan compromising all the 
nutritional elements such as carbohydrates, proteins, Fats (MUFA and PUFA). The 
carbohydrates chosen and advised were the complex carbohydrates including 
multi-cereals bread and fruits in order to assure the intake of vitamins and minerals 
needed to support the function of many organs and system in the human body 
mainly the reproductive system for females. Advising on consuming complex 
carbohydrates had tremendous effect on the fasting blood glucose and insulin 
resistance and this was observed in the biochemical markers tested and the 
changes seen before and after 6 months of intervention. I think we could have tried 
a sub-population using no carbohydrates in the research stages to compare the 
results between the proposed guidelines and non-carbohydrates diet on the 
metabolic profile especially fasting blood glucose and fasting insulin. In the 
research conducted by Douglas et al ., 2006 confirming that a reduction in the 
dietary carbohydrates reduces fasting insulin among PCOS women and thus can 
improve the reproductive outcomes. The employed nutritional guidelines and 
counseling haven’t proposed any reduction in the dietary carbohydrates on the 
contrary, the guidelines motivated on the consumption of a normal dietary regime 
including all food elements with a reduction in caloric intake. 
Many research projects have studied the different type of diets on PCOS features to 
better understand the metabolic aspect of weight loss (Chavaro et al., 2007; 
Douglas et al., 2006; Mehrabani et al., 2012). These studies have focused only on 
selected diets studying selected profile such as metabolic, reproductive, 
anthropometric or psychological. The focus of our research was the reproductive 
outcome especially the changes seen in the hormonal level employing parameters 
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such testosterone, the ovulation date used in the pilot study, the regularity of 
menses and the fertility rate for married women in the scale up phase. I think extra 
reproductive parameters could have been used such thyroid stimulating hormone, 
luteinizing hormone and follicle stimulating hormone to elaborate more on the role 
of the nutritional guidelines affecting the whole reproductive profile of women. The 
advantages of this research are the impact on the Lebanese women reproductive 
profile of ability to conceive and thus giving a therapy to follow. Moreover, the 
nutritional guidelines effects showed that the reduced weight in the intervention 
groups is excess body fat and not lean mass or water. Decreasing body fat is 
essential for the abdominal obesity affecting the ovulation in PCOS women.  
On the other hand, studying the hormonal level changes among PCOS women in 
this study was essential to map the effect of weight loss on testosterone. Some 
hormonal profiles tests should have been added to this study such as Follicule 
stimulation hormone, Luteinizing hormone and Dehydroepiandrosterone sulfate. 
The gained outcomes could have been more elaborated and the effect of weight 
loss could have been widely studied if these hormones were used as parameters in 
this study.    
In addition, one of the advantages of this study is the proposed life-time nutritional 
guidelines for women with PCOS in the Lebanese population facing weight changes 
and weight loss challenges. Weight gain mainly is a factor for PCOS and the 
infertility complications in addition to other metabolic disorders such as type 2 
diabetes and metabolic syndrome. Our considerable challenge that was faced 
involved patients that were seeking CAM treatment for weight loss without avail. 
Those patients who had originally sought rapid results found difficulty adhering to 
long term nutritional treatment. At the end of the study successful results have been 
achieved. 
 
7.2 Limitations and strengths: 
Few limitations set constraints on the study at hand. There was no major problem 
anticipated in this study.  The study methodology was planned to prospectively follow 
the patients using weight management guidelines. The pilot study and scale up 
phase followed the same methodology. During the pilot study few parameters were 
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adjusted in the scale-up technically to obtain better outcomes such as the indication 
of ovulation for reproductive profile analysis. On the other hand, the nutritional 
guidelines used were prepared to fit the overweight/obese group and the lean group. 
Another guideline could have been prepared during this study which is the high 
protein diet. But due to the lifestyle change purposes of this study a hypocaloric 
guidelines were prepared with no dietary restriction. The study parameters were 
measured three times (at baseline, after 3 and 6 months from baseline). During 
weight management the nutritional follow-up should have been done every 2-3 weeks 
but due to the long distances travelled by many patients a phone call follow-up was 
done to track with the patients the study guidelines. During the scale-up testing, body 
temperature measurement was eliminated and period onset, number of cycles, 
pregnancy test and regularity of menses was observed to assess the reproductive 
outcomes. One of the study limitations is the difficulty to follow with the patients due 
their high number, but the researcher with the nurses in the Obstetrics and 
Gynecology department at AUBMC managed to keep calling the patients to remind 
them of their follow-up appointments. The lack of fund is an additional weakness of 
this study where extra funds were needed to further analyze the changes in TSH, 
AMH, and DHEAS to map the hormonal changes correlated with total testosterone 
after weight loss. It limited the work where ultrasound was needed to detect the 
change is cysts size and number among PCOS women before and after the 
intervention. Furthermore, the uses of hormonal treatment for some PCOS women 
caused them to hardly adhere to the guidelines but during the counseling sessions 
patients were educated about the importance of adherence to the dietary plans set.  
On the other hand, the study also had several strengths and future prospective 
applications. For instance, this is the first study that assessed the effect of weight 
loss among PCOS women on metabolic, reproductive, anthropometric, nutritional 
and psychological levels. This study is a randomized control trials with structural 
follow-up to increase the adherence and compliance to the proposed guidelines. In 
addition, it is one of the few dietary interventions employing the high sample size for 
PCOS women.  Low patient dropout (n=8) during the intervention was seen due to 
the high interest of women to regain their body image and restore their reproductive 
profile and conditions. This is due to the cultural background of the society where 
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reproductive concerns play a major role in marriage and life cycle. Attrition rate was 
low(1.3) in this study because women were seeking help to benefit in their treatment 
and this is why in the future PCOS women should start nutritional interventions after 
diagnosis directly. There was no financial barrier to PCOS women in this study 
although hormonal treatment and hospital visits were expensive in Lebanon but 
patients were offered this intervention free of charge along with the blood tests 
conducted regularly.  The body composition machine was used to assess the body 
composition in term of fat and muscle percentage for the PCOS patients. In-body or 
CT imaging is more accurate to tackle body fat changes especially visceral fat. As for 
the biochemical analysis, the laboratory setting was available at the hospital for blood 
withdrawal and this is strength for the study. 
As such, based on the findings provided in this research paper along with the 
comparisons provided against existing literature, we conclude that dietary 
intervention and its proper integration into active healthy lifestyle offers  prospective 
applications in the field treatment of women suffering from PCOS, which must be 
further investigated and refined to tailor it to the needs of the PCOS community. 
 
Confounding factors  
Random assignment, as a result of confounding by indication, does not affect 
randomized trials (Johnston, 2001). Since the control characteristics (inclusion 
criteria) of the various groups (overweight/obese Interventions and controls, lean 
interventions and controls) and subgroups (intervention versus Control) were the 
same, the probability of confounding was smaller in this study. By expanding the 
types and values of analogies performed in the analysis, devaluation in the 
possibility for the occurrence and confounding factors was obtained, such that 
these confounding variables can be classified by their origin. The choice of 
measurement instrument (operational confound), situational characteristics 
(procedural confound), or inter-individual differences (person confound). By 
augmenting the figures of comparisons executed in the proximate analysis, a 
contraction in the probability of happening and results of operational confounding 
factors were realized in this study. Equivalently, to guarantee the strength and 
validity of the findings and a reduction in the potential for operational confound, the 
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data from anthropometric, 24 hour recall , and general assessment  measurements 
were repeated twice and attested by another medical staff. To diminish situations of 
confounding, either before the study implementation or after the analysis, a peer 
review in the advancement of the theoretical scheme and at the end of the pilot 
intervention was used. The peer review likewise, depended on cumulative ability 
within medical colleagues in the care and support program for PCOS, to recognize 
possible shortcomings in the study design and analysis, containing methods where 
the data may depend on confounding. To lessen the incident of self-selection by 
patients or prejudice by the study planner, the people under study were randomly 
split after brief instructions, using the Randomized Control Trial (RCT) design. This 
methodology divides the members into groups (overweight/obese and lean) and 
subgroups (interventions versus control) significant to the criteria that match the 
research question.  
 
7.3 Conclusion 
Implementing nutritional counseling upon the PCOS diagnosis is expected to 
improve lifestyle of PCOS women by the onset of ovulation induction and hormonal 
therapy. Weight losses, resumption of reproductive features and improvement in 
nutritional and biochemical profile have met the study’s objectives. The desired 
results succeeded in making the nutritional framework proposed as part of the 
PCOS treatment and to determine its role in the gynecological framework in 
Lebanon. 
Up to our knowledge this is the first study to demonstrate that the nutritional 
guidelines can lead to weight loss in overweight/ obese women and maintain weight 
in lean PCOS women. This study results confirm that if nutritional guidelines and 
counseling along with structured PA regimen are given upon diagnosis with PCOS 
their weight and metabolic features can be managed and lead to an improved lifestyle 
among Lebanese women with PCOS. The proposed nutritional guidelines for PCOS 
women showed superiority to other elimination diets and pharmaceutical 
interventions in terms of cost effectiveness and sustainability. Such lifestyle 
interventions succeed for women with PCOS and thus can positively impact their 
families and especially daughters given the heritable aspect of PCOS. These 
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guidelines are considered an excellent educational tools for women with PCOS which 
no short term elimination diet or medication could hope to do.   
 
7.4 Future plans 
A 2005 research study has assessed the effect of B Vitamins and folic acid 
supplementation and its effect on serum levels of homocysteine in PCOS women 
(Kilicdag et al., 2005). They concluded that B-group vitamins and folic acid offset 
the increase in homocysteine levels in PCOS women using metformin (Kilicdag et 
al., 2005). Therefore, dietary supplementation and functional food should be further 
studied to ascertain their effects on PCOS women who do not follow the proposed 
nutritional guidelines for both overweight/obese and lean women. 
The following plans are proposed to be done in the future work: 
1- Effect of vitamins B 6, B 12 and folic acid supplementation on homocysteine 
level and fertility outcomes. 
2- Include a structured physical activity plan for PCOS to be tested further and 
be added to the nutritional guidelines. 
3- The nutritional guidelines for overweight/obese and lean PCOS women be 
shared for Lebanese women and applied in the health care institutions. 
4- Workshops and sessions planning for PCOS women following the 
gynecologists treatment at the health institutions in Lebanon including 
sessions on healthy cooking, importance of weight loss for overweight and 
obese, weight maintenance for lean , group support, psychological 
support(such as psychotherapist strategies to each PCOS women). Family 
members (such as father, mother, husband and siblings) should be included 
in these sessions to enlighten them about the conditions and importance of 
support to achieve the desired outcomes. 
5- Expand the nutritional intervention to rural areas in the south, north, 
mountains and Bekaa (Lebanon valley) areas. 
6- Conduct mobile clinics and awareness campaigns to educate the patients 
about the importance of nutritional care for gynecologist, health care 
providers and PCOS women. 
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7- Plan TV and radio interviews to address the nutritional guidelines support 
and team up with health bloggers and digital influencers. 
8- Plan a recipes and cooking book and e-book for PCOS to help them find the 
right meals to eat during their lifestyle modification. Appear on cooking 
programs in the Lebanon and the Middle East region to expand this project 
and reach the highest population. 
9- Workshops for endocrinologists, gynecologists , nurses , health care staff to 
educate them about the importance of nutritional guidelines support for all 
PCOS women to incorporate along with their medical care  
 
 
 
	
	
173	
	
 
Chapter 9 
References and appendices 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	
	
174	
	
9.1 References: 
Abbott, D. H., Barnett, D. K., Bruns, C. M.,  Dumesic, D. A. (2005). Androgen 
excess fetal programming of female reproduction: a developmental aetiology for 
polycystic ovary syndrome?. Human reproduction update, 11(4), 357-374. 
 
Abbott, D. H., Barnett, D. K., Levine, J. E., Padmanabhan, V., Dumesic, D. A., 
Jacoris, S., & Tarantal, A. F. (2008). Endocrine antecedents of polycystic ovary 
syndrome in fetal and infant prenatally androgenized female rhesus 
monkeys. Biology of reproduction, 79(1), 154-163 
 
Abbott, D. H., & Bird, I. M. (2009). Nonhuman primates as models for human 
adrenal androgen production: function and dysfunction. Reviews in Endocrine and 
Metabolic Disorders, 10(1), 33-42. 
 
Abbott, D., Zhou, R., Bird, I., Dumesic, D., & Conley, A. (2008). Fetal programming 
of adrenal androgen excess: lessons from a nonhuman primate model of polycystic 
ovary syndrome. In Disorders of the human adrenal cortex (Vol. 13, pp. 145-158). 
Karger Publishers. 
 
Albano, C., Felberbaum, R. E., Smitz, J., Riethmüller-Winzen, H., Engel, J., 
Diedrich, K.& European Cetrorelix Study Group (2000). Ovarian stimulation with 
HMG: results of a prospective randomized phase III European study comparing the 
luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the 
LHRH-agonist buserelin. Human Reproduction, 15(3), 526-531. 
 
Al-Inany, H., Aboulghar, M. A., Mansour, R. T., & Serour, G. I., (2005). Optimizing 
GnRH antagonist administration: meta-analysis of fixed versus flexible 
protocol. Reproductive biomedicine online, 10(5), 567-570. 
 
Al Khaduri, M., Al Farsi, Y., Al Najjar, T. A. A., & Gowri, V., (2014). Hospital-based 
prevalence of polycystic ovarian syndrome among Omani women. Middle East 
Fertility Society Journal, 19(2), 135-138. 
	
	
175	
	
 
Al-Ruhaily, A.D., Malabu, U.H., Sulimani, R.A .,(2008). Hirsutism in Saudi females 
of reproductive age: a hospital-based stud.Ann Saudi Med , 28(1):28-32. 
 
Apter, D., Bützow, T., Laughlin, G. A., & Yen, S. S., (1994). Accelerated 24-hour 
luteinizing hormone pulsatile activity in adolescent girls with ovarian 
hyperandrogenism: relevance to the developmental phase of polycystic ovarian 
syndrome. The Journal of Clinical Endocrinology & Metabolism, 79(1), 119-125. 
 
Armitage, J., (2007). The safety of statins in clinical practice. The 
Lancet, 370(9601), 1781-1790. 
 
Asuncion, M., Calvo R.M., San Millan, J.L., Sancho, J., Avila, S., Escobar-
Morreale,H.F., (2000). A prospective study of the prevalence of the polycystic ovary 
syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab, 
85(7)2434–2438. 
 
Asemi, Z., Samimi, M., Tabassi, Z., Shakeri, H., Sabihi, S. S., & Esmaillzadeh, A. 
(2014). Effects of DASH diet on lipid profiles and biomarkers of oxidative stress in 
overweight and obese women with polycystic ovary syndrome: a randomized 
clinical trial. Nutrition, 30(11), 1287-1293. 
 
Aubuchon M., Bickaus,J., Gonzalez,F., (2012).  Obesity, Metabolic dysfunction, and 
inflammation in polycystic ovary syndromeIn Polycysitc ovary syndrome. Ed . New 
Haven: Springer, p.117-121. 
 
Baillargeon, J. P., Iuorno, M. J., & Nestler, J. E.(2003). Insulin sensitizers for 
polycystic ovary syndrome. Clinical obstetrics and gynecology, 46(2), 325-340. 
 
Baldani, D.P., Škrgatić, L., Šimunić, V., Zlopaša, G., Čanić, T., & Trgovčić, I. 
(2013). Characteristics of different phenotypes of polycystic ovary syndrome based 
	
	
176	
	
on the Rotterdam criteria in the Croatian population. Collegium 
antropologicum, 37(2), 477-482. 
 
Baldwin,A.,(2001).  Control of oncogenesis and cancer therapy resistance by the 
transcription factor NF-κB. J Clin Invest,107(3),241-246, 
 
Barr, S., Hart, K., Reeves, S., Sharp, K., & Jeanes, Y. M. (2011). Habitual dietary 
intake, eating pattern and physical activity of women with polycystic ovary 
syndrome. European journal of clinical nutrition, 65(10), 1126-1132. 
 
Boutzios, G., Karalaki, M., & Zapanti, E. (2013). Common pathophysiological 
mechanisms involved in luteal phase deficiency and polycystic ovary syndrome. 
Impact on fertility. Endocrine, 43(2), 314-317. 
 
Beck,A.T.,Steer,R.A., Brown,G. ( 1996). Manual for the Beck Depression Inventory-
II.  San Antonio, TX: Psychological Corporation  
 
Bellanger ,S., Battiosta,M.C., Baillargeon,J.P. (2012). Insulin resistance and 
lipotoxicity in PCOS: Causes and consequences. Ed. New Haven,p 97-98. 
 
Boudreaux, M. Y., Talbott, E. O., Kip, K. E., Brooks, M. M., & Witchel, S. F. (2006). 
Risk of T2DM and impaired fasting glucose among PCOS subjects: results of an 8-
year follow-up. Current diabetes reports, 6(1), 77-83. 
 
Burgehn,G.A., Govens,J.R., Kitabchi,E.E.(1980).Correlation of hyperandrogenism 
with hyperinsulinemism in polycystic ovary syndrome.50(1).,113-116. 
 
Bulletins, G. A., & Popkin, B. M. (1998). Dietary fat intake does affect obesity!. The 
American journal of clinical nutrition, 68(6), 1157-1173. 
 
Brown, J., Farquhar, C., Beck, J., Boothroyd, C., & Hughes, E. (2009). Clomiphene 
and anti-oestrogens for ovulation induction in PCOS. The Cochrane Library. 
	
	
177	
	
 
Brüning, J. C., Gautam, D., Burks, D. J., Gillette, J., Schubert, M., Orban, P. C.,& 
Kahn, C. R. (2000). Role of brain insulin receptor in control of body weight and 
reproduction. Science, 289(5487), 2122-2125. 
 
Brehm BJ, Seeley RJ, Daniels SR, D’Alessio DA.( 2003). A randomized trial 
comparing a very low carbohydrate diet and a calorie-restricted low fat diet on body 
weight and cardiovascular risk factors in healthy women. Journal of Clinical 
Endocrinology and Metabolism, 88(4),1617 – 1623. 
 
Burks, D. J., de Mora, J. F., Schubert, M., Withers, D. J., Myers, M. G., Towery, H. 
H., & White, M. F. (2000). IRS-2 pathways integrate female reproduction and 
energy homeostasis. Nature, 407(6802), 377-382. 
 
Byrne, A., & Byrne, D. G. (1993). The effect of exercise on depression, anxiety and 
other mood states: a review. Journal of psychosomatic research, 37(6), 565-574. 
 
Carmina, E., & Lobo, R. A. (2004). Use of fasting blood to assess the prevalence of 
insulin resistance in women with polycystic ovary syndrome. Fertility and 
sterility, 82(3), 661-665. 
 
Carmina, E., Bucchieri, S., Esposito, A., Del Puente, A., Mansueto, P., Orio, F.,  & 
Rini, G. (2007). Abdominal fat quantity and distribution in women with polycystic 
ovary syndrome and extent of its relation to insulin resistance. The Journal of 
Clinical Endocrinology & Metabolism, 92(7), 2500-2505. 
 
Casper, R. F., & Mitwally, M. F. (2006). Aromatase inhibitors for ovulation 
induction. The Journal of Clinical Endocrinology & Metabolism, 91(3), 760-771. 
 
Cha, K. Y., Koo, J. J., Ko, J. J., Choi, D. H., Han, S. Y., & Yoon, T. K. (1991). 
Pregnancy after in vitro fertilization of human follicular oocytes collected from 
	
	
178	
	
nonstimulated cycles, their culture in vitro and their transfer in a donor oocyte 
program. Fertility and sterility, 55(1), 109-113. 
 
Chua, A. K., Azziz, R., & Goodarzi, M. O. (2012). Association study of CYP17 and 
HSD11B1 in polycystic ovary syndrome utilizing comprehensive gene 
coverage. Molecular human reproduction, 18(6), 320-324. 
 
Chen, Z. J., Zhao, H., He, L., Shi, Y., Qin, Y., Shi, Y., & Liang, X. (2011). Genome-
wide association study identifies susceptibility loci for polycystic ovary syndrome on 
chromosome 2p16. 3, 2p21 and 9q33. 3. Nature genetics, 43(1), 55-59. 
 
Chavarro JE, Rich-Edwards JW, Rosner BA, Willett WC.,( 2007). Dietary fatty acid 
intakes and the risk of ovulatory infertility. American Journal of Clinical Nutrition, 85 
(1),231 – 237. 
 
Church, T. S., Thomas, D. M., Tudor-Locke, C., Katzmarzyk, P. T., Earnest, C. P., 
Rodarte, R. Q.,  & Bouchard, C. (2011). Trends over 5 decades in US occupation-
related physical activity and their associations with obesity. PloS one, 6(5), e 
19657. 
 
Connealy, L.E.(2012).  Blood Test Results: Your Guide to Understanding the 
Numbers.  Newport Natural Health. Retrieved from: 
https://www.newportnaturalhealth.com/2012/08/a-guide-to-understanding-blood-
tests/ 
 
Conte, F., Banting, L., Teede, H. J., & Stepto, N. K. (2015). Mental health and 
physical activity in women with polycystic ovary syndrome: a brief review. Sports 
Medicine, 45(4), 497-504. 
 
Conway, G., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., 
Franks, S., Gambineri, A., & Pfeifer, M. (2014). The polycystic ovary syndrome: a 
	
	
179	
	
position statement from the European Society of Endocrinology. European Journal 
of Endocrinology, 171(4), P1-P29. 
 
Costello, M. F., Misso, M. L., Wong, J., Hart, R., Rombauts, L., Melder, A., ... & 
Teede, H. J. (2012). The treatment of infertility in polycystic ovary syndrome: a brief 
update. Australian and New Zealand Journal of Obstetrics and Gynecology, 52(4), 
400-403. 
 
Clark AM, Ledger W, Galletly C .(1995) Weight loss results in significant improvement 
in pregnancy and ovulation rates in anovulatory obese women. Hum 
Reprod10:2705–12. 
 
Clark AM, Thornley B, Tomlinson L, Galletley C and Norman RJ .(1998) Weight loss 
in obese infertile women results in improvement in reproductive outcome for all forms 
of fertility treatment. Human Reproduction13(6):1502–1505. 
 
Crosignani PG, Colombo M, Vegetti W, Somigliana E, Gessati A, Ragni G 
.(2003)Overweight and obese anovulatory patients with polycystic ovaries: Parallel 
improvements in anthropometric indices, ovarian physiology and fertility rate induced 
by diet. Hum Reprod18:1928–32. 
 
Culver, A. L., Ockene, I. S., Balasubramanian, R., Olendzki, B. C., Sepavich, D. M., 
Wactawski-Wende, J.,  & Rahilly-Tierny, C. (2012). Statin use and risk of diabetes 
mellitus in postmenopausal women in the Women's Health Initiative. Archives of 
internal medicine, 172(2), 144-152. 
 
De Paolo LV, chair. (2012) Executive summary. In: National Institutes of Health. 
Evidence-Based Methodology Workshop on Polycystic Ovary Syndrome, Bethesda, 
MD, December 3-5. Retrieved Feb 16 from: 
https://prevention.nih.gov/docs/programs/pcos/FinalReport.pdf 
 
	
	
180	
	
De Fronzo,R.A., Tobin,J.D., Andres,R.,(1979). Glucose clamp technique: a method 
for quantifying insulin secretion and resistance.Am J Physiol,237(3), E214-223. 
 
Debruyne, L., Whitney, I. and Pinna, K., (2011). Illness and nutrition care. In: 
Peggy, W., (ed) Nutrition & Diet Therapy. 8thedition.Cengage Learning, pp. 381-
392. 
 
Diamanti-Kandarakis E., Kouli, C.R., Bergiele, A.T., Filandra, F.A., Tsianateli, T.C., 
Spina,G.G., Zapanti, E.D., Bartzis, M.I .(1999). A survey of the polycystic ovary 
syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin 
Endocrinol Metab, 84(11), 4006-4011. 
 
Dickey, R. P., & Holtkamp, D. E. (1996). Development, pharmacology and clinical 
experience with clomiphene citrate. Human Reproduction Update, 2(6), 483-506. 
 
Dittas A.( 2007). The role of Vitamin D and calcium in type 2 diabetes. A systematic 
review and meta-analysis. J Clin Endocrinol Metab., 92(6), 2017-29. 
 
Douglas,C., Gower,B.,Darnell,B.,Ovalle,F.(2006). Role of diet in the treatment of 
polycystic ovary syndrome. Fertil Steril ,85(3),679-688.Drazen, D.L., Vahl, T.P.,  
 
D’Alessio, D.A., Seeley, R.J., Woods, S.C.,( 2006). Effects of a fixed meal pattern 
on ghrelin secretion: evidence for a learned response independent of nutrient 
status. Endocrinology,141 (1),23 – 30. 
 
Druce, M. R., Wren, A. M., Park, A. J., Milton, J. E., Patterson, M., Frost, G., ... & 
Bloom, S. R. (2005). Ghrelin increases food intake in obese as well as lean 
subjects. International journal of obesity, 29(9), 1130-1136. 
 
Dunaif, A., Scully, R., Andersen, R., Chapin, D., Crowley,W., (1984)/ The effects of 
continuous androgen secretion on the hypothalamic –pituitary axis in women : 
	
	
181	
	
Evidence from a luteinized thecoma of the ovary. The Journal of clinical 
endocrinology and metabolism, 59(3), 389-393. 
 
Dunaif, A. (1997). Insulin resistance and the polycystic ovary syndrome: 
mechanism and implications for pathogenesis 1. Endocrine reviews, 18(6), 774-
800. 
 
Eckel, R.H. (2012). The Metabolic Syndrome.In Longo DL (18th), Harrison's 
Principles of Internal Medicine. United States of America: McGraw-Hill Companies. 
 
Ehrmann, D. A., Kasza, K., Azziz, R., Legro, R. S., & Ghazzi, M. N. (2005). Effects 
of race and family history of type 2 diabetes on metabolic status of women with 
polycystic ovary syndrome. The Journal of Clinical Endocrinology & 
Metabolism, 90(1), 66-71. 
 
Eirlertsen, T. B., Vanky, E., & Carlsen, S. M. (2012). Anti-Mullerian hormone in the 
diagnosis of polycystic ovary syndrome: can morphologic description be 
replaced?. Human reproduction, 27(8), 2494-2502. 
 
Escobar-Morreale HF, Botella-CarreteroJI, Alvarez-Blasco F, Sancho J, San Millán 
JL.(2005)The polycystic ovary syndrome associated with morbid obesity may resolve 
after weight loss induced by bariatric surgery. J ClinEndocrinolMetab90:6364-6369. 
European Society Human Reproduction Emryology, T. R., & ASRM-Sponsored 
PCOS Consensus Workshop Group. (2004). Revised 2003 consensus on 
diagnostic criteria and long-term health risks related to polycystic ovary 
syndrome. Fertility and sterility, 81(1), 19-25. 
 
Farooqi, I. S., & O’Rahilly, S. (2006). Genetics of obesity in humans. Endocrine 
reviews, 27(7), 710-718. 
 
	
	
182	
	
Fauser, B. C., & Devroey, P. (2003). Reproductive biology and IVF: ovarian 
stimulation and luteal phase consequences. Trends in Endocrinology & 
Metabolism, 14(5), 236-242. 
 
Fauzia, H., Omar, A. &Javid, R, .(2007). Clinical, biochemical and ultrasonographic  
features of infertile women with polycystic ovarian syndrome.JCPSP, 17(2)76- 80. 
 
Farshchi, H., Taylor, M., & Macdonald, I.,( 2004). Decreased thermic effect of food 
after an irregular compared with a regular meal pattern in healthy lean women. 
International Journal of Obesity Related Metabolic Disorders, 28, 653 – 660. 
 
Foecking, E. M., Szabo, M., Schwartz, N. B., & Levine, J. E. (2005). 
Neuroendocrine Consequences of Prenatal Androgen Exposure in the Female Rat: 
Absence of Luteinizing Hormone Surges, Suppression of Progesterone Receptor 
Gene Expression, and Acceleration of the Gonadotropin-Releasing Hormone Pulse 
Generator 1. Biology of Reproduction, 72(6), 1475-1483 
 
Ford, E. S., & Li, C. (2008). Metabolic syndrome and health-related quality of life 
among US adults. Annals of epidemiology, 18(3), 165-171. 
 
Forsdike, R. A., Hardy, K., Bull, L., Stark, J., Webber, L. J., Stubbs, S., & Franks, S. 
(2007). Disordered follicle development in ovaries of prenatally androgenized 
ewes. Journal of Endocrinology, 192(2), 421-428. 
 
Franks, S., Adams, J., Mason, H. D., & Polson, D. (1985). Ovulatory disorders in 
women with polycystic ovary syndrome. Clinics in obstetrics and 
gynaecology, 12(3), 605-632. 
 
Franks, S. (2002). Adult polycystic ovary syndrome begins in childhood. Best 
Practice & Research Clinical Endocrinology & Metabolism, 16(2), 263-272. 
 
	
	
183	
	
Freeman, D. J., Norrie, J., Caslake, M. J., Gaw, A., Ford, I., Lowe, G. D., ... & 
Sattar, N. (2002). C-reactive protein is an independent predictor of risk for the 
development of diabetes in the West of Scotland Coronary Prevention 
Study. Diabetes, 51(5), 1596-1600. 
 
Fulghesu, A. M., Ciampelli, M., Belosi, C., Apa, R., Pavone, V., & Lanzone, A. 
(2001). A new ultrasound criterion for the diagnosis of polycystic ovary syndrome: 
the ovarian stroma/total area ratio. Fertility and sterility, 76(2), 326-331. 
 
Fulghesu, A. M., Villa, P., Pavone, V., Guido, M., Apa, R., Caruso, A., & Mancuso, 
S. (1997). The impact of insulin secretion on the ovarian response to exogenous 
gonadotropins in polycystic ovary syndrome. The Journal of Clinical Endocrinology 
& Metabolism, 82(2), 644-648. 
 
Futterweit, W., & Ryan, G. (2006). A Patient's Guide to PCOS: Understanding--and 
Reversing--Polycystic Ovary Syndrome. Macmillan.p11-126. 
 
Galletly, C., Moran, L., Noakes, M., Clifton, P., Tomlinson, L., & Norman, R. (2007). 
Psychological benefits of a high-protein, low-carbohydrate diet in obese women 
with polycystic ovary syndrome—a pilot study. Appetite, 49(3), 590-593. 
 
Gatee, O. B., Al Attia, H. M., & Salama, I. A. (1996). Hirsutism in the United Arab 
Emirates: a hospital study. Postgraduate medical journal, 72(845), 168-171. 
 
Ghazeeri, G., Fakih, A., Abbas, H. A., Harajly, S., & Awwad, J. (2013). Anxiety, 
cognitive, and depressive assessment in adolescents with polycystic ovarian 
syndrome: a pilot study. Journal of pediatric and adolescent gynecology, 26(5), 
269-273. 
 
Gill, S., Taylor, A. E., Martin, K. A., Welt, C. K., Adams, J. M., & Hall, J. E. (2001). 
Specific Factors Predict the Response to Pulsatile Gonadotropin-Releasing 
	
	
184	
	
Hormone Therapy in Polycystic Ovarian Syndrome 1. The Journal of Clinical 
Endocrinology & Metabolism, 86(6), 2428-2436. 
Groemping  Y, Lapouge K, smerdon S, Rittenger K((2003).Understanding activation 
of NADPH oxidase: a structural characterization of p47phox. Biophys,84,356A. 
 
González, F., Sia, C. L., Shepard, M. K., Rote, N. S., & Minium, J. (2012). 
Hyperglycemia-induced oxidative stress is independent of excess abdominal 
adiposity in normal-weight women with polycystic ovary syndrome. Human 
reproduction, 27(12), 3560-3568. 
 
Gilling-Smith, C., Story, H., Rogers, V., & Franks, S. (1997). Evidence for a primary 
abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome. Clinical 
endocrinology, 47(1), 93-99.  
 
Guzick DS, Wing R, Smith D, Berga SL, Winters SJ. (1994) Endocrine consequences 
of weight loss in obese, hyperandrogenic, anovulatory 
women.FertilSterilApr;61(4):598-604. 
 
Goodarzi, M. O. (2008). Looking for polycystic ovary syndrome genes: rational and 
best strategy. In Seminars in reproductive medicine (Vol. 26, No. 01, pp. 005-013). 
New York:Thieme Medical Publishers. 
 
Goodarzi, M. O., Louwers, Y. V., Taylor, K. D., Jones, M. R., Cui, J., Kwon, S., & 
Laven, J. S. (2011). Replication of association of a novel insulin receptor gene 
polymorphism with polycystic ovary syndrome. Fertility and sterility, 95(5), 1736-
1741. 
 
Ha, L., Shi, Y., Zhao, J., Li, T., & Chen, Z. J. (2015). Association study between 
polycystic ovarian syndrome and the susceptibility genes polymorphisms in Hui 
Chinese women. PloS one, 10(5), e0126505. 
 
	
	
185	
	
Hall JE.(2012). The Ovary, Inferitility and Contraception. In: Fauci AS, Kasper DL, 
Braunwald E, Hauser SL, Longo DL, Jameson JL, Loscalzo J, editors. Harrison’s 
Principles of Internal Medicine. 18th ed. New York: McGraw-Hill; 2012. P. 3028-
3029. 
Hall, J. E., Sullivan, J. P., & Richardson, G. S. (2005). Brief wake episodes 
modulate sleep-inhibited luteinizing hormone secretion in the early follicular 
phase. The Journal of Clinical Endocrinology & Metabolism, 90(4), 2050-2055. 
 
Harnack L, Jeffery R, Boutelle K.( 2000). Temporal trends in energy intake in the 
United States: an ecologic perspective. American Journal of Clinical 
Nutrition,71(6),1478 – 1484. 
 
Harrison, C. L., Lombard, C. B., Moran, L. J., & Teede, H. J. (2011). Exercise 
therapy in polycystic ovary syndrome: a systematic review. Human Reproduction 
Update, 17(2), 171-183. 
 
Heijnen, E. M. E. W., Eijkemans, M. J. C., Hughes, E. G., Laven, J. S. E., Macklon, 
N. 3., & Fauser, B. C. J. M. (2006). A meta-analysis of outcomes of conventional 
IVF in women with polycystic ovary syndrome. Human reproduction update, 12(1), 
13-21. 
 
Huijgen, N., Laven J. , Labee,C. , Louwers Y., Willemsen , S., Steegers-Theunissen 
R.(2015). Are dieting and dietary inadequacy a second hit in the association with 
polycystic ovary syndrome severity. PLoS ONE 10(11), e0142772. 
 
Hill, J. O. (2006). Understanding and addressing the epidemic of obesity: an energy 
balance perspective. Endocrine reviews, 27(7), 750-761. 
 
Hoeger KM, Kochman L, Wixom N, Craig K, Miller RK, Guzick DS. (2004) A 
randomized, 48-week, placebo-controlled trial of intensive lifestyle modification 
and/or metformin therapy in overweight women with polycystic ovary syndrome: a 
pilot study.FertilSteril Aug;82(2):421-9. 
	
	
186	
	
 
Hoeger, K. M. (2006). Role of lifestyle modification in the management of polycystic 
ovary syndrome. Best Practice & Research Clinical Endocrinology & 
Metabolism, 20(2), 293-310. 
 
Hoeger, K., Davidson, K., Kochman, L., Cherry, T., Kopin, L., & Guzick, D. S. 
(2008). The impact of metformin, oral contraceptives, and lifestyle modification on 
polycystic ovary syndrome in obese adolescent women in two randomized, 
placebo-controlled clinical trials. The Journal of Clinical Endocrinology & 
Metabolism, 93(11), 4299-4306. 
 
Hoeger, K. M., & Oberfield, S. E. (2012). Do women with PCOS have a unique 
predisposition to obesity?. Fertility and sterility, 97(1), 13-17. 
 
Holte J, Gennarelli G, Berne C, Bergh T, Lithell H (1995) Restored insulin sensitivity 
but persistently increased early insulin secretion after weight loss in obese women 
with polycystic ovary syndrome. J ClinEndocrinolMetab Sep;80(9):2586-93. 
 
Homburg, R. (2005). Clomiphene citrate—end of an era? A mini-review. Human 
Reproduction, 20(8), 2043-2051. 
 
Housman, E., & Reynolds, R. V. (2014). Polycystic ovary syndrome: a review for 
dermatologists: Part I. Diagnosis and manifestations. Journal of the American 
Academy of Dermatology, 71(5), 847-e1. 
 
Hughesdon, P. E. (1982). Morphology and morphogenesis of the Stein-Leventhal 
ovary and of so-called" hyperthecosis". Obstetrical & gynecological survey, 37(2), 
59-77. 
 
Hue, L., & Taegtmeyer, H. (2009). The Randle cycle revisited: a new head for an 
old hat. American Journal of Physiology-Endocrinology and Metabolism, 297(3), 
E578-E591. 
	
	
187	
	
 
Hussein, B., & Alalaf, S. (2013). Prevalence and characteristics of polycystic 
ovarian syndrome in a sample of infertile Kurdish women attending IVF infertility 
center in maternity teaching hospital of Erbil City. Open Journal of Obstetrics and 
Gynecology , 3(7). 
 
Ibáñez, L., de Zegher, F., & Potau, N. (1999). Anovulation after Precocious 
Pubarche: Early Markers and Time Course in Adolescence 1. The Journal of 
Clinical Endocrinology & Metabolism, 84(8), 2691-2695. 
 
Ibanze, L., Potau, N., Zampolli, M., Prat , N., Gussinye, M., Saegner , E., Vicens-
Calvet, E., Carrascosa, A., (1994). Source localization of androgen excess in 
adolescents girls. The Journal of clinical endocrinology and metabolism, 79(6), 
1778-1784. 
 
Imani, B., Eijkemans, M. J., te Velde, E. R., Habbema, J. D. F., & Fauser, B. C. 
(2002). A nomogram to predict the probability of live birth after clomiphene citrate 
induction of ovulation in normogonadotropic oligoamenorrheic infertility. Fertility and 
sterility, 77(1), 91-97. 
 
Jahanfar, S., Eden, J. A., Nguyen, T., Wang, X. L., & Wilcken, D. E. L. (1997). A 
twin study of polycystic ovary syndrome and lipids. Gynecological 
Endocrinology, 11(2), 111-117. 
 
Jahanfar, Shayesteh, Eden, J.A., Warren, P., Seppala, M., Nguyen, T.V. (1995). "A 
twin study of polycystic ovary syndrome." Fertility and Sterility , 63(3), 478-486. 
 
 
Jakubowicz D, Barnea M, Wainstein J, Froy O. (2013) Effects of caloric intake timing 
on insulin resistance and hyperandrogenism in lean women with polycystic ovary 
syndrome.ClinSci (Lond) 125:423–32. 
	
	
188	
	
 
Jayasena, C. N., & Franks, S. (2014). The management of patients with polycystic 
ovary syndrome. Nature Reviews Endocrinology, 10(10), 624-636. 
 
Jakicic JM, Marcus BH, Gallagher KI, Napolitano M, Lang, W.,( 2003). Effect of 
Exercise Duration and Intensity on Weight Loss in Overweight, Sedentary Women: A 
Randomized Trial. Journal of the American Medical Association ,290(10),1323 – 1330. 
 
Jeffery RW, Wing RR, Sherwood NE, Tate,DF.,( 2003). Physical activity and weight 
loss: does prescribing higher physical activity Goals improve outcome? .American 
Journal of Clinical Nutrition, 78(4),684 – 689. 
 
Jeanes, Y. M., Reeves, S., Gibson, E. L., Piggott, C., May, V. A., & Hart, K. H. (2017). 
Binge eating behaviors and food cravings in women with Polycystic Ovary 
Syndrome. Appetite, 109(1), 24-32. 
Jebb, S. A. (1997). Aetiology of obesity. British Medical Bulletin, 53(2), 264-285. 
 
Johnston, SC., (2001). Identifying Confounding by indication through Blinded 
Prospective Review. AM. J. Epidemiol,154(3):276-284. 
 
Jones, M. R., & Goodarzi, M. O. (2016). Genetic determinants of polycystic ovary 
syndrome: progress and future directions. Fertility and sterility, 106(1), 25-32. 
 
Karacan, E., Caglar, G. S., Gürsoy, A. Y., & Yilmaz, M. B. (2014). Body satisfaction 
and eating attitudes among girls and young women with and without polycystic ovary 
syndrome. Journal of pediatric and adolescent gynecology, 27(2), 72-77. 
 
Karimzadeh, M. A., & Javedani, M. (2010). An assessment of lifestyle modification 
versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate–
metformin in patients with polycystic ovary syndrome. Fertility and sterility, 94(1), 216-
220. 
	
	
189	
	
 
Kasim-karakas, S., Almario, R., & Cunningham, W. (2009). Effects of protein versus 
simple sugar intake on weight loss in polycystic ovary syndrome (according to the 
National Institutes of Health criteria). In Fertility and Sterility,92(1)262-270. 
 
Katan, M. B., Zock, P. L., & Mensink, R. P. (1995). Trans fatty acids and their 
effects on lipoproteins in humans. Annual review of nutrition, 15(1), 473-493. 
 
Kaya, C., Cengiz, S. D., Berker, B., Demirtaş, S., Cesur, M., & Erdoğan, G. (2009). 
Comparative effects of atorvastatin and simvastatin on the plasma total 
homocysteine levels in women with polycystic ovary syndrome: a prospective 
randomized study. Fertility and sterility, 92(2), 635-642. 
 
Kennedy RL, Chokkalingam K, Farshchi HR. (2005(. Nutrition in patients with Type 
2 diabetes: are low-carbohydrate diets effective, safe or desirable? Diabetic 
Medicine, 22(7),821 – 832. 
 
Kerver, J.M., Yang, E.J., Obayashi, S., Bianchi, L., Song, W.O.( 2006). Meal and 
snack patterns are associated with dietary intake of energy and nutrients in US 
adults. Journal of the American Dietetic Association, 106(1),46 – 53. 
 
Knochenhauer, E.S., Key, T.J., Kahsar-Miller, M., Waggoner, W., Boots, L.R., 
Azziz, R. (1998). Prevalence of the polycystic ovary syndrome in unselected black 
and white women of the southeastern United States: a prospective study. J Clin 
Endocrinol Metab, 83(9),3078–3082. 
 
Kort, J. D., Winget, C., Kim, S. H., & Lathi, R. B. (2014). A retrospective cohort 
study to evaluate the impact of meaningful weight loss on fertility outcomes in an 
overweight population with infertility. Fertility and sterility, 101(5), 1400-1403. 
 
	
	
190	
	
Kumar, A., Woods, K., Bartolucci, A., Azziz, R., (200) Prevalence of adrenal 
androgen excess in patients with the polycystic ovary syndrome (PCOS). Clinical 
Endocrinology, 62(5),644-649. 
 
Kilicdag, E., Bagis, T., Zeyneloglu.H., Tarim, E., Erkanli, S.,Simek ,E., Aslan, E., 
Haydardedeoglu, B.,Kuscu, E.,( 2005). Administration of B-group vitamins reduces 
circulating homocysteine in polycystic ovari syndrome patients treated with 
metformin: a randomized trial. Human reproduction, 20(6), 1521-1528.  
 
Krystock, A. (2014). Role of Lifestyle and Diet in the Management of Polycystic 
Ovarian Syndrome. In Polycystic Ovary Syndrome (pp. 147-164). Springer New 
York. 
 
Kuijper, E. A., Vink, J. M., Lambalk, C. B., & Boomsma, D. I. (2009). Prevalence of 
polycystic ovary syndrome in women from opposite-sex twin pairs. The Journal of 
Clinical Endocrinology & Metabolism, 94(6), 1987-1990. 
 
La Fontaine, T. P., DiLorenzo, T. M., Frensch, P. A., Stucky-Ropp, R. C., Bargman, 
E. P., & McDonald, D. G. (1992). Aerobic exercise and mood. Sports 
Medicine, 13(3), 160-170. 
 
Lam, Q. L., & Lu, L. (2007). Role of leptin in immunity. Cell Mol Immunol, 4(1), 1-13. 
 
Larsson, I., Hulthén, L., Landén, M., Pålsson, E., Janson, P., & Stener-Victorin, E. 
(2016). Dietary intake, resting energy expenditure, and eating behavior in women 
with and without polycystic ovary syndrome. Clinical Nutrition, 35(1), 213-218. 
 
Lass, N., Kleber, M., Winkel, K., Wunsch, R., & Reinehr, T. (2011). Effect of lifestyle 
intervention on features of polycystic ovarian syndrome, metabolic syndrome, and 
intima-media thickness in obese adolescent girls. The Journal of Clinical 
Endocrinology & Metabolism, 96(11), 3533-3540. 
 
	
	
191	
	
Lee, H., Oh, J. Y., Sung, Y. A., Chung, H., Kim, H. L., Kim, G. S.,  & Kim, J. T. 
(2015). Genome-wide association study identified new susceptibility loci for 
polycystic ovary syndrome. Human Reproduction, 30(3), 723-731. 
 
Legro, R. S., Arslanian, S. A., Ehrmann, D. A., Hoeger, K. M., Murad, M. H.,  
 
Pasquali, R., & Welt, C. K. (2013). Diagnosis and treatment of polycystic ovary 
syndrome: an Endocrine Society clinical practice guideline. The Journal of Clinical 
Endocrinology & Metabolism, 98(12), 4565-4592. 
 
Legro, R. S., Barnhart, H. X., Schlaff, W. D., Carr, B. R., Diamond, M. P., Carson, 
S. A.,  & Gosman, G. G. (2007). Clomiphene, metformin, or both for infertility in the 
polycystic ovary syndrome. New England Journal of Medicine, 356(6), 551-566. 
 
Legro, R. S., Dodson, W. C., Gnatuk, C. L., Estes, S. J., Kunselman, A. R., 
Meadows, J. W., & Cooney, R. N. (2012). Effects of gastric bypass surgery on 
female reproductive function. The Journal of Clinical Endocrinology & 
Metabolism, 97(12), 4540-4548. 
 
Legro, R. S., Driscoll, D., Strauss, J. F., Fox, J., & Dunaif, A. (1998). Evidence for a 
genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proceedings of 
the National Academy of Sciences, 95(25), 14956-14960. 
 
Legro, R. S., Finegood, D., & Dunaif, A. (1998). A fasting glucose to insulin ratio is 
a useful measure of insulin sensitivity in women with polycystic ovary syndrome 
1. The Journal of Clinical Endocrinology & Metabolism, 83(8), 2694-2698. 
 
Li, Z., & Huang, H. (2008). Epigenetic abnormality: a possible mechanism 
underlying the fetal origin of polycystic ovary syndrome. Medical hypotheses, 70(3), 
638-642. 
 
	
	
192	
	
Lin, A. W., & Lujan, M. E. (2014). Comparison of dietary intake and physical activity 
between women with and without polycystic ovary syndrome: a review. Advances in 
Nutrition: An International Review Journal, 5(5), 486-496. 
 
Lin, M. W., & Wu, M. H. (2015). The role of vitamin D in polycystic ovary 
syndrome. The Indian journal of medical research, 142(3), 238. 
 
Linden Hirschberg, A., Naessen, S., Stridsberg, M., Byström, B., & Holte, J. (2004). 
Impaired cholecystokinin secretion and disturbed appetite regulation in women with 
polycystic ovary syndrome. Gynecological endocrinology, 19(2), 79-87 
 
Lindholm A, Andersson L, Eliasson M, Bixo M, Sundström-Poromaa I. (2008) 
Prevalence of symptoms associated with polycystic ovary syndrome. Int J Gynaecol 
Obstet ,102(1),39-43. 
 
Livadas, S., & Diamanti-Kandarakis, E. (2012). Polycystic ovary syndrome: 
definitions, phenotypes and diagnostic approach. In Polycystic Ovary 
Syndrome (Vol. 40, pp. 1-21). Karger Publishers. 
 
Lord, J. M., Flight, I. H., & Norman, R. J. (2003). Metformin in polycystic ovary 
syndrome: systematic review and meta-analysis. Bmj, 327(7421), 951. 
 
Ludwig, M., Finas, D. F., Al-Hasani, S., Diedrich, K., & Ortmann, O. (1999). Oocyte 
quality and treatment outcome in intracytoplasmic sperm injection cycles of 
polycystic ovarian syndrome patients. Human Reproduction, 14(2), 354-358. 
 
Lunenfeld, B. (2004). Historical perspectives in gonadotrophin therapy. Human 
Reproduction Update, 10(6), 453-467. 
 
Macklon, N. S. (2). (2014). IVF in the medically complicated patient: a guide to 
management. CRC Press. London, GB, CRC Press Taylor & Francis Group. 
 
	
	
193	
	
Maciel, G. A., Baracat, E. C., Benda, J. A., Markham, S. M., Hensinger, K., Chang, 
R. J., & Erickson, G. F. (2004). Stockpiling of transitional and classic primary 
follicles in ovaries of women with polycystic ovary syndrome. The Journal of Clinical 
Endocrinology & Metabolism, 89(11), 5321-5327. 
Malik, S. M., & Traub, M. L. (2012). Defining the role of bariatric surgery in 
polycystic ovarian syndrome patients. World J Diabetes, 3(4), 71-79. 
 
March, W.A., Moore, V.M., Willson, K.J., Phillips, D.I., Norman, R.J., Davies, M.J 
.(2010) .The prevalence of polycystic ovary syndrome in a community sample 
assessed under contrasting diagnostic criteria. Hum Reprod ,25(2),544 -551. 
 
Matthaei, S., Stumvoll, M., Kellerer, M., & Haring, H. U. (2000). Pathophysiology 
and pharmacological treatment of insulin resistance 1. Endocrine reviews, 21(6), 
585-618. 
 
McAvey, B., & Lieman, H. (2014). Managing the PCOS-Related Symptoms of 
Hirsutism, Acne, and Hair Loss. In Polycystic Ovary Syndrome (pp. 223-242). 
Springer New York. 
 
McCartney, C. R., Prendergast, K. A., Blank, S. K., Helm, K. D., Chhabra, S., &  
 
Marshall, J. C. (2009). Maturation of luteinizing hormone (gonadotropin-releasing 
hormone) secretion across puberty: evidence for altered regulation in obese 
peripubertal girls. The Journal of Clinical Endocrinology & Metabolism, 94(1), 56-66. 
 
McGee, W. K., Bishop, C. V., Bahar, A., Pohl, C. R., Chang, R. J., Marshall, J. C.,  
& Cameron, J. L. (2012). Elevated androgens during puberty in female rhesus 
monkeys lead to increased neuronal drive to the reproductive axis: a possible 
component of polycystic ovary syndrome. Human reproduction, 27(2), 531-540. 
 
McNatty ,K.P.(1982). Hormonal correlates of follicular growth in the human: a model 
from preliminary results. Aust J Biol Sci ,34(3):249-68. 
	
	
194	
	
 
McAuley ,K.A., Hopkins, C.M., Smith, K.J., McLay, R.T., Williams, S.M., Taylor, 
R.W.,(2005).Comparison of high-fat and high-protein diets with a high-carbohydrate 
diet in insulin-resistant obese women. Diabetologia ,48(1),8 – 16. 
 
Mehrabani, H. H., Salehpour, S., Amiri, Z., Farahani, S. J., Meyer, B. J., & Tahbaz, 
F. (2012). Beneficial effects of a high-protein, low-glycemic-load hypocaloric diet in 
overweight and obese women with polycystic ovary syndrome: a randomized 
controlled intervention study. Journal of the American College of Nutrition, 31(2), 
117-125. 
 
Messinis, I. E. (2005). Ovulation induction: a mini review. Human 
reproduction, 20(10), 2688-2697. 
 
Michelmore, K. F., Balen, A. H., Dunger, D. B., & Vessey, M. P. (1999). Polycystic 
ovaries and associated clinical and biochemical features in young women. Clinical 
endocrinology, 51(6), 779-786. 
 
Milone, M., De Placido, G., Musella, M., Fernandez, L. M. S., Fernandez, L. V. S., 
Campana, G., ... & Milone, F. (2016). Incidence of successful pregnancy after 
weight loss interventions in infertile women: a systematic review and meta-analysis 
of the literature. Obesity surgery, 26(2), 443-451. 
 
Moran, L. J., Noakes, M., Clifton, P. M., Wittert, G. A., Belobrajdic, D. P., & Norman, 
R. J. (2007). C-reactive protein before and after weight loss in overweight women 
with and without polycystic ovary syndrome. The Journal of Clinical Endocrinology 
& Metabolism, 92(8), 2944-2951. 
 
Moran, L. J., Noakes, M., Clifton, P. M., Wittert, G. A., Williams, G., & Norman, R. J. 
(2006). Short-term meal replacements followed by dietary macronutrient restriction 
enhance weight loss in polycystic ovary syndrome. The American journal of clinical 
nutrition, 84(1), 77-87. 
	
	
195	
	
Moran, C., Tena, G., Moran, S., Ruiz, P., Reyna, R., Duque, X. (2010). Prevalence 
of polycystic ovary syndrome and related disorders in mexican women. Gynecol 
Obstet Invest, 69(4),274–80. 
 
Moran, LJ.,Noakes, M., Clifton, PM.  (2003).Dietary composition in restoring 
reproductive and metabolic physiology in overweight women with polycystic ovary 
syndrome. J Clin Endocrinol Metab,88(2),812–819. 
 
Moran, L. J., Norman, R. J., & Teede, H. J. (2015). Metabolic risk in PCOS: 
phenotype and adiposity impact. Trends in Endocrinology & Metabolism, 26(3), 
136-143. 
 
Mozaffarian, D., Hao, T., Rimm, E. B., Willett, W. C., & Hu, F. B. (2011). Changes in 
diet and lifestyle and long-term weight gain in women and men. N Engl J 
Med, 2011(364), 2392-2404. 
 
Muhonen, P., & Holthofer, H. (2009). Epigenetic and microRNA-mediated regulation 
in diabetes. Nephrology Dialysis Transplantation, 24(4), 1088-1096. 
 
Musmar, S., Afaneh, A., & Mo'alla, H. (2013). Epidemiology of polycystic ovary 
syndrome: a cross sectional study of university students at An-Najah national 
university-Palestine. Reproductive Biology and Endocrinology, 11(1), 47. 
Nader, S. (2008). Ovulation induction in polycystic ovary syndrome. Minerva 
ginecologica, 60(1), 53-61. 
 
Naderpoor, N., Shorakae, S., de Courten, B., Misso, M. L., Moran, L. J., & Teede, 
H. J. (2015). Metformin and lifestyle modification in polycystic ovary syndrome: 
systematic review and meta-analysis. Human reproduction update, dmv025. 
 
Nascimento, C. M., Ribeiro, E. B., & Oyama, L. M. (2009). Metabolism and 
secretory function of white adipose tissue: effect of dietary fat. Anais da Academia 
Brasileira de Ciências, 81(3), 453-466. 
	
	
196	
	
 
Navratil, A. M., Song, H., Hernandez, J. B., Cherrington, B. D., Santos, S. J., Low, 
J. M., & Lawson, M. A. (2009). Insulin augments gonadotropin-releasing hormone 
induction of translation in LβT2 cells. Molecular and cellular endocrinology, 311(1), 
47-54. 
 
Nestler, J. E., & Jakubowicz, D. J. (1997). Lean Women with Polycystic Ovary 
Syndrome Respond to Insulin Reduction with Decreases in Ovarian P450c17α 
Activity and Serum Androgens 1. The Journal of Clinical Endocrinology & 
Metabolism, 82(12), 4075-4079. 
 
Newell-Price J. (2014) Endocrine disease. In Walker BR (Ed), Davidson's Principles 
and Practice of Medicine (pp. 733-796). Twenty-Second Edition. London: Churchill 
Livingstone. 
 
Norman ,R.J., Noakes ,M., Wu ,R., Davies, M.J., Moran, L., Wang, J.X.( 2004). 
Improving reproductive performance in overweight/obese women with effective 
weight management. Human Reproduction Update, 10(3),267 – 280. 
 
Nybacka Å, Carlstrom K, Stahle A, Nyren S, Hellstrom PM, Hirschberg AL. (2011) 
Randomized comparison of the influence of dietary management and/or physical 
exercise on ovarian function and metabolic parameters in overweight women with 
polycystic ovary syndrome.FertilSteril96:1508–13. 
 
Oktem, O., & Oktay, K. (2008). The ovary. Annals of the New York Academy of 
Sciences, 1127(1), 1-9. 
 
Ornstein, R. M., Copperman, N. M., & Jacobson, M. S. (2011). Effect of weight loss 
on menstrual function in adolescents with polycystic ovary syndrome. Journal of 
pediatric and adolescent gynecology, 24(3), 161-165. 
 
	
	
197	
	
Palomba, S., Falbo, A., Giallauria, F., Russo, T., Rocca, M., Tolino, A., Zullo F., & 
Orio, F. (2010). Six weeks of structured exercise training and hypocaloric diet 
increases the probability of ovulation after clomiphene citrate in overweight and 
obese patients with polycystic ovary syndrome: a randomized controlled 
trial. Human Reproduction, 25(11),2783-2791. 
 
Palomba S., Giallauria, F., Russo, T.,Oppedisano, R., Tolino, A., 
Coao,A.,Vigorito,C., Zullo,F., Orio,F.,(2008). Structured exercise training 
programme versus hypocaloric hyperproteic diet in obese polycystic ovary 
syndrome patients with anovulatory infertility: a 24-week pilot study. Human 
Reprod,23(3),642-650. 
 
Pasquali, R., Gambineri, A., Cavazza, C., Gasparini, D. I., Ciampaglia, W., 
Cognigni, G. E., & Pagotto, U. (2011). Heterogeneity in the responsiveness to long-
term lifestyle intervention and predictability in obese women with polycystic ovary 
syndrome. European journal of endocrinology, 164(1), 53-60. 
 
Pagan, Y.; Srouji, S.; Jimenez, Y.; Emerson, A.; Gill, S.; Hall, J. (2003). Inverse 
relationship between luteinizing hormone and body mass index in polycystic ovary 
syndrome: investigation of hypothalamic and pituitary contributions. Clin Endocrinol 
Metab, 91(4), 1309-1316. 
 
Pavone, M. E., & Bulun, S. E. (2013). The use of aromatase inhibitors for ovulation 
induction and superovulation. The Journal of Clinical Endocrinology & 
Metabolism, 98(5), 1838-1844. 
 
Pawlak, D. B., Ebbeling, C. B., & Ludwig, D. S. (2002). Should obese patients be 
counselled to follow a low-glycaemic index diet? Yes. Obesity reviews, 3(4), 235-
243. 
 
	
	
198	
	
Pereira-Lancha, L. O., Coelho, D. F., de Campos-Ferraz, P. L., & Lancha Jr, A. H. 
(2010). Body fat regulation: is it a result of a simple energy balance or a high fat 
intake?. Journal of the American College of Nutrition, 29(4), 343-351. 
 
Phy, J. L., Pohlmeier, A. M., Cooper, J. A., Watkins, P., Spallholz, J., Harris, K. S.,  
& Boylan, M. (2015). Low starch/low dairy diet results in successful treatment of 
obesity and co-morbidities linked to polycystic ovary syndrome (PCOS). Journal of 
obesity & weight loss therapy, 5(2),259. 
 
Pittas, A. G., Lau, J., Hu, F. B., & Dawson-Hughes, B. (2007). The role of vitamin D 
and calcium in type 2 diabetes. A systematic review and meta-analysis. The Journal 
of Clinical Endocrinology & Metabolism, 92(6), 2017-2029. 
 
Pollack, P. S., Shields, K. E., Burnett, D. M., Osborne, M. J., Cunningham, M. L., & 
Stepanavage, M. E. (2005). Pregnancy outcomes after maternal exposure to 
simvastatin and lovastatin. Birth Defects Research Part A: Clinical and Molecular 
Teratology, 73(11), 888-896. 
 
Polycystic ovary syndrome; weight loss, exercise improve fertility in women with 
PCOS. (2015). Women's Health Weekly, , 3875. Retrieved from: 
http://search.proquest.com/docview/1720033809?accountid=8555 
 
Qureshi, A. I., Nussey, S. S., Bano, G., Musonda, P., Whitehead, S. A., & Mason, 
H. D. (2008). Testosterone selectively increases primary follicles in ovarian cortex 
grafted onto embryonic chick membranes: relevance to polycystic 
ovaries. Reproduction, 136(2), 187-194. 
 
Qublan HS, Yannakoula EK, Al-Qudah MA, El Uri FI. (2007) Dietary intervention 
versus metformin to improve the reproductive outcome in women with polycystic 
ovary syndrome. A prospective comparative study.Saudi Med J 28:1694–1699. 
 
	
	
199	
	
Ragni, G., Vegetti, W., Riccaboni, A., Engl, B., Brigante, C., & Crosignani, P. G. 
(2005). Comparison of GnRH agonists and antagonists in assisted reproduction 
cycles of patients at high risk of ovarian hyperstimulation syndrome. Human 
reproduction, 20(9), 2421-2425. 
 
Rice, S., Ojha, K., Whitehead, S., & Mason, H. (2007). Stage-specific expression of 
androgen receptor, follicle-stimulating hormone receptor, and anti-Mullerian 
hormone type II receptor in single, isolated, human preantral follicles: relevance to 
polycystic ovaries. The Journal of Clinical Endocrinology & Metabolism, 92(3), 
1034-1040. 
 
Rossi, A., Cantisani, C., Melis, L., Iorio, A., Scali, E., & Calvieri, S. (2012). Minoxidil 
use in dermatology, side effects and recent patents. Recent patents on 
inflammation & allergy drug discovery, 6(2), 130-136. 
 
Rosenfield, R.L., Mortensen,M., Wroblewski, K., Littlejohn,E.,Ehrmann,D.A., 
(2011).Determination of the source of androgen excess in functionally atypical 
polycystic ovary syndrome by a short dexa-methasone androgen-suppression test 
and a low-dose ACTH test.Hum Reprod, 26(11),3138-3146. 
 
Rondanelli, M., Perna, S., Faliva, M., Monteferrario, F., Repaci, E., & Allieri, F. 
(2014). Focus on metabolic and nutritional correlates of polycystic ovary syndrome 
and update on nutritional management of these critical phenomena. Archives of 
gynecology and obstetrics, 290(6), 1079-1092. 
 
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group .(2004) 
Revised 2003 consensus on diagnostic criteria and long-term health risks related to 
polycystic ovary syndrome. Fertil Steril, 81(1),19-25. 
 
Ruel, M. T., Alderman, H., & Maternal and Child Nutrition Study Group. (2013). 
Nutrition-sensitive interventions and programmes: how can they help to accelerate 
	
	
200	
	
progress in improving maternal and child nutrition?. The Lancet, 382(9891), 536-
551. 
 
Riccardi ,G., Rivellese, A.( 2000). Dietary treatment of the metabolic syndrome – 
the optimal diet. British Journal of Nutrition ,83(1),S143 – S148. 
 
Sam, S. (2007). Obesity and polycystic ovary syndrome. Obesity 
management, 3(2), 69-73. 
 
Samaha, F.F., Iqbal, N., Seshadri, P., Chicano, K.L., Daily, D.A., McGrory, J.( 
2003). A Low-Carbohydrate as Compared with a Low-Fat Diet in Severe Obesity. 
New England Journal of Medicine ,348, 2074 – 2081. 
 
Sedighi, S., Afrakhteh, M., Esteki, T., & Mahmoodi, Z. (2014). Comparison of lifestyle in 
women with polycystic ovary syndrome and healthy women. Global journal of health 
science, 7(1), 228-234. 
 
Sen, A., Kushnir, V. A., Barad, D. H., & Gleicher, N. (2014). Endocrine autoimmune 
diseases and female infertility. Nature Reviews Endocrinology, 10(1), 37-50. 
 
Shabir, I., Ganie, M. A., Zargar, M. A., Bhat, D., Mir, M. M., Jan, A., ... & Naqati, A. 
(2014). Prevalence of metabolic syndrome in the family members of women with 
polycystic ovary syndrome from North India. Indian journal of endocrinology and 
metabolism, 18(3), 364. 
 
Sharma, T. P., Herkimer, C., West, C., Ye, W., Birch, R., Robinson, J. E., ... & 
Padmanabhan, V. (2002). Fetal programming: prenatal androgen disrupts positive 
feedback actions of estradiol but does not affect timing of puberty in female 
sheep. Biology of reproduction, 66(4), 924-933. 
 
	
	
201	
	
Shi, Y., Zhao, H., Shi, Y., Cao, Y., Yang, D., Li, Zhang B. & Shen, J. (2012). Genome-
wide association study identifies eight new risk loci for polycystic ovary 
syndrome. Nature genetics, 44(9), 1020-1025. 
 
Sirmans, S. M., & Pate, K. A. (2013). Epidemiology, diagnosis, and management of 
polycystic ovary syndrome. Clin Epidemiol, 6(12), 1-13. 
 
Speliotes, E. K., Willer, C. J., Berndt, S. I., Monda, K. L., Thorleifsson, G., Jackson, A. 
U., & Randall, J. C. (2010). Association analyses of 249,796 individuals reveal 18 new 
loci associated with body mass index. Nature genetics, 42(11), 937-948. 
 
Speroff L, Fritz M(2011). Induction of oculation . In: Speroff L, Fritza M, editors. Clinical 
gynecologic endocrinology and infertility.7th edition. Philadephia , PA: Lippincott 
Williams & Wilkins;2011.p.145-85. 
 
Stein, A. D., Kahn, H. S., Rundle, A., Zybert, P. A., van der Pal–de Bruin, K., & Lumey, 
L. H. (2007). Anthropometric measures in middle age after exposure to famine during 
gestation: evidence from the Dutch famine. The American journal of clinical 
nutrition, 85(3), 869-876. 
Stamets, K., Taylor, D. S., Kunselman, A., Demers, L. M., Pelkman, C. L., & Legro, 
R. S. (2004). A randomized trial of the effects of two types of short-term hypocaloric 
diets on weight loss in women with polycystic ovary syndrome. Fertility and 
sterility, 81(3), 630-637. 
 
Stern, L., Iqbal, N., Seshadri, P., Chicano, K.L., Daily, D.A., McGrory, J.( 2004). The 
effects of low-carbohydrate versus conventional weight loss diets in severely obese 
adults: one-year follow-up of a randomized trial. Annals of Internal Medicine, 
140(10),778 – 785. 
 
Tang, T., Glanville, J., Hayden, C. J., White, D., Barth, J. H., & Balen, A. H. (2006). 
Combined lifestyle modification and metformin in obese patients with polycystic 
	
	
202	
	
ovary syndrome. A randomized, placebo-controlled, double-blind multicentre 
study. Human reproduction, 21(1), 80-89. 
 
Tang, T., Lord, J. M., Norman, R. J., Yasmin, E., & Balen, A. H. (2009). Insulin-
sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women 
with polycystic ovary syndrome, oligo amenorrhoea and subfertility. The Cochrane 
Library. 
 
Tarlatzis, B. C., Fauser, B. C. J. M., Legro, R. S., Norman, R. J., Hoeger, K., 
Pasquali, R., & Lobo, R. (2008). Consensus on infertility treatment related to 
polycystic ovary syndrome. Human Reproduction, 23(3), 462-477. 
 
Tehrani,F., Simbar, M., Tohidi,M., Hosseinpanah,F., Azizi,F.,(2011). The 
prevalence ofpolycysitc ovary syndrome in a community sample of Iranian 
population:Iranian PCOS prevalence study.  Reproductive Biology and 
endocrinology , 9(39). 
 
The Thessaloniki.  ESHRE /ASRM-sponsored PCOS consenus criteria workshop 
group. Consensus on infertility treatment related to polycystic ovary syndrome. 
Fertil Steril,89(3),505-22. 
 
Thomson,R., Buckley, J., Lim,S., Noaks,M., Clifton,P., Norman,R., Grant,G.,(2010). 
Lifestyle management improves quality of life and depression in overweight and 
obese women with polycystic ovary syndrome.Fertil Steril ,94(5), 1812-1816. 
 
Tossi ,.F., Negri,C.,Perrone,F.,Dorizzi,R.,Castello,R.,Bonora,E., & Bonora,E., 
(2012). Hyperinsulinemia amplifies GnRH agonist stimulated ovarian steroid 
secretion  in women with polycystic ovary syndrome. J Clin Endocrinol Metab,97(5) 
,1712-1719. 
 
Turner-McGrievy,G., Davidson,C., Wingard,E., Billings,D.,(2014).Low glycemic 
index vegan or low-calorie weight loss diets for women with polycystic ovary 
	
	
203	
	
syndrome:a randomized controlled feasibility study. Nutition research ,34(6), 552-
558. 
 
Vause, T., Cheung, A., Sierra, S., Claman, P., Graham, J., Guillemin, J., Lapensee, 
L., Steward (2010). Ovulation induction in polycystic ovary syndrome. International 
Journal of Gynecology and Obsterics, 111(1), 95-100. 
 
Vassiliadi,D.A., Barber, T.M., Hughes, B.A.,  McCarthy,M.I., Wass,J.A., 
Franks,S.,(2009) Increased 5 aplha-redcutase activity and adrenocortical drive in 
women with polycystic ovary syndrome. J Clin Endocrinol Metab ,94(9),3558-3566. 
 
Vendola, K., Zhou, J., Wang, J., Famuyiwa, O. A., Bievre, M., & Bondy, C. A. 
(1999). Androgens promote oocyte insulin-like growth factor I expression and 
initiation of follicle development in the primate ovary. Biology of 
Reproduction, 61(2), 353-357. 
 
Vessby, B., Uusitupa, M., Hermansen, K., Riccardi, G., Rivellese, A.A., Tapsell, 
L.C. (2001). Substituting dietary saturated for monounsaturated fat impairs insulin 
sensitivity in healthy men and women: The KANWU study. Diabetologia ,44(3),312 
–319. 
 
Vink, J. M., Sadrzadeh, S., Lambalk, C. B., & Boomsma, D. I. (2006). Heritability of 
polycystic ovary syndrome in a Dutch twin-family study. The Journal of Clinical 
Endocrinology & Metabolism, 91(6), 2100-2104. 
 
Walker, B. R., & Colledge, N. R. (2013). Davidson's principles and practice of 
medicine. Elsevier Health Sciences. 
 
Webber, L. J., Stubbs, S., Stark, J., Trew, G. H., Margara, R., Hardy, K., & Franks, 
S. (2003). Formation and early development of follicles in the polycystic ovary. The 
Lancet, 362(9389), 1017-1021. 
	
	
204	
	
Welt, C. K., Pagan, Y. L., Smith, P. C., Rado, K. B., & Hall, J. E. (2003). Control of 
follicle-stimulating hormone by estradiol and the inhibins: critical role of estradiol at 
the hypothalamus during the luteal-follicular transition. The Journal of Clinical 
Endocrinology & Metabolism, 88(4), 1766-1771. 
 
Wild, R. A. (2012). Dyslipidemia in PCOS. Steroids, 77(4), 295-299. 
 
Wild, R. A., Painter, P. C., Coulson, P. B., Carruth, K. B., & Ranney, G. B. (1985). 
Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic 
ovary syndrome. The Journal of Clinical Endocrinology & Metabolism, 61(5), 946-
951. 
 
Wren, A. M., Seal, L. J., Cohen, M. A., Brynes, A. E., Frost, G. S., Murphy, K. G., & 
Bloom, S. R. (2001). Ghrelin enhances appetite and increases food intake in 
humans. J Clin Endocrinol Metab, 86(12), 5992. 
 
Wright, C. E., Zborowski, J. V., Talbott, E. O., McHugh-Pemu, K., & Youk, A. 
(2004). Dietary intake, physical activity, and obesity in women with polycystic ovary 
syndrome. International journal of obesity, 28(8), 1026-1032. 
 
Weisberg, S. P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R. L., & Ferrante, 
A. W. (2003). Obesity is associated with macrophage accumulation in adipose 
tissue. The Journal of clinical investigation, 112(12), 1796-1808. 
 
Yildirim, B., Sabir, N., & Kaleli, B. (2003). Relation of intra-abdominal fat distribution 
to metabolic disorders in nonobese patients with polycystic ovary 
syndrome. Fertility and sterility, 79(6), 1358-1364. 
 
Yildiz, B. O., Knochenhauer, E. S., & Azziz, R. (2008). Impact of obesity on the risk 
for polycystic ovary syndrome. The Journal of Clinical Endocrinology & 
Metabolism, 93(1), 162-168. 
	
	
205	
	
Yoshida, N., Sekiba, K,,Ynaihara, T., Sano, Y.,Shibusawa,H., Okinaga, S.,(1978). 
Ihibition of fetal adrenal 21-hydroxylase by naturally occurring streoids. Endocrinol 
Jpn,63(4),349-353 
 
Zacur, H. A. (2003). Epidemiology, clinical manifestations and pathophysiology of 
polycystic ovary syndrome. Adv Stud Med, 3, S733-9. 
 
Zreik, T. G., Mazloom, A., Chen, Y., Vannucci, M., Pinnix, C. C., Fulton, S., & 
Shihadeh, F. (2010). Fertility drugs and the risk of breast cancer: a meta-analysis 
and review. Breast cancer research and treatment, 124(1), 13-26. 
 
Zreik, R. S., & Nasrallah, M. P. (2014). The prevalence of endocrinopathies among 
Lebanese women presenting with hirsutism to an endocrine clinic. 
. Lebanese Medical Journal, 62(1), 27. 
 
 
 
 
 
 
 
 
 
 
 
 
 
	
	
206	
	
 
9.2 Appendices 
Appendix 1: Patient consent form (available in Arabic language also) 
Patient information sheet is duplicated because AUBMC uses this practice form as 
consent to patients. 
Consent to participate in a research study 
Study title: “Public health nutrition intervention to enhance healthy eating and 
lifestyle modification among Lebanese patients with polycystic ovarian syndrome.” 
 
Principal Investigator: Dr. GhinaGhazeeri 
Co-investigator: Caroline Hamadi 
Address:   American University Hospital  
Cairo Street 
  Beirut, Lebanon 
Phone:      (01) 350 000 ext 5618  
 
Setting:AUBMC , in the Women’s Health Center private clinics , and Obstetrics and 
Gynecology outpatient clinics. 
 
You are being asked to participate in a clinical research study conducted at the 
American University of Beirut. Please take time to read the following information 
carefully before you decide whether you want to take part in this study or not.  Feel 
free to ask your doctor if you need more information or clarification about what is 
stated in this form and the study as a whole. 
Why is this study being done? 
Polycystic Ovary Syndrome (PCOS) is one of the common disease which affect 
women in their reproductive age. Obesity co-exists with PCOS and nutritional 
guidelines for healthy eating is an essential issue to be discussed with PCOS 
women. Other metabolic disease are accompanied with PCOS women which 
causing PCOS to be a public health disease .Thus research towards nutritional 
treatment is potential to improve the abnormalities .Weight loss was proposed as a 
major treatment for obese PCOS women .Other nutritional guidelines were also 
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noted as part of the metabolic abnormalities treatment. Specific nutrients in the 
daily diet were found to help improve the health status of PCOS patients whether 
lean or obese. 
The aim of the study is to address nutritional education to lean, overweight and 
obese women with PCOS as a step towards lifestyle modification and dietary 
behavioral changes. In our public health intervention, we aim to provide educational 
tools about healthy food choices, healthy eating pattern and promoting physical 
activity as an influence for these PCOS patients to control their weight.  
This study is very important in order to decrease PCOS complications. 
This study is in the purpose of a PhD degree for the research assistant of Dr Ghina 
GHazeeri,Caroline Hamadi and data will be used to complete her PhD degree at 
the University of Westminster, London, United Kingdom. 
This study will take place at AUBMC in the Women’s Health Center private clinics 
and Obstetrics and Gynecology outpatient clinics. 
A consent form will be distributed only at these units. 
Up to 294 PCOS women will be recruited in the whole study. In the first year 76 
patients will be recruited for the pilot study. 
 
What will happen if you take part in this study? 
Potential candidates for the study will be approached by the research assistant who 
will explain the study and its objectives and then will ask eligible women to 
participate and sign a consent form approved by the institutional review board 
(IRB). 
After the Informed consent has been signed, an assessment form will be filled and 
candidates will fill some questionnaires; food frequency questionnaire, 24- hour 
recall, physical activity, reproductive health, psychological(anxiety and depression) 
and socio-demographics questions. Then a nutritional assessment with body 
analysis( by analyzing  the percentage body fat, percentage body muscle ,basal 
metabolic rate  using ELG 3rdgeneration impedance machine with no invasive 
method ),  weight, height and BMI measurements will take place. You will be asked 
to withdraw 3 ml of blood sample. You will be subject to routine checkup for women 
with polycystic ovary syndrome regarding medical history, physical examination and 
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hematologic laboratory tests. You will then randomly grouped according to your 
weight (lean versus overweigh/obese) into 1 of 4 groups. 
One group (lean): one subgroup will receive their gynecologist treatment, second 
subgroup will receive an extra nutritional education sessions on their visits. Second 
group (Overweight/obese): one subgroup will receive the gynecologist treatment 
and a second subgroup will receive nutritional education sessions on their visits and 
weight loss therapy by diet management. 
The study involves a total of 3 visits (At the beginning of the study, at 3 and 6 
months) .Each visit will take a maximum 1 hour of your time .At each visit you will 
be subject to the different questionnaires and assessments and be subject to 3 ml 
of blood sample withdrawal for laboratory analysis performed at AUB-MC in each 
visit. Therefore there will be a total of 3 blood samples taken over a period of 6 
months during which you will be subject to our nutritional intervention and your 
results will be compared for changes. You should be fasting before taking your 
blood sample at each visit. 
 
How long will I be in the study? 
You will be in the study for a 6 months period. 
The investigator may decide to take you off the study if she feels that is in your best 
interest .If you will not follow the guidelines of the study you will be asked to stop in 
the study. 
You can choose at any time stop being part of the study and if you decide so you 
should inform the researcher. 
Significant new findings in this study will be conveyed to you. 
 
What side effects or risk could result from being in this study? 
Blood withdrawal may cause a discomfort or blue discoloration at the site of blood 
withdrawal. Other risk such as the feeling of being forced to lose weight will cause 
an additional risk. 
Dr Ghina Ghazeeri will be contacted in case any occurrence of risk in the study. 
 
What are the benefits of participating in this study? 
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You will receive your blood results and be gaining nutritional information regarding 
your medical status. You will be able to modify your lifestyle and increase your daily 
physical activity. 
We hope to set up the nutritional guidelines of PCOS patients in this study and help 
your condition in the future. 
 
How is confidentiality assured? 
 
If you agree to participate in this research study, the information will be kept 
confidential. Your name or other personal identifiers will not be used during the study. 
All information about you from this research project will be kept in a locked office .  
Unless required by law, only the study doctor and designee, the ethics committee 
and inspectors from governmental agencies will have direct access to your medical 
records which may be audited without violating confidentiality, your name will not be 
used. 
Would you like to be informed of new studies conducted in the future?  
Yes               No   
 
You have not given up any of your legal rights by signing this form. There will be 
confidentiality of subjects’ records. 
 
A refusal to participate will involve no loss of benefits. 
 
Investigator’s Statement: 
 
I have reviewed, in detail, the informed consent document for this research 
study with       (name of patient, legal representative, 
or parent/guardian) the purpose of the study and its risks and benefits.  I have 
answered to all the patient’s questions clearly.  I will inform the participant in 
case of any changes to the research study. 
_______ _____         
Name of Investigator or designee   Signature 
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Date & Time 
 
 
 
 
 
 
 
 
 
 
 
 
Patient’s Participation: 
I have read and understood all aspects of the research study and all my questions 
have been answered.  I voluntarily agree to be a part of this research study and I 
know that I can contact Dr.  GhinaGhazeeri at 5618 or any of his/her 
designee involved in the study in case of any questions.  If I feel that my questions 
have not been answered, I can contact the Institutional Review Board for human 
rights at  5445 .  I understand that I am free to withdraw this consent and 
discontinue participation in this project at any time, even after signing this form, and 
it will not affect my care or benefits.I know that I will receive a copy of this signed 
informed consent. 
__________________________        
Name of Patient or Legal Representative    Signature 
or Parent/Guardian 
 
      
Date & Time 
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Witness’s Name      Witness’s Signature 
(if patient, representative or parent do not read)     
 
      
Date & Time 
Appendix 2: Patient information sheet 
 
Public health nutrition intervention to enhance healthy eating and lifestyle 
modification among Lebanese patients with polycystic ovarian syndrome. 
Principal Investigator: Dr. Ghina Ghazeeri 
 
 
Co-Investigator: Caroline Hamadi 
We would like to invite you to participate in this research study. Please read the 
following details regarding the study and your involvement carefully before you 
decide to take part. If you require further clarification or have additional questions 
contact us. 
 
What is the purpose of the study? 
Polycystic ovarian syndrome (PCOS) is a common endocrine syndrome and the 
most common cause of anovulatury infertility affecting women in the reproductive 
age. Diet management , increasing healthy food choice and physical activity 
promotion may improve the metabolic , clinical and reproductive outcomes by 
educating patients with PCOS on healthy food and promote physical activity. 
Therefore the aim of this study is to enhance healthy eating and lifestyle 
modification among polycystic ovarian syndrome patients attending the obstetrics 
gynecology clinic at the American University of Beirut Medical Center(AUBMC) 
Beirut , Lebanon. 
This study is in the purpose of a PhD degree for the research assistant of Dr Ghina 
Ghazeeri,Caroline  Hamadi and data will be used to complete her PhD degree at 
the University of Westminster , London , United Kingdom. 
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Can I take part in the study? 
Yes if you are: 
• Patients aged 18 years or above and less than 49 years  
• Diagnosed with PCOS according to the Rotterdam ESHRE / ASRM 
sponsored PCOS consensus workshop group, 2004. 
 
What is expected from me? 
You will be asked to sign a “consent form” and a copy of the “information sheet” will 
be provided. Physical, biochemical , psychological, nutritional and anthropometric 
assessments will be taken and you will be subject  certain questionnaires(food 
frequency questionnaires, physical activity questionnaire , 24-hour recall).You will 
be then subject to nutritional education/counseling and follow the guidelines 
proposed ( intervention  groups only) and structural weight loss program for obese 
patients.Obese patients will be subject to monthly follow-up with their diet and 
weight change .During the intervention the patients focus should be on the 
outcomes of the lifestyle modification as positive issue to their health status. You 
will be grouped according to your weight and the treatment you are following. 
What types of measurements / tests will be performed on me? 
On the first day of the study following measurements will be taken: 
• Body composition (Weight ,Height and BMI,percentage body fat , percentage 
body muscle , percentage body water ) 
• Nutritional assessment: Food frequency questionnaire and 24 hour recall, 
physical activity questionnaire 
• Pschychologicalquestionnaires : GAD-7 and BDI-II. 
• Medical assessment : reproductive questions , hirsutism score and 
hypertension 
• Biochemical analysis: FBS, HDL ,LDL ,TG total cholesterol , CRP, serum 
testosterone and Vitamin D. 
 
All the above mentioned measurements will be repeated at start, the end of 3 
months , 6 months of participation.  
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Are there any risks of taking part in the study? 
Blood withdrawal may cause a discomfort or blue discoloration at the site of blood 
withdrawal. Other risk such as the feeling of being forced to lose weight will cause 
an additional risk. 
DrGhinaGhazeeri will be contacted in case any occurrence of risk in the study. 
How will privacy be kept during the study? 
If you agree to participate in this research study, the information will be kept 
confidential.Your name or other personal identifiers will not be used during the 
study.All information about you from this research project will be kept in a locked 
office .  Unless required by law, only the study doctor and designee, the ethics 
committee and inspectors from governmental agencies will have direct access to 
your medical records which may be audited without violating confidentiality, your 
name will not be used. 
What are the benefits of taking part in the study? 
You will receive your blood results and be gaining nutritional information regarding 
your medical status. You will be able to modify your lifestyle and increase your daily 
physical activity. 
We hope to set up the nutritional guidelines of PCOS patients in this study and help 
your condition in the future. 
Significant new findings in this study will be conveyed to you 
Refusing to participate will involve no loss of benefits. 
 
What is the process to withdraw from the study? 
If you decide not to be a part of the study, you are free to withdraw at any time. 
Your participation in the study is completely voluntary. On withdrawal all your 
records will be erased. Subject’s participation may be ended by the investigator. 
How will the results be used after the study? 
The results would be taken and written by the investigator and will be used for 
research outcomes (but individuals will not be identified). The data will be used as 
part of the PhD degree of Caroline Hamadi in University of Westminster,London , 
United Kingdom .The research outcome will be available to you. If you wish to read 
a copy of the final report please contact the researcher. 
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What should I do next to take part in the study?  
Please fill in the “consent form” and contact me to arrange for an appointment.  
 
Please note that the decision to participate in this study should be your own 
and choosing not to take part will not disadvantage you in any way. 
For any further questions or information please contact me: 
DrGhinaGhazeeri and Caroline Hamadi:  
Gg02@aub.edu.lb 
c.hamadi@my.westminster.ac.uk 
Or call on00961- 01350000 extension 5618  
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Appendix 3 : Assessment form used  
 
Assessment form 
A.Personal information 
Date of visit:                                                                    Type of visit : 1     2      3                                                                                           
Patient number: 
 
Age bins : 18-20           20-25              25-30        30-35       35-40          40-45         
45-50         50-55  
Marital status:   Married                   Single          Divorced              Widowed           
 
Insurance : None         NSSF        HIP        Private          Other 
 
B.Personal/Family history: 
Medical history 
Do you have any history of PCOS? Yes                         No 
Do you suffer from any present health condition ? Yes( specify )                                 
nO 
Surgical history  
Medications (name, dose and frequency) 
Family history of disease 
Personal history of disease 
 
C.Social assessment 
Alcohol intake:No          Yes            Specify 
Smoking :  No         Yes                    Specify 
 
D.Obstetrical and gynecological  history: 
Gravida       Para      Abortion       Ectopic 
Mode of delivery  
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Age at menarche:     years 
Current symptoms of PCOS: 
Duration of PCOS? 
Period: Regular              Irregular:             specify  
Are sexually active? 
Are you pregnant? 
Acne: 
Hirsutism score: 
Infertility ? Yes              No 
Thinning of hair sculp? Yes                No 
Current treatment of PCOS? 
Oral contraceptives                                         Metformin                        Anti-
androgen 
Fertility agent                                                  Lipid lowering drugs                       
Others 
 
E.Hypertension measurement: 
Systolic BP 
Diastolic BP: 
 
F.Nutritonal assessment : 
Have you had any weight loss/weight gain in the last 3 months? 
Weight :        kg                                           Height:         cm 
Waist circumference:              cm                     Hip circumference :           cm                 
Wait/Hip ratio: 
Percentage body fat :       % 
Percentage excess body fat :         % 
Percentage body muscle :                 % 
BMI( Body mass index): 
BMR(Basal metabolic rate): 
G.Biochemical analysis : 
C-reactive protein: 
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Fasting blood sugar (FBS ) : 
Lipid profile : LDL-C:  
                        HDL-C: 
                       Triglyceride: 
Serum testosterone : 
Insulin: 
Vitamin D(25)OH : 
 
H.Socio-demographic section: 
What is the highest education level you have completed ? 
How many people are currently living in your household including yourself? 
Please describe the home where you live: owned,rented, friends,family : 
How do you pay your healthcare ?Goverment, private insurance, self-pay ? 
Do you have a job? No         Yes(specify) 
What is your total combined family income for the past 12 months,from all sources 
and wages? 
<500 $                 500-1000$                               1000-2000$                              
>2000$ 
 
E. Psychological assessment  
1.BDI-II  
2.GAD-7 
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Appendix 4 : Physical activity Questionnaire 
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Appendix 5: Psychological assessment forms 
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Appendix 6: Prevalence of PCOS according to the different criteria 
Population NIH criteria Rotterdam 
criteria 
AE-PCOS criteria 
728 Australian 
women 
8.7% 17.8% 12.0% 
820 Iranian 
women 
7% 15.2% 7.92% 
929 Iranian 
women 
7.1% 14.6% 11.7% 
392 Turkish 
women 
6.1% 19.9% 15.3% 
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Appendix 7: Effects of LSM and weight loss programs on metabolic correlates of PCOS (1994-2013) 
Table 20 Literature review on the effects of LSN and weight loss programs on metabolic correlates of PCOS (1994- 2013) 
Studies Intervention Variables Outcome Limitations/comm
ents 
Guzick et al., 
1994 
 
12 obese, 
hyperandrogenic, 
anovulatory women 
randomized to 12-
week weight loss 
program or 12-week 
"waiting list" in control 
group 
 
• Ovulation 
• Fasting insulin and 
glucose 
measurement 
• Sex hormone-
binding globulin 
(SHBG) 
• Total and non-
SHBG bound 
testosterone (non-
SHBG-T) 
concentrations 
• Luteinizing 
hormone (LH) 
pulse frequency, 
amplitude, and 
concentration 
• Follicle stimulating 
hormone (FSH) 
concentration 
• Women in the treatment 
group lost an average of 
16.2 kg 
• They showed a significant 
increase in SHBG, decline in 
non-SHBG-T, and decline 
(though non-significant) in 
fasting insulin  
• Four of six subjects in 
treatment group resumed 
ovulation 
• No changes were evident in 
LH pulse frequency or 
amplitude or in mean LH and 
FSH concentrations 
Weight loss in 
obese, 
hyperandrogenic, 
anovulatory women 
appears to reduce 
insulin and non-
SHBG-T 
concentrations 
despite the 
absence of a 
change in 
gonadotropin 
secretion and may 
lead to resumption 
of ovulation 
Holte et al., 
1995 
13 obese  insulin-
resistant women with 
PCOS on weight loss 
program 
• Insulin sensitivity 
• Basal sex steroid 
hormones 
• Mean weight loss was 12.4 
kg  
• Reduction from a BMI of 
32.2 kg/m2 to 27.6 kg/m2 
Insulin resistance in 
obese women with 
PCOS was reduced 
by weight loss to 
similar levels as 
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• Gonadotropins 
and free fatty acids 
(FFA) 
• Skin folds and 
waist hip ratio 
• Insulin sensitivity index 
improved on average 132% 
and plasma FFA by 32%  
• Serum SHBG levels 
increased by 35%  
• The sum of truncal-
abdominal skin-folds were 
reduced by 28% 
BMI-matched 
control subjects, 
suggesting that 
insulin resistance in 
PCOS is not a 
feature of PCOS 
per se 
Clark et al., 
1995 
Subjects underwent 
weekly program of 
behavioral 
modification  for 6 
months 
• Weight 
• Pregnanediol as a 
marker for the 
return of ovulation 
• Pregnancy 
• Waist/Hip ratios 
• Serum 
testosterone, 
insulin 
concentrations, 
SHBG 
concentrations, 
fasting glucose, 
and LH 
concentrations  
• Psychometric 
assessment 
• Weight loss 6.3 ± 4.2 kg 
• 12 of the 13 women in the 
study group were ovulating 
spontaneously 
• Of the 13 women who 
completed the program, only 
two had not conceived 12 
months after completion of 
the program 
• Waist/Hip ratio >0.8. Weight 
loss did not significantly alter 
the ratios over 6 months 
• Drop in serum testosterone 
and insulin concentrations, 
rise in SHBG concentrations, 
and no change in the fasting 
glucose or LH 
concentrations 
• Significant improvement in 
all the psychological 
parameters measured 
Weight loss with a 
resultant 
improvement in 
ovulation, 
pregnancy 
outcome, self-
esteem and 
endocrine 
parameters is the 
first therapeutic 
option for women 
who are infertile 
and overweight 
The subjects 
underwent the 
program but the 
results didn’t show 
the sustainability of 
these patient once 
the behavioral 
modification 
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program has been 
stopped 
Clark et al ., 
1998 
 
Obese infertile women 
underwent a weekly 
program aimed at 
lifestyle changes in 
relation to exercise 
and diet for 6 months 
 
• Weight 
• Ovulation 
• Pregnancy and 
live birth 
• Miscarriage rate 
• Psychometric 
measurements 
• Weight loss an average of 
10.2 kg/m2  
•  60 of the 67 anovulatory 
subjects resumed 
spontaneous ovulation 
• 52 achieved pregnancy (18 
spontaneously) and 45 a live 
birth 
• The miscarriage rate was 
18%, compared to 75% for 
the same women prior to the 
program 
• Psychometric measurements 
improved 
These results 
continue to support 
the view that all 
who treat infertility 
should consider 
weight loss to be a 
prerequisite for 
obese women prior 
to any assisted 
reproduction 
program 
Crosignani et 
al., 2003 
33 anovulatory 
overweight patients 
with PCOS were 
recommended a 1200 
kcal/day diet and 
physical exercise 
• Anthropometric 
indices 
• Ovarian imaging 
parameters were 
assessed at 
baseline and after 
weight loss of 5 
and 10% 
• 76% lost at least 5% of their 
body weight 
• Anthropometric indices were 
significantly reduced 
• Significant reduction in 
ovarian volume and in the 
number of microfollicles per 
ovary 
• 18 had a resumption of 
regular cycles and 15 
experienced spontaneous 
ovulation 
Weight loss is an 
effective treatment 
and should be 
considered the first-
line approach for 
infertile overweight 
PCOS patients 
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• 10 spontaneous pregnancies 
occurred in patients who lost 
at least 5% of their weight 
Hoeger et 
al., 2004 
 
38 overweight or 
obese women with 
PCOS were 
randomized to one of 
four 48-week 
interventions: 
metformin 850 mg two 
times per day, LSM 
plus metformin 850 
mg two times per day, 
LSM plus 
placebo, or placebo 
alone 
 
• Dropout and 
compliance with a 
long-term LSM 
• Weight loss 
• Preliminary 
estimates of 
treatment effect on 
ovulation 
(measured by 
weekly urinary 
pregnanediolglucu
ronide), and on 
total total and free 
androgen index 
• Dropout rate was 39% 
• Modest weight reduction was 
found in all treatment 
groups, with the most 
significant reduction 
occurring with the 
combination of metformin 
and lifestyle intervention 
• Significant androgen 
reduction occurred in the 
combination group only 
• Women who lost weight, with 
or without metformin, were 
estimated to be 9 times more 
likely to become regularly 
ovulatory  
• Women in the metformin 
group who lost weight were 
esti- mated to be 16 times 
more likely to become 
regularly ovulatory  
Weight reduction 
might play the most 
significant role in 
restoration of 
ovulation in obese 
women with PCOS 
Stamets et 
al., 2004 
Examined the effects 
of a 1 month dietary 
intervention on the 
PCOS phenotype. 
Patients were 
randomized to one of 
• Change in body 
weight 
• Biometric, 
hormonal, lipid and 
lipoprotein, and 
markers of glucose 
• Both the HP (_3.7 ±1.9 kg) 
and HC (_4.4 ±1.5 kg) diets 
resulted in significant weight 
loss 
• No differences between diets 
on a variety of measures 
It is important to try 
decreasing 
androgen level by 
diet management. 
Weight loss has 
shown that 
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two energy-restricted 
diets; high protein 
(HP: 30% protein, 
40% carbohydrate, 
and 30% fat) or high 
carbohydrate (HC: 
15% protein, 55% 
carbohydrate, and 
30% fat). The fat 
content was held 
constant in both diets 
homeostasis and 
energy metabolism 
including circulating 
androgens, measures of 
glucose metabolism, and 
leptin. 
• Decline in circulating 
androgens, fasting and area 
under the curve (AUC) 
insulins on a 3-hour oral 
glucose tolerance test, and 
fasting and AUC leptin levels 
• There was a high prevalence 
of menstrual bleeding during 
the trial  
decreasing weight 
can affect androgen 
level and thus affect 
any related PCOS 
complications 
Escobar –
Morreale et 
al., 2005 
17 premenopausal 
women studied 
prospectively for the 
effect of bariatric 
surgery on PCOS 
• Hyperandrogenism 
• Menstrual function 
• Insulin resistance 
• Weight loss (41 ± 9 kg after 
12 ± 5 months) was 
paralleled by decreases in 
the hirsutism score and free 
testosterone 
androstenedione and 
dehydroepiandrosterone 
sulfate 
• Amelioration of insulin 
resistance  
• Restoration of regular 
menstrual cycles and/or 
ovulation in all patients 
Bariatric surgery is 
a choice of weight 
loss but not all 
PCOS are qualified 
candidate for this 
option. Healthy food 
choice and physical 
activity promotion is 
essential in PCOS 
patients 
Mavropoulus 
et al., 2005 
6-months effects of a 
low-carbohydrate-
ketogenic diet (LCKD) 
on overweight and 
• Weight 
• Free testosterone 
• LH/FSH ratio 
• Fasting insulin 
• Significant reductions from 
baseline to 24 weeks in body 
weight (-12%), percent free 
testosterone (-22%), LH/FSH 
Further research is 
needed to 
determine if the 
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obese PCOS women. 
Patients were 
instructed to limit their 
carbohydrate intake to 
20g or less per day for 
24 weeks 
• Insulin glucose 
• Testosterone 
• Triglyceride 
• Body hair 
• Pregnancy 
ratio (-36%), and fasting 
insulin (-54%). 
• Non-significant decrease in 
insulin, glucose, 
testosterone, triglyceride, 
and perceived body hair 
• Two women became 
pregnant  
benefits were from 
weight loss or from 
carbohydrate 
restriction 
specifically 
Tang et al., 
2006 
Obese, oligo-
/amenorrhoeic women 
with PCOS received 
metformin (850 mg) 
twice daily compared 
with placebo group 
over 6 months. All 
received the same 
advice from a dietitian 
• Change in 
menstrual cycle 
• Changes in the 
insulin sensitivity 
and lipid profile 
• Change in 
arthropometric 
measurements 
• Both groups showed 
significant improvements in 
menstrual frequency and 
weight loss  
• No significant changes in 
insulin sensitivity or lipid 
profiles in either of the 
groups 
• Those who received 
metformin achieved a 
significant reduction in waist 
circumference and free 
androgen index 
Metformin did not 
improve weight loss 
or menstrual 
frequency in obese 
patients with PCOS 
Weight loss alone 
through lifestyle 
changes improves 
menstrual 
frequency 
Moran et al., 
2006 
Short-term(8 weeks) 
and longer-term (6 
months) 
carbohydrate- or fat-
restriction strategies 
in overweight women 
with PCOS  
• Weight 
maintenance 
• Improvements in 
reproductive and 
metabolic 
variables 
• Significant reductions in 
weight, waist circumference, 
body fat, insulin, total 
testosterone, and free 
androgen index 
• Improvements in menstrual 
cyclicity occurred for 16 
(57.1%) of 28 subjects 
Mealreplacements 
are an effective 
strategy for the 
short-term 
management of 
PCOS. Moderate 
fat or carbohydrate 
restriction was 
equally effective  
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Qublan et 
al., 2007 
64 women randomly 
divided into 2 groups 
for 6 months: Group 1 
was assigned to take 
1200-1400 kcal/day 
diet (25% proteins, 
25% fat, and 50% 
carbohydrates plus 
25-30g of fiber per 
week). Group 2 was 
prescribed 850 mg of 
metformin twice in a 
continuous manner 
• Menstrual cyclicity 
• BMI 
• LH 
• Androgen 
concentrations 
• Pregnancy rate 
• Both groups had a significant 
improvement in the 
menstrual cyclicity, reduction 
in BMI, LH, and androgen 
(testosterone, 
androstenedione, 
dehydroepiandrosterone 
sulfate) concentrations 
• The clinical, biochemical, 
and reproductiveoutcome 
including menstrual cycle 
pattern, ovulation, and 
pregnancy rates were similar 
in both groups 
Amelioration of 
hyperinsulinemia 
and 
hyperandrogenemia 
with dietary 
intervention or 
metformin 
treatment improves 
significantly the 
clinical features and 
reproductive 
function in 
overweight PCOS 
women 
Hoeger et 
al., 2008 
79 obese adolescent 
women with PCOS 
were randomized to 
single treatment trial 
and combination 
treatment trial: 
The single treatment 
trial contains 
metformin, placebo, 
LSM,oral 
contraceptives (OC) 
groups. The 
combination treatment 
trial contains LSM 
plus OC plus 
• Serum 
concentrations of 
androgens and 
lipids  
• LSM alone resulted in a 59% 
reduction in free androgen 
index with a 122% increase 
in SHBG 
• OC resulted in a significant 
decrease in total 
testosterone (44%) and free 
androgen index (86%) but 
also resulted in an increase 
in C-reactive protein (39.7%) 
and cholesterol (14%) 
• The combination of LSM, 
OC, and metformin resulted 
in a 55% decrease in total 
testosterone, as compared 
Both LSM and OC 
significantly reduce 
androgens and 
increase SHBG in 
obese adolescents 
with PCOS 
Metformin, in 
combination with 
LSM and OC, 
reduces central 
adiposity, reduces 
total testosterone, 
but does not 
enhance overall 
weight reduction 
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metformin, or LSM 
plus OC plus placebo 
to 33% with combined 
treatment and placebo 
Brown et al., 
2009 
 
37 sedentary PCOS 
women were 
randomized to either 
an 8-12 week ramp-
up followed by a 12-
week moderate-
intensity exercise 
program or control (no 
change in lifestyle) 
• Fasting lipoprotein 
profiles 
• Lipid parameters 
• In exercisers group, 
significant changes were 
seen in concentrations of 
lipoprotein parameters that 
are associated with 
decreased insulin resistance 
Moderate-intensity 
exercise without 
significant weight 
loss improved 
several 
components of the 
lipoprotein profiles 
of women with 
PCOS 
 
Karimzadeh 
et al., 2010 
 
Overweight infertile 
women with PCOS 
were assigned to four 
groups: clomiphene, 
metformin, 
clomiphene plus 
metformin, and LSM. 
The patients in each 
group received 
standardized dietary 
and exercise advice 
from a dietitian 
• Change in 
menstrual cycle  
• Waist 
circumference 
measurements 
• Endocrine 
parameters 
• Lipid profile 
• Clinical pregnancy 
rate 
• Improvement rates of 
menstrual cycle in the 
clomiphene (66.6%), 
clomiphene plus metformin 
(62.5%), metformin (55.5%), 
and LSM (66.6%)  
• Clinical pregnancy rate was 
12.2% in clomiphene group, 
14.4% in metformin group, 
14.8% in clomiphene plus 
metformin group, and 20% in 
LSM group 
• LSM group achieved a 
significant reduction in waist 
circumference, total 
androgen, and lipid profile 
compared to the other 
groups 
Regarding the side 
effects of medical 
treatment for 
PCOS, such as 
hyperinsulinemia, 
hyperanderogenemi
a, and 
cardiovascular 
disorders, LSM 
proves to be the 
first and foremost 
way of dealing with 
the problem 
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• Improvement of SHBG in the 
LSM and\ metformin groups 
showed significant 
differences compared with 
the other two groups 
Palomba et 
al., 2010 
 
96 overweight and 
obese clomiphene 
citrate (CC) resistant 
PCOS patients were 
randomized in a 
three-arm trial: 
structured exercise 
training (SET) plus 
hypocaloric diet for 6 
weeks (Group A), 2 
weeks of observation 
followed by one cycle 
of CC therapy (Group 
B), or SET plus 
hypocaloric diet for 6 
weeks, with one cycle 
of CC after the first 2 
weeks (Group C) 
 
• Ovulation rate 
• Anthropometric, 
hormonal and 
metabolic data 
• After 6 weeks of SET plus 
hypocaloric diet, the 
ovulation rate was 
significantly higher in Group 
C than in Groups A and B 
• Compared with baseline, in 
Groups A and C, a 
significant improvement in 
clinical and biochemical 
androgen and insulin 
sensitivity indexes was 
observed. In the same two 
groups, the insulin sensitivity 
index was significantly better 
than that in Group B 
In overweight and 
obese CC resistant 
PCOS patients, a 6- 
week intervention of 
SET and a 
hypocaloric diet 
was effective in 
increasing the 
probability of 
ovulation under CC 
treatment 
Nybacka et 
al., 2011 
 
4-month trial with 
three interventions 
and a long-term 
follow-up (dietary 
management, 
• Ovarian function 
• Endocrinologic, 
and metabolic 
status  
• Body composition 
• Body mass index was 
reduced 6% by the dietary 
management, 3% by the 
exercise, and 5% by the 
combined interventions 
LSM is suggested 
as the first line of 
treatment to 
improve 
reproductive and 
metabolic health in 
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physical exercise, or 
both) 
• Lower body fat and lean 
body mass were significantly 
decreased in the dietary 
groups 
• Upper body fat was lowered 
and lean body mass 
maintained by exercise 
alone 
• Menstrual pattern was 
significantly improved 
• Follow-up of one-half of the 
patients for a median of 2.8 
years revealed sustained 
weight reduction and 
improvement in menstrual 
pattern 
overweight or 
obese patients with 
PCOS 
Barr et al., 
2013 
12-week low-glycemic 
index (GI) dietary 
intervention, preceded 
by a 12-week habitual 
diet control phase and 
proceeded by a 12-
week follow-up phase  
• Change in insulin 
sensitivity 
• Changes of lipids, 
body composition, 
and estimated 
macronutrient 
intake 
• No significant changes 
occurred during the 12-week 
habitual diet control phase  
• During the dietary 
intervention phase, dietary 
GI significantly decreased 
with a concurrent small 
reduction in saturated fat 
intake 
• Measures of insulin 
sensitivity and non-esterified 
fatty acid improved after 
intervention 
This is the first 
study to implement 
an isocaloric low-GI 
diet in women with 
PCOS. Findings 
warrant further 
investigation via 
larger, long-term 
randomized clinical 
trials in either 
hypocaloric or 
isocaloric 
conditions to fully 
elucidate the effects 
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of a low-GI diet in 
PCOS 
Jakubowicz 
et al., 2013 
60 lean PCOS women 
randomized into two 
isocaloric 
maintenance diets 
with different meal 
timing distribution: a 
BF (breakfast diet) 
(980 kcal breakfast, 
640 kcal lunch and 
190 kcal dinner) or a 
D (dinner diet) group 
(190 kcal breakfast, 
640 kcal lunch and 
980 kcal dinner) for 90 
days 
• Insulinre sistance 
• Hyperandrogenism 
• In the BF group, a significant 
decrease was observed in 
both glucose and insulin 
AUC 
• In the BF group, free 
testosterone decreased by 
50% and SHBG increased 
by 105% 
• No change in these 
parameters was observed in 
the D group 
In lean PCOS 
women, a high 
caloric intake at 
breakfast with 
reduced intake at 
dinner results in 
improved insulin 
sensitivity indices 
and reduced 
cytochrome 
P450c17α activity, 
which ameliorates 
hyperandrogenism 
and improves 
ovulation rate 
	
	
234	
	
Appendix 8: Nutritional guidelines for lean PCOS patients 
The nutritional guidelines you need to follow 
1- You will follow a weight maintenance regimen by consuming adjusted 
amount of food sizes appropriate to your body fat and muscle analysis 
composition and energy expenditure. 
2- You will need to follow a healthy diet and deviate to healthy food 
choices(Less fat and sugar, and more fruits, vegetables and whole grains 
products). 
 Think about serving sizes and begin with small portion of food. 
3- When dining out choose a starter with leafy vegetables.  
If you don’t feel full and satisfied after your meal add leafy vegetables and 
finish with a fruit. 
4- Take your time to eat and chew your food, this will help you control your 
portion size of meal. Stop your meal before feeling full. 
5- Try to eat a rainbow of fruits and vegetables everyday with every meal.  
You need to eat 5 fistful sized fruits and vegetables per day, fruits and 
vegetables are rich in fibers and enhance your satiety. 
These can be taken through preparing salads from different kinds of 
vegetables. 
One counted fistful vegetables is 1/2 cup (1/2 handful) cooked, or 1 cup (1 
handful) raw. One fistful fruit is around 1 cup 
 
6- Your diet should contain 50 % of healthy carbohydrates such as brown 
bread, multi-cereals bread, brown pasta, brown rice, whole grain products 
and bread made of oats.  
Reduce white unhealthy carbohydrates such as white bread, white toast, and 
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cake, candies of different forms, white rice, white pasta, donuts and sugar 
products. 
The plate figure will help you understand your daily nutrition needs. 
7- Your proteins daily consumption  should be around 20 % of your daily caloric 
intake chosen from lean meat products such as turkey meat (breast , no 
skin) , chicken ( breast , no skin ) ,fish ( filet , no skin) and red meat ( filet , no 
fat ). 
 Dairy products protein sources should from white cheese (ex hallumi cheese 
and traditional white cheese...), skimmed milk and milk products. 
 Vegetarian or vegan individuals are advised to eat grains such as beans, 
peas, edamame, quinoa, chia seeds and soy.  
8- Avoid consuming organ meat such as intestine due to their high content of 
unhealthy fat (Saturated fat responsible for cardiac disease) 
Avoid consuming high fat milk, full fat soft cheese, meat or chicken with skin 
and fat  on it, sausages, burgers, salamis, palm oil, coconut oil and 
packaged cakes and biscuits. 
9- Your daily fat intake should be around 30 % from your daily caloric of which: 
  10 %of which should be from polyunsaturated fat such as seeds, almonds, 
nuts, walnuts, salmon fish. 
 Mono-unsaturated fat should encompass around 13 % taken from olive oil, 
olives and avocado.  
Saturated fat intake should not exceed 7 % of the total fat allowance (such 
as butter, lard, margarine and grease). 
Reduce from your diet saturated fats such as animal sources and whole milk 
products.  
Reduce trans-fat such as candies, fried food, baked goods, margarines and 
crackers.  
Add to your diet mono-unsaturated fats such as plants oil, avocados, nuts 
and seeds with limited quantities of maximum 3 tablespoons per day.   
10- Consume twice a week fish meat with one of these portionsis from oily fish 
such as tuna, salmon and mackerel.  
The portion should weigh between 120 grams and 140 grams. 
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11- Replace frying food by grilling or boiling to decrease the unhealthy fat intake 
caused by frying. 
12- Avoid consuming high caloric meals (containing more than 500 calories with 
more than 40 % sugar and unhealthy fat) such as sweets, cakes, chocolates 
bars, donuts and pastries, fried food and junk meals. 
13- Eat daily 3main meals (divided as breakfast, lunch and dinner) and 2 snacks 
on regular time of the day to regulate your metabolism. 
Make sure to leave 3-4 hours between each meal. 
A healthy breakfast can boost your metabolism. 
The below table is an example of your meals composition. 
Eat smaller meals during the day rather than larger meals to keep having 
energy in your body.  
14- Breakfast is important as it will regulate your appetite during the day and 
prevent you from consuming large amounts of food on lunch and dinner time. 
15- Avoid any meal after 7 pm because the body metabolism decreases by 70 % 
after 7 o’clock.  
16- Regular amount of sleep helps you regulate your appetite. So try to sleep an 
average of 8 hours per day. 
17- Exercise is able not only able to decrease your body weight but it has also 
shown its effectiveness in PCOS treatment. Exercise has numerous health 
benefits 
 Physical activity for at least 30 minutes at least 3 days per week is 
recommended.  
You can be engaged in aerobic, endurance, suppleness and flexibility and 
resistance training activity types. 
 
 
 
Your daily menu plan: 
 Breakfast Snack Lunch Snack Dinner 
Carbohydrates 2 servings 1 serving 3 servings  2 servings 
Fruits 1 serving 1 serving 1 fruit   
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Vegetables 1 serving  2 servings  1 serving 
Meat or meat 
substitutes 
  4 servings  2 servings 
Milk 1 serving   1 serving   
Fat 2 servings  2 servings  1 serving 
1 serving of vegetables = 1 cup of raw vegetables = 1 fistful vegetable 
 
 
 
Thee palm not including fingers and thumb is about 3 ounces of meat. 
 
 
 
 
 
 
 
 
 
Bread Serving 
Size   
Bagel, large 
(about 4 oz) 1/4 
(1 oz)  
Fruit  
1 serving = 
Apple, 
unpeeled, 
Lean Meats 
and Meat 
Substitutes  
1 serving = 
Fat-Free 
(skim) or 
Low-Fat 
(1%) Milk 
SERVING 
CHOICES  
Monounsaturate
d Fats 1 serving= 
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Or Biscuit, 2.5” 
wide 1  
Or Bread 
(white/wheat/rye
) 1 slice (1 oz)  
Or Cornbread, 
1.75” cube (1 
1/2 oz)  
Or English 
muffin 1/2  
Or Hot dog or 
hamburger bun 
1/2 (1 oz)  
Or Pancake, 4” 
wide, ¼” thick 1  
Or Pita pocket 
bread (6” 
across) 1/2  
Or Roll, plain, 
small 1 (1 oz)  
Or Tortilla, corn 
or flour (6” 
across) 1  
Or  Waffle, 4” 
square or round 
1  
Cereals and 
Grains Serving 
Size  
Or Cereals, 
cooked (oats, 
oatmeal) 1/2 cup  
small 1 (4 
oz)  
Or 
Applesauce, 
unsweetene
d 1/2 cup  
Or Banana, 
extra small 1 
(4 oz)  
Or Berries  
Blackberries 
3/4 cup  
Or 
Blueberries 
3/4 cup  or 
Raspberries 
1 cup  or 
Strawberries 
1.25 cup 
whole 
berries  
Or 
Cantaloupe, 
small 1/3 
melon  
or 1 cup 
cubed (11 
oz)  
Cherries, 
sweet fresh 
12 (3 oz)  
Beef, Select 
or Choice 
grades—  
Ground 
round, roast 
(chuck, rib,  
rump), 
round, 
sirloin, steak  
(cubed, 
flank, 
porterhouse,  
T-bone), 
tenderloin 1 
oz 
Or Cheeses 
with < 3 
grams of fat 
per oz 1 oz 
Or Cottage 
cheese 1/4 
cup  
Or Egg 
whites 2  
Or Fish, 
fresh or 
frozen, plain: 
catfish,  
cod, 
flounder, 
haddock, 
halibut,  
and 
Yogurt  
1 serving = 
Milk, 
buttermilk, 
acidophilus 
milk,  
Lactaid 1 
cup  
 
Or 
Evaporate
d milk 1/2 
cup  
 
Or Yogurt, 
low-fat, 
plain or 
flavored 
with  
a low 
calorie 
sweetener 
2/3 cup  
 
or Yogurt, 
fat-free, 
plain or 
flavored 
with  
a low 
calorie 
Avocado, medium 
2 Tbsp (1 oz)  
Or Nut butters 
(trans-fat free) 1.5 
tsp 
Nuts  
Or Almonds, 
cashews 6 nuts  
Or Macadamia 3 
nuts  
Or Peanuts 10 
nuts  
Or Pecans 4 
halves  
Or Oil—Canola, 
olive, peanut 1 tsp 
Or Olives, black 
(ripe) 8 large  
Or Olives, green 
(stuffed) 10 large  
Polyunsaturated 
Fats 
 1 serving =  
Margarine  
Lower-fat spread 
1 Tbsp 
Or Stick, tub or 
squeeze 1 tsp 
Or Mayonnaise  
Reduced-fat 1 
Tbsp 
Or Regular 1 tsp 
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Or Cereals, 
unsweetened, 
ready-to-eat 3/4 
cup  
Or Granola, low-
fat 1/4 cup  
Or Pasta, 
cooked 1/3 cup  
Or Rice, white or 
brown, cooked 
1/3 cup  
Starchy 
Vegetables 
Serving Size  
Or Corn, cooked 
1/2 cup  
Or Corn on cob, 
large 1/2 cob (5 
oz)  
Or Hominy, 
canned 3/4 cup  
Or Peas, green, 
cooked 1/2 cup 
Or Dried 
fruits 
(blueberries, 
cherries,  
cranberries, 
mixed fruit, 
raisins) 2 
Tbsp 
or 
Grapefruit, 
large 1/2 (11 
oz)  
or Grapes, 
small 17 (3 
oz)  
or Guava 1/2 
cup  
or  Kiwi 1 (3 
1/2 oz)  
or Mandarin 
oranges, 
canned 3/4 
cup  
or Mango, 
small 1/2 
fruit (5.5 oz) 
or 1/2 cup  
or Orange, 
small 1 (6 
1/2 oz)  
or Papaya 
1/2 fruit or 1 
orange 
roughy, 
salmon, 
tilapia,  
trout, tuna 1 
oz 
or Hot dog 
with < 3 
grams of fat 
per oz 1  
or Pork, 
lean—
Canadian 
bacon, rib or  
loin 
chip/roast, 
ham, 
tenderloin 1 
oz 
or Poultry, 
without skin 
1 oz 
or 
Processed 
sandwich 
meats with  
< 3 grams of 
fat per oz 1 
oz 
Or Tuna, 
canned in 
sweetener 
1 cup  
 
or Hot 
cocoa mix, 
sugar-free 
1 envelope  
 
Hot cocoa 
mix, sugar-
free 1 
envelope  
 
 
Or Oil—Corn, 
cottonseed, 
flaxseed,  
grape seed, 
safflower, 
soybean,  
sunflower 1 tsp 
or Salad dressing  
Reduced-fat 2 
Tbsp 
Or Regular 1 Tbsp 
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cup cubed (8 
oz)  
or Passion 
fruit 1/4 cup  
or Peaches 
(fresh, 
medium) 1 
(6 oz)  
orPears 
(fresh, large) 
1/2 (4 oz)  
or Pineapple 
(fresh) 3/4 
cup  
or Plums  
Small fresh 2 
(5 oz)  
Or Dried 
(prunes) 3  
Or 
Watermelon 
1 slice  
or 1.25 cups 
cubes (13.5 
oz)  
Fruit Juice 
Serving 
Size  
Or Apple, 
grapefruit, 
orange, 
water or oil, 
drained 1 oz 
Plant-Based 
Proteins  
Serving 
Size  
Baked beans 
1/3 cup  
Or 
Beans/lentils
, cooked 
(black,  
garbanzo, 
kidney, lima, 
navy, pinto) 
1/2 cup  
or Peas, 
cooked 1/2 
or cup  
Hummus 1/4 
cup  
or Nut 
spreads—
Almond 
butter,  
cashew 
butter, 
peanut 
butter,  
soy nut 
butter 1 
Tbsp 
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If you have further questions please do not hesitate to contact the researcher ( 
CarolineHamadi ) to provide you with the information needed.
 
 
 
 
pineapple 
1/2 cup  
Or Grape, 
prune, and 
100% fruit 
juice  
blends  
or Tempeh 
1/4 cup  
or Tofu 4 oz 
(1/2 cup) 
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Appendix 9: Nutritional guidelines for overweigh and obese PCOS patients 
The nutritional guidelines you need to follow 
1- You will follow a low calorie diet by consuming adjusted amount of food sizes 
appropriate to your body fat and muscle analysis composition and energy 
expenditure. 
2- You will need to follow a healthy diet and deviate to healthy food choices 
(Less fat and sugar, and more fruits, vegetables and whole grains products). 
Decrease your meal portion size by half and use smaller plates rather than 
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large plates in order to decrease the amount of your meal. 
 Think about serving sizes and begin with small portion of food. 
3- When dining out choose a starter with leafy vegetables.  
If you don’t feel full and satisfied after your main meal add leafy vegetables 
and finish with a fruit. 
4- Take your time to eat and chew your food, this will help you control your 
portion size of meal.  
Stop your meal before feeling full. 
5- Try to eat a rainbow of fruits and vegetables everyday with every meal.  
You need to eat 5 fistful sized fruits and vegetables per day, fruits and 
vegetables are rich in fibers and enhance your satiety. 
These can be taken through preparing salads from different kinds of 
vegetables. 
One counted fistful vegetables is 1/2 cup (1/2 handful) cooked, or 1 cup (1 
handful) raw. One fistful fruit is around 1 cup. 
 
6- Your diet should contain 50 % of healthy carbohydrates such as brown 
bread, multi-cereals bread, brown pasta, brown rice, whole grain products 
and bread made of oats.  
Reduce white unhealthy carbohydrates such as white bread, white toast, and 
cake, candies of different forms, white rice, white pasta, donuts and sugar 
products. 
The plate figure will help you understand your daily nutrition needs. 
7- Your proteins daily consumption  should be around 20 % of your daily caloric 
intake chosen from lean meat products such as turkey meat (breast , no 
skin) , chicken ( breast , no skin ) ,fish ( filet , no skin) and red meat ( filet , no 
fat ). 
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 Dairy products protein sources should from white cheese (ex hallumi cheese 
and traditional white cheese..) , skimmed milk and milk products. 
 Vegetarian or vegan individuals are advised to eat grains such as beans, 
peas, edamame, quinoa, chia seeds and soy.  
8- Avoid consuming organ meat such as intestine due to their high content of 
unhealthy fat (Saturated fat responsible for cardiac disease) 
Avoid consuming high fat milk, full fat soft cheese, meat or chicken with skin 
and fat  on it, sausages, burgers, salamis, palm oil, coconut oil and 
packaged cakes and biscuits. 
9- Your daily fat intake should be around 30 % from your daily caloric of which: 
  10 %of which should be from polyunsaturated fat such as seeds, almonds, 
nuts, walnuts, salmon fish. 
 Mono-unsaturated fat should encompass around 13 % taken from olive oil, 
olives and avocado.  
Saturated fat intake should not exceed 7 % of the total fat allowance (such 
as butter, lard, margarine and grease).  
Reduce from your diet saturated fats such as animal sources and whole milk 
products.  
Reduce trans-fat such as candies, fried food, baked goods, margarines and 
crackers.  
Add to your diet mono-unsaturated fats such as plants oil, avocados, nuts 
and seeds with limited quantities of maximum 3 tablespoons per day.  
10- Consume twice a week fish meat with one of these portionsis from oily fish 
such as tuna, salmon and mackerel.  
The portion should weigh between 90 grams and 100 grams. 
11- Replace frying food by grilling or boiling to decrease the unhealthy fat intake 
caused by frying. 
12- Avoid consuming high caloric meals (containing more than 500 calories with 
more than 40 % sugar and unhealthy fat) such as sweets, cakes, chocolates 
bars, donuts and pastries, fried food and junk meals. 
13- Eat daily 3main meals (divided as breakfast, lunch and dinner) and 2 snacks 
on regular time of the day to regulate your metabolism. 
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Make sure to leave 3-4 hours between each meal. 
A healthy breakfast can boost your metabolism. 
The below table is an example of your meals composition. 
Eat smaller meals during the day rather than larger meals to keep having 
energy in your body.  
14- Breakfast is important as it will regulate your appetite during the day and 
prevent you from consuming large amounts of food on lunch and dinner time. 
15- Avoid any meal after 7 pm because the body metabolism decreases by 70 % 
after 7 o’clock.  
16- Regular amount of sleep helps you regulate your appetite. So try to sleep an 
average of 8 hours per day. 
17- Exercise is able not only able to decrease your body weight but it has also 
shown its effectiveness in PCOS treatment. Exercise has numerous health 
benefits 
 Physical activity for at least 30 minutes per day at least 5 days per week is 
recommended.  
You can be engaged in aerobic, endurance, suppleness and flexibility and 
resistance training activity types. 
 
 
Your daily menu plan: 
 Breakfast Snack Lunch Snack Dinner 
Carbohydrates 1 serving 1 serving 2 servings  1 serving 
Fruits 1 serving 1 serving    
Vegetables 1 serving  2 servings  1 serving 
Meat or meat 
substitutes 
  2 servings  2 servings 
Milk 1 serving   1 serving   
Fat 1 serving  1 serving  1 serving 
1 serving of vegetables = 1 cup of raw vegetables = 1 fistful vegetable 
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Thee palm not including fingers and thumb is about 3 ounces of meat. 
 
 
 
 
 
 
 
Carbohydrates                                         
1 serving = 
Bread Serving 
Size   
Bagel, large 
(about 4 oz) 1/4 
(1 oz)  
Or Biscuit, 2.5” 
wide 1  
Or Bread 
(white/wheat/rye
) 1 slice (1 oz)  
Fruit
1 serving = 
Apple, 
unpeeled, 
small 1 (4 
oz)  
Or 
Applesauce, 
unsweetene
d 1/2 cup  
Or Banana, 
extra small 1 
(4 oz)  
Or Berries  
Lean Meats 
and Meat 
Substitutes  
1 serving = 
Beef, Select 
or Choice 
grades—  
Ground 
round, roast 
(chuck, rib,  
rump), 
round, 
sirloin, steak  
Fat-Free 
(skim) or 
Low-Fat 
(1%) Milk 
and 
Yogurt  
1 serving = 
Milk, 
buttermilk, 
acidophilus 
milk,  
Lactaid 1 
cup  
 
SERVING 
CHOICES  
Monounsaturate
d Fats 1 serving= 
Avocado, medium 
2 Tbsp (1 oz)  
Or Nut butters 
(trans-fat free) 1.5 
tsp 
Nuts  
Or Almonds, 
cashews 6 nuts  
Or Macadamia 3 
nuts  
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Or Cornbread, 
1.75” cube (1 
1/2 oz)  
Or English 
muffin 1/2  
Or Hot dog or 
hamburger bun 
1/2 (1 oz)  
Or Pancake, 4” 
wide, ¼” thick 1  
Or Pita pocket 
bread (6” 
across) 1/2  
Or Roll, plain, 
small 1 (1 oz)  
Or Tortilla, corn 
or flour (6” 
across) 1  
Or  Waffle, 4” 
square or round 
1  
Cereals and 
Grains Serving 
Size  
Or Cereals, 
cooked (oats, 
oatmeal) 1/2 cup  
Or Cereals, 
unsweetened, 
ready-to-eat 3/4 
cup  
Blackberries 
3/4 cup  
Or 
Blueberries 
3/4 cup  or 
Raspberries 
1 cup  or 
Strawberries 
1.25 cup 
whole 
berries  
Or 
Cantaloupe, 
small 1/3 
melon  
or 1 cup 
cubed (11 
oz)  
Cherries, 
sweet fresh 
12 (3 oz)  
Or Dried 
fruits 
(blueberries, 
cherries,  
cranberries, 
mixed fruit, 
raisins) 2 
Tbsp 
or 
Grapefruit, 
(cubed, 
flank, 
porterhouse,  
T-bone), 
tenderloin 1 
oz 
Or Cheeses 
with < 3 
grams of fat 
per oz 1 oz 
Or Cottage 
cheese 1/4 
cup  
Or Egg 
whites 2  
Or Fish, 
fresh or 
frozen, plain: 
catfish,  
cod, 
flounder, 
haddock, 
halibut,  
orange 
roughy, 
salmon, 
tilapia,  
trout, tuna 1 
oz 
or Hot dog 
with < 3 
Or 
Evaporate
d milk 1/2 
cup  
 
Or Yogurt, 
low-fat, 
plain or 
flavored 
with  
a low 
calorie 
sweetener 
2/3 cup  
 
or Yogurt, 
fat-free, 
plain or 
flavored 
with  
a low 
calorie 
sweetener 
1 cup  
 
or Hot 
cocoa mix, 
sugar-free 
1 envelope  
 
 
Or Peanuts 10 
nuts  
Or Pecans 4 
halves  
Or Oil—Canola, 
olive, peanut 1 tsp 
Or Olives, black 
(ripe) 8 large  
Or Olives, green 
(stuffed) 10 large  
Polyunsaturated 
Fats 
 1 serving =  
Margarine  
Lower-fat spread 
1 Tbsp 
Or Stick, tub or 
squeeze 1 tsp 
Or Mayonnaise  
Reduced-fat 1 
Tbsp 
Or Regular 1 tsp 
Or Oil—Corn, 
cottonseed, 
flaxseed,  
grape seed, 
safflower, 
soybean,  
sunflower 1 tsp 
or Salad dressing  
Reduced-fat 2 
Tbsp 
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Or Granola, low-
fat 1/4 cup  
Or Pasta, 
cooked 1/3 cup  
Or Rice, white or 
brown, cooked 
1/3 cup  
Starchy 
Vegetables 
Serving Size  
Or Corn, cooked 
1/2 cup  
Or Corn on cob, 
large 1/2 cob (5 
oz)  
Or Hominy, 
canned 3/4 cup  
Or Peas, green, 
cooked 1/2 cup  
 
large 1/2 (11 
oz)  
or Grapes, 
small 17 (3 
oz)  
or Guava 1/2 
cup  
or  Kiwi 1 (3 
1/2 oz)  
or Mandarin 
oranges, 
canned 3/4 
cup  
or Mango, 
small 1/2 
fruit (5.5 oz) 
or 1/2 cup  
or Orange, 
small 1 (6 
1/2 oz)  
or Papaya 
1/2 fruit or 1 
cup cubed (8 
oz)  
or Passion 
fruit 1/4 cup  
or Peaches 
(fresh, 
medium) 1 
(6 oz)  
grams of fat 
per oz 1  
or Pork, 
lean—
Canadian 
bacon, rib or  
loin 
chip/roast, 
ham, 
tenderloin 1 
oz 
or Poultry, 
without skin 
1 oz 
or 
Processed 
sandwich 
meats with  
< 3 grams of 
fat per oz 1 
oz 
Or Tuna, 
canned in 
water or oil, 
drained 1 oz 
Plant-Based 
Proteins  
Serving 
Size  
Baked beans 
1/3 cup  
Or Regular 1 Tbsp 
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orPears 
(fresh, large) 
1/2 (4 oz)  
or Pineapple 
(fresh) 3/4 
cup  
or Plums  
Small fresh 2 
(5 oz)  
Or Dried 
(prunes) 3  
Or 
Watermelon 
1 slice  
or 1.25 cups 
cubes (13.5 
oz)  
Fruit Juice 
Serving 
Size  
Or Apple, 
grapefruit, 
orange, 
pineapple 
1/2 cup  
Or Grape, 
prune, and 
100% fruit 
juice  
blends  
 
Or 
Beans/lentils
, cooked 
(black,  
garbanzo, 
kidney, lima, 
navy, pinto) 
1/2 cup  
or Peas, 
cooked 1/2 
or cup  
Hummus 1/4 
cup  
or Nut 
spreads—
Almond 
butter,  
cashew 
butter, 
peanut 
butter,  
soy nut 
butter 1 
Tbsp 
or Tempeh 
1/4 cup  
or Tofu 4 oz 
(1/2 cup) 
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If you have further questions please do not hesitate to contact the researcher ( 
Caroline Hamadi ) to provide you with the information need. 
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Appendix 10:Food frequency questionnaire 
 
FOOD FREQUENCY QUESTIONNAIRE 
 
Think about your eating patterns during the past year while answering this 
questionnaire. Please indicate your usual intake of each of the following food items per 
Day, Week, or Month.  
For example: Apple. If you consume 3 apples daily, write 3 in the “Day” column, if you 
think you average 3 apples a week over the year, write 3 in the “Week” column. 
However, if you rarely consume a food, let’s say once or twice a year, then tick below 
“Rarely/Never”. 
Please be precise as much as you can.  
Remember! The accuracy of the study results depends on the accuracy of your 
answers.  
 
 
Food item Serving size Day Week Month Rarely / Never 
Example: Apple  1 item  3   
Bread and Cereals      
1. White bread (1 slice) 1 slice (30g)     
2. Brown or whole wheat bread 1 slice     
3. Bread, markouk ¼ loaf (30g)     
4. Breakfast cereals, regular/ bran  1 cup     
5. Sugar coated cereals 1 cup     
6. Rice, white, cooked 1 cup     
7. Pasta, plain, cooked 1 cup     
8. Wheat, whole, cooked / Bulgur 1 cup     
9. Popcorn 1 cup     
Dairy products      
10. Low-fat milk (2% fat) 1 cup     
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11. Whole fat milk 1 cup     
12. Milk, condensed and sweetened  1 cup     
13. Fat free / low fat yogurt 1 cup     
14. Whole fat yogurt 1 cup     
15. Cheese regular yellow ( 
Kashkawan, cheddar,etc..) 
1 slice (30g)     
16. Cheese low fat yellow ( 
Kashkawan, cheddar,etc..) 
1 slice (30g)     
17. Cheese white ( Akkawi, feta,etc..) 1 slice (30g)     
18. Cheese white low fat ( Akkawi, 
feta,etc..) 
1 slice (30g)     
19. Cheese spread ( picon, Kraft,etc.) 1 slice (30g)     
20. Cheese spread low fat 1 slice (30g)     
21. Labneh 2 Tbsp     
Fruits & Juices      
22. Apple, fresh, small 1 item      
23. Banana, medium  1 item     
24. Orange (1 item) / Grapefruit (1/2 
item) 
1 serving     
25. Kiwi 1 small     
26. Mango 1  item     
27. Grapes, fresh  1 cup     
28. Dried fruits: raisins (2 Tbsp), 
dates (2), apricots (4) 
1 serving     
29. Canned fruits 1 cup     
30. Fresh fruit juice 1 cup     
31. Fresh vegetable juice: tomato / 
other vegetables 
1 cup     
32. Fruit drinks: canned/bottled 1 cup     
Food item Serving size Day Week Month Rarely / Never 
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Vegetables       
33. Salad – green: lettuce, celery, 
green peppers, onions 
1 cup     
34. Dark green vegetables (e.g.: 
spinach, silq, hindbeh,…) 
1 cup     
35. Carrots, raw or cooked 1 cup     
36. Tomatoes, fresh, medium 1 item     
37. Cucumber  1 cup     
38. Corn / green peas, cooked 1 cup     
39. White potato, baked / boiled / 
mashed 
1 item     
40. Squash, summer (kussa), 
Eggplant /cooked 
1 cup     
41. Cauliflower/ Cabbage/ broccoli 1 cup     
Meat & Alternates      
42. Legumes: lentils, broad beans, 
chickpeas, etc., cooked 
1 cup     
43. Nuts and seeds: peanuts, 
almonds, sunflower seeds, etc. 
1 cup     
44. Beef 1 item (90gr.)     
45. Lamb 1 item (90gr.)     
46. Chicken  1 item (90gr.)     
47. Fish, canned with oil: tuna, 
sardines 
1 serving (90gr.)     
48. Tuna canned with water 1 serving (90gr.)     
49. Shellfish: shrimp, lobster, clams 1 cup     
50. Fish, fresh 1 serving (90gr.)     
51. Eggs, whole, large 1 item     
52. Organ Meats( Liver, kidneys, 
brain) 
1 cup     
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53. Luncheon meats: Bologna, 
salami, etc. 
1 slice (20g)     
54. Sausages, makanek, hot dogs 1 item (30g)     
Fats and oils      
55. Vegetable oil: corn / sunflower / 
soy 
1 Tbsp     
56. Olive oil 1 Tbsp     
57. Olives 1 item     
58. Vegetable ghee 1 Tbsp     
59. Butter 1 Tbsp     
60. Mayonnaise 1 Tbsp     
61. Lard / animal ghee 1 cup     
Sweets &Desserts       
62. Cookies: chocolate chips, 
oatmeal, peanut butter, etc. 
1 small item     
63. Doughnut / muffin 1 item     
64. Cake  1 item     
65. Pudding or custard, regular 1 cup     
66. Ice cream 1 cup     
67. Chocolate bar  1 item     
68. Sugar,  1 Tbsp     
69. Halawa 1 potion (40g)     
70. Molasses , honey, jam 1 Tbsp     
71. Arabic sweets, baklawa, 
maamoul,  Knefeh 
1 item (40g)     
 
Food item Serving size Day Week Month Rarely / Never 
Beverages      
72. Soft drinks, regular (1 can = 1½ 
cup) 
1½ cup (11 fl. 
oz) 
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73. Soft drinks, diet (1 can = 1½ cup) 1½ cup (11 fl. 
oz) 
    
74. Turkish coffee (1 small cup = ¼ 
cup) 
¼ cup (2 floz)     
75. Coffee/Nescafe or tea 1 cup     
76. Coffee or tea, decaffeinated 1 cup     
77. Hot chocolate or cocoa 1 cup     
78. Beer, regular (1 can = 1½ cup) 1½ cup     
79. Wine: red, white, or blush ½ cup (4 fl. oz)     
80. Liquor: whiskey, vodka, gin, rum 1/6 cup (1.5 fl 
oz.) 
    
Miscellaneous      
81. Manaeesh, zaatar, cheese 1 large     
82. French fries 1 cup     
83. Chips: potato, corn, tortilla  1 cup     
84. Falafel  sandwich, medium 1 item     
85. Chawarma sandwich, medium 1 item     
86. Burgers( Beef, chicken, fish) 1 item     
87. Burgers with cheese 1 item     
88. pizza 2 slices     
89. Croissant (plain, cheese, zaatar, 
chocolat) 
1 item     
 
Are there any other foods not mentioned above that you usually eat at least 
once per week? 
Example: pâté, cream sauce, fava beans, etc (do not include dry spices). Do not list 
foods that have been listed in the previous section. 
 
Other foods that you usually eat at 
least once /week 
Usual serving size Servings/week 
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257	
	
     Appendix 11: 24 hour recall 
Questions 
 
Menu 
 
Ingredients 
 
Amount in 
household 
measure 
 
Consistency 
(Dry/Liquid/ 
Thick/Soft/NA) 
 
Final 
Weights (for 
investigators 
use only) 
Did you eat 
or drink 
anything after 
you got up in 
the morning 
yesterday? 
 
What did you 
have? 
1.      
   
   
   
2.      
   
   
   
Did you eat 
/drink 
anything else 
in the 
morning? (if 
working ,then 
specify; 
“before going 
for work”) 
 
 
 
What did you 
have? 
1.      
   
   
   
2.      
   
   
 
 
 
  
3. 
 
 
   
 
 
 
   
   
   
Did you 
eat/drink 
anything 
in the 
afternoon?  
 
What did you 
have? 
1. 
 
 
 
    
   
   
   
2.     
   
   
   
3.      
   
   
   
1.     
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Did you eat/ 
drink in the 
evening (if 
working, then 
specify; “after 
coming from 
work”) 
 
 
 
What did you 
have? 
 
 
 
 
 
   
   
   
   
2.     
   
   
   
3.     
   
   
   
Did you 
eat/drink 
anything at 
night? 
 
 
 
What did you 
have? 
 
 
1.     
   
   
   
2.     
   
   
 
 
  
3. 
 
   
 
 
   
   
   
4.      
   
   
   
Did you eat 
or drink 
anything else 
just before 
going to bed? 
 
 
 
What did you 
have? 
1.     
   
   
   
2.     
   
   
3. 
 
 
   
 
 
 
   
   
Is there 
anything else 
1. 
2. 
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that you 
ate/drank 
yesterday 
which you 
haven’t told 
me already? 
What did you 
have? 
 
3.    
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Appendix 12 
Table 21 : Average change in food items intake for the sub-population 
recruited in the scale-up phase  
Food type 
PCOS Non-PCOS 
Intervention  Control p-value Intervention  Control p-value 
White bread  -2.5 (±0.5) 3.0 (±1.0) <0.001 -4.0 (±4.0) 5.0 (± 3.0) **<0.001 
Brown bread  -3.0 (±1.0) 2.0 (±1.0) <0.001 0.0 (±4.0) 6.5 (±0.5) **<0.001 
Markouk  0.0 (±0.0) 1.0 (±1.0) <0.001 -4.0 (±7.0) 2.0 (±2.0) **<0.001 
Cereals  -2.0 (±2.0) 1.0 (±0.0) <0.001 -3.5 (±3.5) 0.0 (±0.0) **<0.001 
Sugar 
Cereals -2.5 (±0.5) 2.0 (±0.0) <0.001 -2.0 (±1.0) 0.5 (±0.5) **<0.001 
Rice  -2.0 (±0.0) 3.0 (±1.0) <0.001 -5 (±2.0) 1.5 (±2.5) **<0.001 
Pasta -4.0 (±2.0) 2.5 (±1.5) <0.001 -2.5 (±1.5) 1.0 (±2.0) **<0.001 
Wheat  -0.5 (±0.5) 1.0 (±0.0) <0.001 -4.0 (±2.0) 1.0 (±1.0) **<0.001 
Pop corn  0.0 (±0.0) 2.5 (±0.5) <0.001 0.0 (±0.0) 2.5 (±2.5) **<0.001 
Low fat milk 5.0 (±2.0) -1.5 (±0.5) <0.001 1.5 (±0.5) 0.0 (±0.0) **<0.001 
Whole fat milk -2.0 (±2.0) 2.5 (±1.5) <0.001 -1.5 (±0.5) 1.5 (±1.5) **<0.001 
Condensed 
milk -1.5 (±1.5) 1.5 (±0.5) <0.001 -1.5 (±0.5) 2.5 (±2.5) **<0.001 
Fat free yogurt  3.0 (±1.0) -1.0 (±1.0) <0.001 1.5 (±1.5) 0.0 (±0.0) **<0.001 
Whole fat 
yogurt -1.5 (±1.5) 2.5 (±0.5) <0.001 -2.0 (±0.0) 0.0 (±2.0) **<0.001 
Regular 
cheese -4.0 (±3.0) 5.5 (±2.5) <0.001 -2.0 (±0.0) -0.5 (±1.5) **<0.001 
Low fat 
cheese -1.0 (±3.0) 0.0 (±0.0) 0.012 2.0 (±3.0) 1.0 (±1.0) 0.018 
White cheese 4.0 (±1.0) 3.0 (±1.0) <0.001 1.0 (±1.0) -1.5 (±1.5) **<0.001 
Low fat white 
cheese 5.5 (±2.5) 
-2.0 
(±5.0) <0.001 3.0 (±1.0) 2.0 (±2.0) *0.001 
Spread 
cheese -2.5 (±2.5) 2.5 (±0.5) <0.001 -4.0 (±3.0) 0.0 (±1.0) **<0.001 
Low fat 
spread 
cheese 
2.0 (±0.0) -1.0 (±1.0) <0.001 5.0 (±1.0) 2.0 (±1.0) **<0.001 
Labneh  0.0 (±0.0) 0.5 (±0.5) <0.001 0 0 - 
Apple  -2.5 (±3.5) 2.0 (±1.0) <0.001 -1.5 (±2.5) 0.5 (±0.5) **<0.001 
Banana -1.5 (±1.5) 0.0 (±1.0) <0.001 -4.0 (±3.0) 0.5 (±0.5) **<0.001 
	
	
261	
	
Orange  0.0 (±0.0) 1.5 (±3.5) 0.002 0.0 (±1.0) 0.5 (±0.5) *0.001 
Kiwi  -0.5 (±0.5) -1.5 (±2.5) 0.003 -0.5 (±0.5) 0.0 (±0.0) **<0.001 
Mango  0.0 (±0.0) 1.5 (±0.5) <0.001 -1.0 (±1.0) -0.5 (±0.5) *0.001 
Grapes  -1.0 (±1.0) 5.0 (±1.0) <0.001 -5.0 (±5.0) 2.0 (±2.0) **<0.001 
Dried fruits  -1.0 (±1.0) 4.0 (±0.0) <0.001 -2.0 (±1.0) -0.5 (±0.5) **<0.001 
Canned fruits  -2.0 (±2.0) 1.5 (±0.5) <0.001 -2.0 (±1.0) -0.5 (±0.5) **<0.001 
Fresh juice  -2.5 (±4.5) 4.0 (±0.0) <0.001 -3.0 (±3.0) -0.5 (±0.5) **<0.001 
Fresh 
vegetables 
juice  
-0.5 (±0.5) 1.5 (±2.5) <0.001 -2.0 (±1.0) 0.0 (±0.0) **<0.001 
Fruit drink  -4.0 (±4.0) 4.0 (±0.0) <0.001 -3.0 (±2.0) 0.5 (±0.5) **<0.001 
Green salad 5.0 (±4.0) -3.5 (±0.5) <0.001 5.0 (±2.0) -0.5 (±0.5) **<0.001 
Dark green 
vegetables 2.0 (±2.0) 
-0.5 
(±0.5) <0.001 4.0 (±2.0) 0.0 (±0.0) **<0.001 
Carrots  2.5 (±1.5) 5.0 (±1.0) <0.001 4.0 (±1.0) 0.0 (±0.0) **<0.001 
Tomato  3.0 (±3.0) 1.0 (±1.0) <0.001 2.5 (±1.5) 0.0 (±0.0) **<0.001 
Cucumber  3.5 (±3.5) 0.0 (±0.0) <0.001 3.0 (±3.0) 0.0 (±0.0) **<0.001 
Corn/ peas/ -4.0 (±4.0) 0.5 (±2.5) <0.001 3.0 (±4.0) 0.0 (±0.0) **<0.001 
Potato  -5.5 (±3.5) 3.0 (±1.0) <0.001 -0.5 (±4.5) 0.0 (±0.0) *0.397 
Squash  -2.0 (±1.0) 0.5 (±0.5) <0.001 0.1 (±1.8) 0.1 (±0.1) 0.836 
Cauliflower  -3.0 (±3.0) -0.5 (±1.5) <0.001 3.0 (±0.0) 0.6 (±1.4) **<0.001 
Legumes  2.5 (±1.5) -4.0 (±1.0) <0.001 3.0 (±1.0) -1.0 (±1.0) **<0.001 
Nuts  -3.0 (±1.0) 1.5 (±1.5) <0.001 1.5 (±2.5) 0.5 (±2.5) *0.032 
Beef  2.5 (±0.5) -2.0 (±2.0) <0.001 -2.0 (±3.0) -1.0 (±1.0) *0.018 
Lamb  -3.5 (±3.5) 4.0 (±2.0) <0.001 -5.5 (±2.5) -1.0 (±2.0) **<0.001 
Chicken  1.0 (±1.0) 2.0 (±2.0) 0.001 -2.0 (±4.0) 0.5 (±0.5) **<0.001 
Fish  -4.0 (±4.0) 1.0 (±1.0) <0.001 -4.0 (±3.0) -1.5 (±1.5) **<0.001 
Tuna  3.5 (±2.5) -1.0 (±1.0) <0.001 3.5 (±2.5) 1.0(±1.0) **<0.001 
Shellfish 2.0 (±1.0) 0.0 (±0.0) <0.001 0.5 (±0.5) 1.0 (±1.0) *0.001 
Fresh fish  0.5 (±0.5) 0.0 (±0.0) 0.003 0.5 (±2.5) 0.0 (±0.0) *0.002 
Eggs -3.0 (±3.0) 2.0 (±0.0) <0.001 -2.5 (±0.5) -0.5 (±2.5) **<0.001 
Organ meats -2.5 (±2.5) 0.0 (±0.0) <0.001 0.5 (±0.5) 0.5 (±0.5) 1.000 
Luncheon 
meat -1.5 (±1.5) 0.0 (±0.0) <0.001 0.0 (±0.0) 0.0(±1.0) 1.000 
Sausage  -1.0 (±1.0) 2.5 (±1.5) <0.001 -2.0 (±2.0) 0.0 (±1.0) **<0.001 
Vegetable oil  -1.5 (±2.5) 1.0 (±1.0) <0.001 -0.5 (±3.5) 1.5 (±0.5) **0.001 
Olive oil  -5.0 (±4.0) 0.5 (±0.5) <0.001 -2.0 (±4.0) 1.5 (±0.5) **<0.001 
Olives  -2.5 (±2.5) 0.0 (±0.0) <0.001 -2.5 (±5.5) 0.5 (±0.5) **<0.001 
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Vegetable 
ghee  -3.5 (±2.5) 0.0 (±0.0) <0.001 -1.5 (±1.5) 0.0 (±0.0) **<0.001 
Butter  -2.5 (±0.5) 1.5 (±0.5) <0.001 -2.5 (±1.5) -1.0 (±1.0) **<0.001 
Mayonnaise -4.0 (±1.0) 3.0 (±2.0) <0.001 -3.5 (±1.5) 0.5 (±1.5) **<0.001 
Animal Ghee -2.5 (±1.5) 0.0 (±0.0) <0.001 -0.5 (±0.5) 0.0 (±0.0) **<0.001 
Cookies  -5.0 (±4.0) 4.5 (±1.5) <0.001 -3.0 (±1.0) -0.5 (±0.5) **<0.001 
Doughnuts  -3.5 (±1.5) 4.5 (±1.5) <0.001 -1.7 (±1.3) -0.6 (±0.6) **<0.001 
Cake  -4.0 (±3.0) 4.0 (±0.0) <0.001 -2.1 (±0.1) -0.1 (±0.1) **<0.001 
Pudding  -1.5 (±0.5) 2.5 (±1.5) <0.001 -0.8 (±0.2) 0.0 (±0.0) **<0.001 
Ice cream  -3.5 (±1.5) 2.5 (±1.5) <0.001 -1.5 (±0.5) -0.5 (±0.5) **<0.001 
Chocolate  -5.0 (±4.0) 4.0 (±0.0) <0.001 -2.0 (±0.0) -1.0 (±1.0) **<0.001 
Sugar  -4.0 (±4.0) 4.0 (±2.0) <0.001 0.0 (±0.0) 2.5 (±3.5) **<0.001 
Halawa -1.5 (±0.5) 3.0 (±3.0) <0.001 -0.5 (±0.5) -4.0 (±0.0) **<0.001 
Molasses -2.5 (±1.5) 4.0 (±1.0) <0.001 -0.5 (±0.5) -0.9 (±0.9) *0.012 
Arabic 
sweets -1.5 (±0.5) 2.5 (±1.5) <0.001 -0.5 (±0.5) -0.5 (±1.5) 1.000 
Soft drinks  -5.5 (±4.5) 3.5 (±3.5) <0.001 -4.0 (±3.0) 0.5 (±0.5) **<0.001 
Diet soft 
drinks 0.0 (±0.0) 
-2.0 
(±2.0) <0.001 1.5 (±1.5) 0.5 (±0.5) **<0.001 
Turkish 
coffee 0.5 (±0.5) 
-5.5 
(±5.5) <0.001 0 0 **<0.001 
Caffeinated 
beverages 0.0 (±0.0) 
-2.0 
(±2.0) <0.001 0 0 **<0.001 
Decaffeinated 
beverages 0.0 (±0.0) 
-1.5 
(±1.5) <0.001 0 0 **<0.001 
Hot chocolate  -1.5 (±0.5) 0.5 (±0.5) <0.001 -2.0 (±1.0) -0.6 (±0.0) **<0.001 
Beer  -1.5 (±1.5) 0.5 (±0.5) <0.001 -2.0 (±2.0) 0.0 (±0.2) **<0.001 
Wine  -3.5 (±2.5) 0.0 (±0.0) <0.001 0.0 (±0.0) -0.2 (±0.4) **<0.001 
Liquor  -2.0 (±2.0) 0.0 (±0.0) <0.001 -0.05 (±0.05) 0.2 (±0.2) **<0.001 
Manaeesh  -2.5 (±1.5) 5.0 (±4.0) <0.001 -2.2 (±1.7) 0.2 (±0.05) **<0.001 
French fries  -3.0 (±1.0) 2.5 (±1.5) <0.001 -3.4 (±2.4) 0.5 (±0.3) **<0.001 
Chips  -1.5 (±0.5) 3.0 (±1.0) <0.001 -2.0 (±1.0) 0.6 (±0.05) **<0.001 
Falafel  -1.3 (±0.3) 2.0 (±0.0) <0.001 -0.7 (±0.3) 0.3 (±0.3) **<0.001 
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Appendix 13 
Table 22 : Average change in food items intake for the sub-population 
recruited after 12 months   
Food type 
PCOS 
Intervention  Control p-value 
White bread  -3.1 (±0.5) 3.1 (±1.0) **<0.001 
Brown bread  -3.4 (±1.0) 2.8 (±1.0) **<0.001 
Markouk  0.0 (±0.0) 1.8(±1.0) **<0.001 
Cereals  -2.5 (±2.0) 1.7 (±0.0) **<0.001 
Sugar 
Cereals 
-2.8 (±0.5) 2.1 (±0.0) **<0.001 
Rice  -2.9(±0.0) 3.8 (±1.0) **<0.001 
Pasta -4.5(±2.0) 2.9 (±1.5) **<0.001 
Wheat  -1.2 (±0.5) 1.8 (±0.0) **<0.001 
Pop corn  0.5 (±0.0) 2.9 (±0.5) **<0.001 
Low fat milk 5.3 (±2.0) -1.9 (±0.5) **<0.001 
Whole fat milk -2.5 (±2.0) 2.9 (±1.5) **<0.001 
Condensed 
milk 
-1.6 (±1.5) 1.9 (±0.5) **<0.001 
Fat free yogurt  3.5 (±1.0) -2.0 (±1.0) **<0.001 
Whole fat 
yogurt 
-1.6 (±1.5) 2.9 (±0.5) **<0.001 
Regular 
cheese 
-4.7 (±3.0) 6.3 (±2.5) **<0.001 
Low fat 
cheese 
-1.8 (±3.0) 1.0 (±0.0) *0.012 
White cheese 4.7 (±1.0) 4.0 (±1.0) **<0.001 
Low fat white 
cheese 
6.0 (±2.5) -3.0 (±5.0) **<0.001 
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Spread 
cheese 
-2.9 (±2.5) 3.5 (±0.5) **<0.001 
Low fat 
spread 
cheese 
2.1 (±0.0) -2.0 (±1.0) **<0.001 
Labneh  0.0 (±0.0) 1.5 (±0.5) **<0.001 
Apple  -2.9 (±3.5) 3.0 (±1.0) **<0.001 
Banana -1.9(±1.5) 1.0 (±1.0) **<0.001 
Orange  0.0 (±0.0) 2.5 (±3.5) *0.002 
Kiwi  -0.9 (±0.5) -2.5 (±2.5) *0.003 
Mango  1.2 (±0.0) 2.5 (±0.5) **<0.001 
Grapes  -1.6 (±1.0) 6.0 (±1.0) **<0.001 
Dried fruits  -1.7 (±1.0) 5.0 (±0.0) **<0.001 
Canned fruits  -2.1 (±2.0) 2.5 (±0.5) **<0.001 
Fresh juice  -2.7 (±4.5) 5.0 (±0.0) **<0.001 
Fresh 
vegetables 
juice  
-0.5 (±0.5) 2.5 (±2.5) **<0.001 
Fruit drink  -4.1 (±4.0) 4.5 (±0.0) **<0.001 
Green salad 5.7 (±4.0) -4.5 (±0.5) **<0.001 
Dark green 
vegetables 
2.7(±2.0) -1.5 (±0.5) **<0.001 
Carrots  2.6 (±1.5) 6.0 (±1.0) **<0.001 
Tomato  3.8(±3.0) 2.0 (±1.0) **<0.001 
Cucumber  3.9 (±3.5) 1.0 (±0.0) **<0.001 
Corn/ peas/ -4.1(±4.0) 1.5 (±2.5) **<0.001 
Potato  -5.7(±3.5) 4.0 (±1.0) **<0.001 
Squash  -2.1 (±1.0) 1.5 (±0.5) **<0.001 
Cauliflower  -3.8 (±3.0) -1.5 (±1.5) **<0.001 
Legumes  2.9 (±1.5) -5.0 (±1.0) **<0.001 
	
	
266	
	
Nuts  -3.7 (±1.0) 2.5 (±1.5) **<0.001 
Beef  3.5 (±0.5) -2.0 (±2.0) **<0.001 
Lamb  -4.5 (±3.5) 4.1(±2.0) **<0.001 
Chicken  2.0 (±1.0) 2.1 (±2.0) *0.001 
Fish  -3.4 (±4.0) 1.2 (±1.0) **<0.001 
Tuna  4.0 (±2.5) -1.5 (±1.0) **<0.001 
Shellfish 2.2 (±1.0) 0.1 (±0.0) **<0.001 
Fresh fish  0.7 (±0.5) 0.1 (±0.0) **<0.001 
Eggs -3.5 (±3.0) 2.1 (±0.0) **<0.001 
Organ meats -2.8 (±2.5) 0.1 (±0.0) **<0.001 
Luncheon 
meat 
-1.7 (±1.5) 0.2(±0.0) **<0.001 
Sausage  -1.8 (±1.0) 2.7 (±1.5) **<0.001 
Vegetable oil  -1.9 (±2.5) 1.2 (±1.0) **<0.001 
Olive oil  -5.7 (±4.0) 0.7 (±0.5) **<0.001 
Olives  -2.8 (±2.5) 0.2 (±0.0) **<0.001 
Vegetable 
ghee  
-3.9 (±2.5) 0.8 (±0.0) **<0.001 
Butter  -2.8 (±0.5) 1.9 (±0.5) **<0.001 
Mayonnaise -4.4 (±1.0) 3.1 (±2.0) **<0.001 
Animal Ghee -2.9 (±1.5) 0.1 (±0.0) **<0.001 
Cookies  -5.5 (±4.0) 4.9 (±1.5) **<0.001 
Doughnuts  -3.7 (±1.5) 4.5 (±1.5) **<0.001 
Cake  -4.7 (±3.0) 4.1 (±0.0) **<0.001 
Pudding  -1.9 (±0.5) 2.7 (±1.5) **<0.001 
Ice cream  -3.8 (±1.5) 2.6 (±1.5) **<0.001 
Chocolate  -5.4 (±4.0) 4.1 (±0.0) **<0.001 
Sugar  -4.8 (±4.0) 4.1(±2.0) **<0.001 
Halawa -1.9 (±0.5) 3.1 (±3.0) **<0.001 
Molasses -2.7 (±1.5) 4.1 (±1.0) **<0.001 
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Arabic sweets -1.9 (±0.5) 2.6 (±1.5) **<0.001 
Soft drinks  -5.8 (±4.5) 3.6 (±3.5) **<0.001 
Diet soft 
drinks 
1.1(±0.0) -2.1 (±2.0) **<0.001 
Turkish coffee 0.9(±0.5) -5.6 (±5.5) **<0.001 
Caffeinated 
beverages 
0.9(±0.0) -2.1 (±2.0) **<0.001 
Decaffeinated 
beverages 
0.9(±0.0) -16 (±1.5) **<0.001 
Hot chocolate  -1.9 (±0.5) 0.5 (±0.5) **<0.001 
Beer  -1.9 (±1.5) 0.9 (±0.5) **<0.001 
Wine  -3.9 (±2.5) 0.9 (±0.0) **<0.001 
Liquor  -2.1 (±2.0) 0.9 (±0.0) **<0.001 
Manaeesh  -2.9 (±1.5) 5.1 (±4.0) **<0.001 
French fries  -3.1 (±1.0) 2.4 (±1.5) **<0.001 
Chips  -1.9 (±0.5) 3.1 (±1.0) **<0.001 
Falafel  -1.8 (±0.3) 2.1 (±0.0) **<0.001 
All food measures showed statistically significant changes  
 
 
 
 
 
 
 
	
	
268	
	
Appendix 14 
 Variation in statins intake between the 4 study groups 
 
 
Figure 7 Variation in statins medication intake between the 4 study groups 
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